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ABSTRACT 
Nicole M. Ashpole 
 
THE EFFECTS OF CAMKII SIGNALING ON NEURONAL VIABILITY 
 
Calcium/calmodulin-dependent protein kinase II (CaMKII) is a critical 
modulator of synaptic function, plasticity, and learning and memory. In neurons 
and astrocytes, CaMKII regulates cellular excitability, cytoskeletal structure, and 
cell metabolism. A rapid increase in CaMKII activity is observed within the first 
few minutes of ischemic stroke in vivo; this calcium-dependent process is also 
observed following glutamate stimulation in vitro. Activation of CaMKII during 
pathological conditions is immediately followed by inactivation and aggregation of 
the kinase. The extent of CaMKII inactivation is directly correlated with the extent 
of neuronal damage. The studies presented here show that these fluctuations in 
CaMKII activity are not correlated with neuronal death; rather, they play a causal 
role in neuronal death. Pharmacological inhibition of CaMKII in the time 
immediately surrounding glutamate insult protects cultured cortical neurons from 
excitotoxicity. Interestingly, pharmacological inhibition of CaMKII during 
excitotoxic insult also prevents the aggregation and prolonged inactivation of the 
kinase, suggesting that CaMKII activity during excitotoxic glutamate signaling is 
detrimental to neuronal viability because it leads to a prolonged loss of CaMKII 
activity, culminating in neuronal death. In support of this, CaMKII inhibition in the 
absence of excitotoxic insult induces cortical neuron apoptosis by dysregulating 
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intracellular calcium homeostasis and increasing excitatory glutamate signaling. 
Blockade of the NMDA-receptors and enzymatic degradation of the extracellular 
glutamate signal affords neuroprotection from CaMKII inhibition-induced toxicity. 
Co-cultures of neurons and glutamate-buffering astrocytes also exhibit this slow-
induced excitotoxicity, as CaMKII inhibitors reduce glutamate uptake within the 
astrocytes. CaMKII inhibition also dysregulates calcium homeostasis in 
astrocytes and leads to increased ATP release, which was neurotoxic when 
applied to naïve cortical neurons. Together, these findings indicate that during 
aberrant calcium signaling, the activation of CaMKII is toxic because it supports 
aggregation and prolonged inactivation of the kinase. Without CaMKII activity, 
neurons and astrocytes release stores of transmitters that further exacerbate 
neuronal toxicity.   
 
                                                                                 Andy Hudmon, Ph.D.- Chair 
 
 
 
 
 
 
 
 
 
viii 
 
TABLE OF CONTENTS 
LIST OF TABLES xi 
 
LIST OF FIGURES xii 
 
LIST OF ABBREVIATIONS xiv 
 
INTRODUCTION 
 
1 
 
CAMKII EXPRESSION 4 
CAMKII STRUCTURE 8 
ACTIVATION OF CAMKII BY CA2+/CAM 11 
CAMKII AUTOPHOSPHORYLATION 14 
INACTIVATION OF CAMKII 18 
REGULATORS OF CAMKII SIGNALING 19 
CAMKII INHIBITORS 20 
TARGETS OF CAMKII IN THE NERVOUS SYSTEM 24 
Glutamate Receptors 
Ion Channels and Extracellular Receptors 
Cytoskeletal Proteins 
24 
27 
29 
PHYSIOLOGICAL CAMKII SIGNALING 
Synaptic Plasticity 
Evolutionary Insight 
Insight from other Tissue Systems 
PATHOLOGICAL CAMKII SIGNALING 
Changes in CaMKII Signaling during Cerebral Ischemia 
      The Role of CaMKII Inactivation 
      The Role of Aberrant CaMKII Activation 
      Self-Association 
RESEARCH GOALS 
30 
30 
32 
36 
39 
39 
42 
44 
45 
49 
  
PART I: EXCITOTOXIC NEUROPROTECTION AND 
VULNERABILITY WITH CAMKII INHIBITION  
 
51 
 
SUMMARY 
INTRODUCTION 
EXPERIMENTAL PROCEDURES 
RESULTS 
Characterization of Neuronal Cultures and Their Death 
Following Glutamate-Glycine Application in Cortical Neurons 
51 
52 
54 
61 
 
61 
Validation of CaMKII Inhibitors and Controls 65 
Pretreatment with CaMKII Inhibitors Afford Neuroprotection from 
Excitotoxicity 
 
70 
CaMKII Inhibitors Afford Neuroprotection when Applied 
Following an Excitotoxic Insult 
 
74 
CaMKII Inhibition Predisposes Neurons to Excitotoxicity 78 
ix 
 
DISCUSSION 
 
82 
PART II: CALCIUM/CALMODULIN-DEPENDENT PROTEIN 
KINASE II INHIBITION INDUCES NEUROTOXICITY VIA 
DYSREGULATION OF GLUTAMATE/CALCIUM SIGNALING AND 
HYPEREXCITABILITY  
 
 
 
 
89 
 
SUMMARY 
INTRODUCTION 
EXPERIMENTAL PROCEDURES 
RESULTS 
Neurotoxicity with CaMKII Inhibition 
89 
90 
92 
97 
97 
CaMKII Inhibition Induces Apoptosis 104 
Calcium Dysregulation with CaMKII Inhibition 106 
Enhanced Neuronal Excitability with CaMKII Inhibition  111 
CaMKII Inhibition Predisposes Neurons to Excitotoxic Insults 
Glutamate Dysregulation with CaMKII Inhibition 
DISCUSSION 
 
113 
114 
126 
PART III: LOSS OF CALCIUM/CALMODULIN-DEPENDENT 
PROTEIN KINASE II ACTIVITY IN CORTICAL ASTROCYTES 
INDUCES NEUROTOXIC ATP RELEASE  
 
SUMMARY 
INTRODUCTION 
EXPERIMENTAL PROCEDURES 
RESULTS 
 
 
133 
 
133 
134 
136 
140 
Calcium Dysregulation with CaMKII Inhibition in Neuronal/Glial 
Cultures 
 
140 
CaMKII Inhibition in Astrocytes 145 
Decreased Glutamate Uptake in Astrocytes 148 
Calcium Dysregulation in Astrocytes 150 
CaMKII Inhibition Induces ATP Release 154 
CaMKII Inhibition in Astrocytes is Detrimental for Neuronal 
Viability 
 
159 
DISCUSSION 162 
 
DISCUSSION 
 
167 
 
GENERAL CONCLUSIONS 
BENEFITS AND LIMITATIONS OF THE MODEL SYSTEM 
167 
171 
SUBSTRATES DYSREGULTED DURING ABERRANT CAMKII 
SIGNALING  
 
177 
A NEED FOR UNDERSTANDING MECHANISMS OF SELF-
ASSOCIATION   
 
180 
IMPLICATIONS TOWARDS OTHER NEURODEGENERATIVE  
x 
 
 
  
DISEASES 
CONCLUSIONS 
186 
189 
  
REFERENCES 
 
CURRICULUM VITAE 
190 
 
xi 
 
LIST OF TABLES 
   
Table 1. Neuronal ion channels and receptors regulated by 
CaMKII 
28 
   
 
  
xii 
 
LIST OF FIGURES 
   
Figure 1. Multifunctional CaMKII signaling 3 
Figure 2.   Sequence alignment of the major human CaMKII 
isoforms 
 
5 
Figure 3. Structure of CaMKII 9 
Figure 4. 
 
Schematic of CaMKII activity in the time surrounding 
excitotoxic insult 
 
43 
Figure 5. Glutamate-glycine induced excitotoxicity in cortical 
neuron cultures 
 
63 
Figure 6. Characterization of glutamate/glycine induced 
excitotoxicity in 7-8 DIV cortical neurons 
 
64 
Figure 7.  Effects of tat-conjugated inhibitory and control 
peptides on CaMKII substrate phosphorylation and 
identification of critical amino acids in CN21 required 
for CaMKII binding 
 
 
 
67 
Figure 8.   Characterization of tat-CN21, tat-CN21c and tat-
CN21Ala binding to CaMKII 
 
68 
Figure 9. Characterization of tat-CN21-Fam and tat-CN21Ala-
Fam uptake in neurons 
 
71 
Figure 10.  Neuroprotection from excitotoxicity using CaMKII 
inhibitors 
 
72 
Figure 11.  tat-CN21 neuroprotection at 14 DIV and 48 hours 
following stimulation 
 
73 
Figure 12. Time-dependent neuroprotection of tat-CN21 from 
excitotoxicity 
 
76 
Figure 13. tat-CN21 application following onset of excitotoxic 
insult does not affect αCaMKII protein levels 
 
79 
Figure 14. tat-CN21 enhances neuronal vulnerability to 
excitotoxicity 
 
81 
Figure 15. Prolonged tat-CN21 treatment does not affect 
αCaMKII or NR2B protein levels 
 
83 
Figure 16. Neurotoxicity with CaMKII inhibition 100 
Figure 17. Characterization of co-cultures of neurons and 
astrocytes 
 
101 
Figure 18. Time-dependence of neurotoxicity and CaMKII 
inactivation with CaMKII inhibition 
 
103 
Figure 19. Neurotoxicity is predominantly found in neurons that 
have CaMKII inhibitor uptake 
 
105 
Figure 20.  Neuronal apoptosis with CaMKII inhibition 107 
Figure 21.  CaMKII inhibitor tat-AIP also induces apoptosis 108 
Figure 22.  Calcium dysregulation with CaMKII inhibition in 
hippocampal neurons 
 
110 
Figure 23. CaMKII inhibition augments neuronal excitability 112 
Figure 24. Prolonged CaMKII inhibition sensitizes neurons to 
excitotoxic-related insults 
 
115 
xiii 
 
Figure 25. CaMKII inhibition results in increased glutamate in 
conditioned neuronal media 
 
116 
Figure 26. CaMKII inhibition results in increased glutamate in 
the media 
 
118 
Figure 27.  Enzymatic catalysis of glutamate prevents acute and 
prolonged effects of CaMKII inhibition 
 
119 
Figure 28. Pharmacological antagonism of the NMDA receptor 
prevents acute and prolonged effects of CaMKII 
inhibition 
 
 
121 
Figure 29. Calcium influx with CaMKII inhibition is blunted by 
synaptic blockade 
 
123 
Figure 30. Conditioned media from neurons treated with 
CaMKII inhibitors does not induce neurotoxicity 
 
125 
Figure 31. Calcium dysregulation in neuronal/astrocyte cultures 
with CaMKII inhibition 
 
143 
Figure 32. CaMKII inhibition dysregulates calcium in neurons 
and astrocytes 
 
144 
Figure 33. CaMKII expression and activity in cultured cortical 
astrocytes 
 
146 
Figure 34. CaMKII inhibitors are rapidly taken up by astrocytes 149 
Figure 35. CaMKII inhibitors decrease glutamate uptake in 
astrocytes 
 
151 
Figure 36. Calcium dysregulation in astrocytes with CaMKII 
inhibition 
 
152 
Figure 37. Aberrant gliotransmitter release with CaMKII 
inhibition 
 
156 
Figure 38. Pharmacological purinergic signaling modulators had 
no effect on basal extracellular ATP 
 
158 
Figure 39. ATP signaling contributes to calcium dysregulation 
with CaMKII inhibition 
 
160 
Figure 40. Neuronal death with conditioned media from 
astrocytes treated with CaMKII inhibitors 
 
161 
Figure 41. 
 
 
Figure 42. 
 
Figure 43. 
Working model of CaMKII signaling following 
activation under physiological and pathophysiological 
conditions 
Model of dysregulated CaMKII signaling following 
excitotoxic activation or inactivation in neurons 
Model of CaMKII inactivation in astrocytes and 
subsequent effects on neuronal viability 
 
 
168 
 
175 
 
179 
   
   
   
   
xiv 
 
LIST OF ABBREVIATIONS 
 
AC-2 
ADP 
AIP2 
AMPA-R 
ANOVA 
ATP 
BSA 
Ca2+ 
CaM 
CaMKII 
CaMKIIN 
CaMKIINtide 
CN21 
CNQX 
DAPI 
DMSO 
EDTA 
EGTA 
GAPDH 
GPT 
HEPES 
KN-62 
 
 
KN-92 
 
KN-93 
 
 
LTP 
MAP2 
MK801 
 
Myr 
NMDA-R 
PBS 
PSD 
SD 
SDS-PAGE 
SEM 
Tat 
TTX 
 
Autocamtide 2 
Adenosine diphosphate 
Autocamtide 2-like peptide 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
Analysis of Variance 
Adensosine triphosphate 
Bovine serum albumin 
Calcium 
Calmodulin 
Calcium/calmodulin-dependent protein kinase II 
CaMKII-Inhibitory protein 
CaMKII-inhibitory peptide (27 residues) 
CaMKII-inhibitory peptide (21 residues) 
6-Cyano-7-nitroquinoxaline-2,3-dione 
4',6-diamidino-2-phenylindole 
Dimethyl sulfoxide 
Ethylenediaminetetraacetic acid 
ethylene glycol tetraacetic acid 
Glyceraldehyde 3-phosphate dehydrogenase 
Glutamate pyruvate transaminase 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
4-[(2S)-2-[(5-isoquinolinylsulfonyl)methylamino]-3-oxo-3-(4-
phenyl-1-piperazinyl)propyl] phenyl isoquinolinesulfonic acid 
ester 
2-[N-(4-Methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-
N-methylbenzylamine, monohydrochloride 
N-[2-[[[3-(4-Chlorophenyl)-2-
propenyl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4 
-methoxybenzenesulphonamide 
Long-term potentiation 
Microtubule-associated protein II 
(5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-
dibenzo[a,d]cyclohepten-5,10-imine maleate 
Myristolated 
N-methyl-D-aspartate receptor 
Phosphate buffered saline 
Post-synaptic density 
Standard deviation 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Standard error of the mean 
HIV-1 transactivating protein 
Tetrodotoxin 
 
1 
 
INTRODUCTION  
Our brains are aging. As they age, our probability of developing a 
neurodegenerative disease increases. Whether these diseases are inherited 
(Huntington’s Disease), slowly manifesting (Alzheimer’s Disease), or rapidly 
acquired (ischemic stroke), the devastating effects of neurodegenerative 
diseases can play both an emotional and financial toll on patients, family 
members, and society. Ischemic stroke alone is known to affect nearly 800,000 
Americans annually and nationwide costs associated with stroke exceed 30 
billion dollars each year (Roger et al., 2012). Medical and societal advances have 
led to a longer life-span; thus, the incidences and costs of neurodegenerative 
diseases are only expected to grow. In order to develop better therapeutics for 
the treatment of these diseases, a deeper understanding of the mechanisms 
underlying how neurons die is essential.  
One common feature of neurodegenerative diseases is the dysregulation 
of intracellular calcium (Ca2+) signaling. Under physiological conditions, 
intracellular Ca2+ is maintained at a very low concentration (~100 nM) until 
stimulation induces a transient increase through influx and release of Ca2+ from 
intracellular stores (Figure 1) (Maravall et al., 2000). Through a variety of 
downstream Ca2+-effector proteins, this increase in Ca2+can regulate a wide 
array of cellular processes including transcription, translation, excitability, and 
cellular metabolism (Ghosh and Greenberg, 1995, Trewavas and Malho, 1998, 
Graef et al., 1999, McCormack and Denton, 1999, Santella and Bolsover, 1999). 
Excitable cells like neurons tolerate these increases in intracellular Ca2+ as long 
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as they are quickly buffered and the downstream Ca2+-effector pathways are 
effectively reset. The inability to buffer the increased Ca2+ and the continued 
transduction of the Ca2+ signal can cause physiological signaling pathways to 
become pathophysiological. This dysregulation is prevalent within several 
neurodegenerative diseases and is subsequently associated with a number of 
deleterious effects such as synaptic dysfunction, metabolic impairment, gliosis, 
macrophage infiltration, and ultimately cellular necrosis and/or apoptosis.  
This dissertation focuses on understanding the role of the 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) pathway in aberrant 
calcium signaling. Upon activation, this kinase is known to target a variety of 
substrates in a variety of cellular compartments, thereby impacting a wide array 
of cellular processes, including gene transcription, cytoskeletal rearrangement, 
and protein degradation (Figure 1) (reviewed by (Colbran, 1992, Hudmon and 
Schulman, 2002)). Activation of CaMKII during aberrant calcium signaling could 
be pathological for neurons and their support cells as both increases and/or 
decreases in CaMKII are associated with neurodegenerative insults marked by 
dysregulated calcium signaling (Aronowski et al., 1992, Perlin et al., 1992, 
Hanson et al., 1994, Westgate et al., 1994, Churn et al., 1995, Zalewska and 
Domanska-Janik, 1996). Whether these fluctuations- both the transient increase 
and prolonged inactivation- play a causal role in the ensuing cell death is not 
known. By examining the influence of aberrant activation and inactivation of 
CaMKII in neurons and astrocytes, we will be able to identify how CaMKII 
signaling influences normal and pathophysiological conditions in the brain.  
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Figure 1: Multifunctional CaMKII signaling. CaMKII is activated by 
increases in cytosolic calcium via ligand-gated and voltage-gated calcium 
channels as well as release of calcium from intracellular stores. Activation 
of CaMKII following increases in cytosolic calcium leads to the targeting of 
the enzyme to a wide variety of substrates in several cellular 
compartments, thereby influencing numerous cellular processes.  
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The next few sections will provide insights into the structure, regulation, 
and function of CaMKII. I will also examine the influence of CaMKII signaling in 
other model systems. Together, this knowledge is necessary to understand how 
CaMKII function may be altered by, and contribute to aberrant calcium signaling 
within the brain. 
CAMKII EXPRESSION 
CaMKII is a Ca2+-signaling Ser/Thr kinase ubiquitously-expressed 
throughout the body. There are four major isoforms of CaMKII- α β δ and γ- with 
several identified splice variants for each isoform. These isoforms are encoded 
by different genes that in humans are found on chromosome 5, 7, 4, and 10, 
respectively (Li et al., 1994, Epigenomics, 2012). Alignment of the entire full-
length protein of all four isoforms indicates that over 60% of the sequence is 
conserved. As might be expected, this conservation is highest within the catalytic 
domain of the kinase. Sequence alignment of the catalytic domain of the four 
major isoforms found in humans indicates that 95% of the sequence is conserved 
(Figure 2). The most divergence between isoforms is found in an area termed the 
variable region (within the hub domain), where sequence inserts known to 
contain substrate targeting motifs unique to each isoform exist. 
  CaMKII isoform expression is regulated by tissue specific expression, cell-
specific patterning, developmental patterning, and subcellular distribution (as 
reviewed by (Hanson and Schulman, 1992b, Hudmon and Schulman, 2002)). 
Robust αCaMKII expression is observed in skeletal muscle, while βCaMKII is 
found in immune cells, δCaMKII predominates in cardiomyocytes, and γCaMKII 
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Figure 2: Sequence alignment of the four human isoforms of CaMKII. 
 * indicates sequence identity while the : indicates conservation. The colored 
lines delineate the subunits of CaMKII: catalytic (green), autoregulatory 
(purple), and hub (orange). 
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is found in the lungs (Tobimatsu and Fujisawa, 1989, Karls et al., 1992). Within 
the nervous system, particularly within the brain, all four isoforms are expressed 
(Sakagami et al., 1992, Sakagami and Kondo, 1993, Bayer et al., 1999). The 
most abundant isoforms within neurons are αCaMKII and βCaMKII (Ouimet et 
al., 1984, Erondu and Kennedy, 1985, McGuinness et al., 1985, Burgin et al., 
1990a). Meanwhile, δCaMKII and γCaMKII expression has also been observed, 
albeit at lower levels than αCaMKII and βCaMKII (Bayer et al., 1999). While 
αCaMKII and βCaMKII are the predominant isoforms in neurons, δCaMKII 
predominates within astrocytes (Takeuchi et al, 2000). Interestingly, because the 
CaMKII holoenzyme within the cell consists of twelve kinase subunits, co-
assembly of various isoforms can occur (Vallano, 1989, Kolb et al., 1998, Brocke 
et al., 1999). Functional changes within the nervous system following CaMKII 
inhibitor application are often identified as αCaMKII-regulated changes because 
of the predominant expression of αCaMKII in excitatory neurons; however, it is 
important to recognize that these other isoforms may be contributing to observed 
effects.  
Within the brain, there appears to be a general tissue-specific patterning 
of αCaMKII and βCaMKII expression. αCaMKII expression predominates in the 
cortex and βCaMKII expression predominates in the cerebellum (Erondu and 
Kennedy, 1985, McGuinness et al., 1985, Miller and Kennedy, 1985). 
Interestingly, there are specific cell types within each of these areas that do not 
conform to this pattern. Purkinje cells within the cerebellum largely expressed 
αCaMKII (Walaas et al., 1988). Moreover, within the dentate gyrus of the 
7 
 
hippocampus, granule cells express βCaMKII (Churn et al., 1992b). Thus, while 
there does appear to be a pattern of expression within tissues, some cell types 
differ and express an isoform different than their counterparts within that tissue.  
Despite different tissue and cellular expression patterns, not much is 
known about the influence this variance in isoforms has on substrate selection 
within cells. In vitro studies to date have not identified differences in substrate 
affinity depending on which isoform is present. We have observed that the 
phosphorylation motif on the NR2B subunit of the N-methyl-D-Aspartate receptor 
(NMDA-R), which was first identified as an αCaMKII substrate, is also a high-
affinity δCaMKII substrate (personal communication with A Hudmon and D 
Johnson). However, differences in substrate targeting have been observed. 
βCaMKII has been shown to have an F-actin binding domain within the variable 
region that is not present in the other isoforms (Fink et al., 2003). Therefore, 
βCaMKII and not αCaMKII can bind this cytoskeletal protein. On the other hand, 
αCaMKII has been shown to bind substrates such as densin-180 which βCaMKII 
appears incapable of binding (Robison et al., 2005). This isoform-specific binding 
cannot be attributed to the variable domain as it appears that residues deep 
within the hub domain (residues 421-480, will be discussed later) confer αCaMKII 
binding to densin-180 (Robison et al., 2005). Another example of isoform-specific 
binding was observed with the ubiquitin proteasome system. Genetic knock-
down of αCaMKII, and not βCaMKII, disrupted the recruitment of the ubiquitin 
proteasome system to post-synaptic densities in neurons (Bingol et al., 2010). 
Thus, there appear to be differences in the ability of isoforms to target and 
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regulate substrates in situ. While it is possible that structural differences between 
isoforms (specifically in the variable region) may contribute to binding substrate 
selection, the true mechanism underlying this difference is not known.  
CAMKII STRUCTURE 
CaMKII is a dodecameric protein composed of twelve 50 to 60 kDa kinase 
subunits (Kuret and Schulman, 1984, Chao et al., 2010). Thus, the size of the 
CaMKII holoenzyme within a cell is roughly 600 kDa (Bennett et al., 1983, Kuret 
and Schulman, 1984). Each subunit of the holoenzyme consists of an N-terminal 
catalytic domain, an autoregulatory domain, and a C-terminal hub domain (Figure 
3). The catalytic domain contains the ATP binding pocket, catalytic cleft, and 
substrate targeting groove, making this domain the enzymatic mainstay of the 
CaMKII protein. The catalytic domain is tethered to the autoregulatory domain 
which is responsible for lying over the catalytic cleft thereby inhibiting kinase 
activity in the absence of Ca2+/calmodulin (CaM) (Colbran et al., 1989) (Figure 3). 
CaM is a ubiquitously-expressed Ca2+-binding protein that serves as an 
intermediate between cytosolic Ca2+ and downstream Ca2+/CaM-effector 
proteins, such as CaMKII (Babu et al., 1985, Zhang et al., 1995, Tjandra et al., 
1999). A CaM-binding motif is found on the C-terminal portion of the 
autoregulatory domain of CaMKII (Figure 3). When Ca2+/CaM binds this motif, 
the helical autoregulatory domain is pulled away from the catalytic surface, 
allowing kinase activity (Rellos et al., 2010, Chao et al., 2011). Downstream of 
the CaM-binding motif, lay the hub domain of the kinase which is responsible for 
associating or interacting with other subunits to form the dodecameric 
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Figure 3: Structure of CaMKII. A, Linear schematic (top) and crystal 
structure (bottom) of one CaMKII subunit (derived from pdb 3SOA). The 
colors of the schematic correspond with the structures throughout the 
figure. B, The crystal structure of autoinhibited CaMKII holoenzyme (as 
solved by Chao et al., 2011, pdb 3SOA). C, Structure of the autoregulatory 
domain laying across the catalytic cleft. D, Catalytic surface of CaMKII with 
highlighted catalytic cleft (white), substrate binding groove (pink), inhibitory 
groove (yellow). 
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holoenzyme (Figure 3). Of note, the start of the hub domain is marked by the 
variable region which, as explained above, contains inserts found in different 
splice variants of CaMKII isoforms (Figures 2 and 3).  
Much work has gone into understanding the unique architecture of 
CaMKII. Early studies using transmission electron microscopy indicated that 
CaMKII appeared to be a hexagonal ring with a hollow center (Woodgett et al., 
1983). Subsequent cryoetching was in agreement with this, and further 
suggested that arm-like structures appeared to radiate out from the center ring 
(Kanaseki et al., 1991). Over ten years later, modern biophysical approaches, 
such as small-angle X-ray scattering and 3-D reconstruction of electron 
microscopy, suggested that the hub domains within the CaMKII holoenzyme are 
responsible for the formation of the ring-like structure from which the catalytic 
heads radiate outwards (Hoelz et al., 2003, Gaertner et al., 2004, Rosenberg et 
al., 2005, Rellos et al., 2010). This hypothesis was recently verified when the 
crystal structure for inactive human αCaMKII (with a β7-CaMKII variant linker) 
was solved (pdb# 3SOA)(Chao et al., 2011). The crystal structure confirmed that 
hub domains come together to form hexameric rings, one ring on top of another, 
with the connected catalytic subunits tightly packed towards the rings like ‘petals’ 
(Figure 3). This multivalent architecture allows intraholoenzyme autoregulation 
(will be discussed later). It is interesting to note that monomeric subunits of 
CaMKII are able to bind and phosphorylate substrates; thus, it is possible that 
this unique architecture of the dodecamer may also alter substrate selection or 
regulation within the cell. 
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ACTIVATION OF CAMKII BY CA2+/CAM  
As mentioned, the activation of CaMKII is dependent on the binding of 
Ca2+-bound CaM to the autoregulatory domain of the kinase. A crystal structure 
of one active catalytic/autoregulatory domain has been solved (pdb #2WEL) and 
indicates that Ca2+/CaM binding does lead to the exposure of the catalytic cleft 
by removal of the autoregulatory domain from the catalytic surface (Rellos et al., 
2010). However, there is currently no crystal structure for an activated CaMKII 
holoenzyme. Thus, inferences on the how the entire holoenzyme structurally 
changes following activation remain largely speculative. Because the crystal 
structure of the inactive holoenzyme suggests that the CaM binding region of 
CaMKII appears to be buried within a tightly-packed interface between the 
catalytic and association domain, it is plausible that a dramatic structural 
rearrangement occurs in order to reach an active state (Hoffman et al., 2011).  
Residues 293 and 310 within the autoregulatory domain are recognized as 
the CaM binding motif on CaMKII (Figure 3) (Colbran et al., 1988, Payne et al., 
1988, Meador et al., 1993). A crystal structure of CaM bound to a peptide 
encompassing these residues indicates that the two lobes of CaM tightly wrap 
this binding domain (Meador et al., 1993). CaM binds in an antiparallel fashion 
with the C-terminal lobe of CaM binding on the N-terminal half of the binding 
domain, and the N-terminal lobe of CaM binding on the C-terminal portion of the 
binding domain (Evans and Shea, 2009). While both lobes ultimately bind, this 
binding occurs in a stepwise manner. The N-terminal lobe forms a contact with 
the autoregulatory domain and then if nucleotides are present, the C-terminal 
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lobe will flex and form contacts as well (Jama et al., 2011). Recent biochemical 
studies have revealed that while both lobes may wrap the binding motif, the N-
terminal lobe alone is able to bind and partially activate CaMKII (Shifman et al., 
2006, Forest et al., 2008). While the C-lobe may make more contacts with the 
kinase autoregulatory domain, binding of the C-lobe is not necessary for kinase 
activation (Forest et al., 2008, Evans and Shea, 2009). However, the C-terminal 
lobe does increase the affinity of Ca2+/CaM for the autoregulatory domain (Evans 
and Shea, 2009).   
The binding kinetics of CaM to CaMKII exhibit positive cooperativity. Hill 
coefficients of 2 to 3 have been reported for CaM activation of CaMKII (Gaertner 
et al., 2004, Forest et al., 2008, Byrne et al., 2009, Chao et al., 2010, Chao et al., 
2011). This indicates that the binding of Ca2+/CaM to one subunit of the 
holoenzyme alters the activation state of nearby subunits that are not yet in 
contact with CaM. While the mechanism of this is not yet understood, it is thought 
that activation of one subunit induces conformational changes that can affect 
other components of the holoenzyme. Consistent with fact that the N-lobe is 
sufficient to activate the kinase, the N-lobe alone has also been shown to exhibit 
cooperative binding with a Hill coefficient of nearly 3 (Forest et al., 2008). The 
presence of nucleotides has been shown to decrease the cooperativity of CaM 
activation (Forest et al., 2008). This may be a consequence of the binding of the 
second lobe of CaM to CaMKII when nucleotides are present. It is possible that 
when the second lobe binds, there is another rearrangement within the 
corresponding catalytic subunit that decreases the ability of nearby subunits to 
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find CaM partners. Another possibility is that when nucleotides are present, a 
previously-identified autophosphorylation event (Thr286- will be discussed later) 
occurs that alters the holoenzyme conformation. Interestingly, introduction of 
extended linkers between the CaM binding region and the hub domain have 
been shown to significantly impact the cooperativity of Ca2+/CaM activation 
(Chao et al., 2011). These data suggest that CaMKII relies on dynamic sampling 
of the environment in order to become activated and that the architecture of the 
holoenzyme plays a critical role in regulation of CaMKII activity. 
Despite this cooperativity in CaM binding, CaMKII exhibits a weak affinity 
for CaM with the Kd of activation around 1 μM in the absence of ATP (Forest et 
al., 2008). However, the presence of ATP increases this affinity to around 20-100 
nM (Gaertner et al., 2004, Forest et al., 2008). Ca2+/CaM activation in the 
presence of saturating levels of ATP can lead to an autophosphorylation event 
(discussed below); this autophosphorylation further increases the affinity of 
CaMKII to CaM roughly 1000-fold, to 20 picomolar (Meyer et al., 1992). This 
means that CaMKII transitions from being one of the weaker CaM targets in cells 
to one of the best targets identified to date. Because of this, CaMKII is thought to 
‘trap’ calmodulin (Meyer et al., 1992). The functional consequence of this CaM 
trapping is not fully understood; however, it is possible that CaMKII may serve as 
a CaM sink which, when activated, prevents the activation of other CaM signaling 
pathways. If this were true, then the trapping of CaM by CaMKII could impact a 
multitude of cellular processes.  
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 As mentioned above, ATP can impact the binding affinity of Ca2+/CaM to 
CaMKII. Similarly, CaM binding can impact ATP binding affinity. For instance, the 
Km of ATP for autophosphorylation is roughly 150 μM when Ca2+/CaM is not 
present (Colbran, 1993). When Ca2+/CaM is present, the Km of ATP decreases 
to 20 μM (Colbran, 1993). Thus, it appears as though the catalytic domain 
structure impacts both CaM and ATP binding affinities. This ATP affinity 
determined in the presence of activating Ca2+/CaM is within a similar range for 
other neuronal kinases in the presence of their activators, such as PKC (13 μM), 
PKA (15 μM), and CaMKI (30 μM ) (Cook et al., 1982, Nairn and Greengard, 
1987, Spitaler et al., 2000). The ATP binding pocket, which is fully conserved 
between the four CaMKII isoforms, is found on the face of the catalytic subunit, 
near where the autoregulatory domain lays (Figure 3). Thus, it is possible that 
there are interactions between the ATP binding pocket and the autoregulatory 
domain that allow them to influence each other, as previously proposed (Smith et 
al., 1992, Brickey et al., 1994, Praseeda et al., 2004, Pradeep et al., 2009).  
CAMKII AUTOPHOSPHORYLATION 
The unique architecture of the CaMKII holoenzyme affords opportunities 
for intraholoenzyme modulation of one kinase subunit by another nearby subunit. 
One example of this is the autophosphorylation of the autoregulatory domain. 
This domain contains a classical CaMKII consensus sequence (R-X-X-S/T) with 
the potential phosphorylation residue at Thr286. Indeed, CaMKII has been shown 
to phosphorylate this residue following kinase activation (Lou and Schulman, 
1989). Interestingly, this phosphorylation has been shown to be an 
15 
 
intraholoenzyme event in which one subunit within the holoenzyme 
phosphorylates a nearby subunit in the holoenzyme (Mukherji et al., 1994, 
Bradshaw et al., 2002). Phosphorylation of Thr286 leads to a unique enzymatic 
state in which the kinase is no longer dependent on Ca2+/CaM for activity; a state 
known as autonomy, or Ca2+/CaM-independent activity (Lai et al., 1986, Lou et 
al., 1986, Miller and Kennedy, 1986, Schworer et al., 1986, Schworer et al., 
1988). It is important to point out that while autonomous activity is not dependent 
on Ca2+/CaM, the autophosphorylation event that leads to autonomy is, as 
Thr286 is not accessible for phosphorylation in the absence of Ca2+/CaM binding 
(Chao et al., 2011, Hoffman et al., 2011). Interestingly, even though CaMKII 
autophosphorylation at Thr286 renders the kinase autonomous of Ca2+/CaM, this 
state is recognized as the high-affinity calmodulin binding state, ie CaM trapping 
state (Meyer et al., 1992).  
Mutation of Thr286 has been shown to have dramatic effects on kinase 
function. Introducing the phosphomimetic Asp at Thr286 renders the kinase 
constitutively active (Fong et al., 1989, Waldmann et al., 1990). Mutation of 
Thr286 to non-phosphorylatable Ala prevents the induction of autonomous 
activity (Fong et al., 1989, Waxham et al., 1990). Furthermore, this mutation 
disrupts the ability of the kinase to trap CaM (Meyer et al., 1992). Mutant 
Thr286Ala also causes a loss of CaMKII substrate targeting in neurons (Shen et 
al., 2000). Importantly, while CaM trapping and substrate targeting are disrupted, 
mutant Thr286Ala appears to phosphorylate substrates normally, because 
Ca2+/CaM can still activate the kinase (Fong et al., 1989). Thus, while 
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autophosphorylation may enhance CaMKII activity, it is not an absolute 
requirement for enzymatic phosphorylation of substrates.  
Neuronal stimulation induces a rise in intracellular calcium which leads to 
increased CaMKII autophosphorylation (Fukunaga and Soderling, 1990, 
Fukunaga et al., 1992). The extent of autonomous activity can be used as a 
read-out for CaMKII autophosphorylation. For this, Ca2+/CaM-independent 
activity can be compared to total CaMKII activity (in the presence of Ca2+/CaM) in 
vitro (Saitoh and Schwartz, 1985). Using percent autonomy as a read-out of 
autophosphorylation, 10-20% of CaMKII is autophosphorylated under basal 
conditions, suggesting that some CaMKII activity is still present under resting 
conditions. Neuronal stimulation increases the extent of autonomy to nearly 50% 
of total CaMKII activity (Molloy and Kennedy, 1991, Ocorr and Schulman, 1991). 
Because Ca2+ levels within cells can rapidly change, it is thought that CaMKII 
autonomy serves as a molecular memory device for Ca2+ signals in cells even 
when the increased Ca2+ has subsided. This concept is central to my studies, as 
it is possible that CaMKII can continue to signal during neurodegenerative 
calcium signaling, further perpetuating the toxicity cascade.  
Because phosphorylation of Thr286 renders the kinase autonomous of 
Ca2+/CaM regulation, cells have devised multiple mechanisms for reversing this 
phosphorylation in order to properly reset CaMKII activity. First, CaMKII itself can 
reverse this phosphorylation. The presence of high levels of ADP in vitro can 
lead to dephosphorylation of Thr286, resulting in a subsequent loss of 
autonomous activity (Kim et al., 2001). Furthermore, several protein 
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phosphatases have been shown to dephosphorylate Thr286, including Ca2+/CaM 
protein phosphatase, protein phosphatase 1, 2a, and 2c (Hashimoto et al., 1987, 
Fukunaga et al., 1993, Strack et al., 1997a). As expected, these phosphatases 
also reduce CaMKII autonomy (Hashimoto et al., 1987, Fukunaga et al., 1993). 
The presence of multiple avenues to dephosphorylate Thr286 suggesting that 
maintaining the proper level of CaMKII activity within the cell is critical for cellular 
physiology.  
Thr286 is not the only residue shown to be autophosphorylated by 
CaMKII. Thr253, Ser279, Thr305, and neighboring Thr306 have all been shown 
to be phosphorylated by CaMKII as well (Hanson et al., 1989, Lou and 
Schulman, 1989, Patton et al., 1990, Hanson and Schulman, 1992a, Colbran, 
1993). Recent studies suggest that while Thr253 phosphorylation does not have 
a direct effect on enzymatic activity, subcellular targeting of the enzyme is 
enhanced following this phosphorylation event (Migues et al., 2006). To date, the 
functional consequence of Ser279 phosphorylation is unknown, as it does not 
appear to effect enzymatic activity (Hanson et al., 1989). Unlike Ser279, 
phosphorylation of Thr305 and Thr306 plays a critical role in regulating kinase 
activity, as it prevents Ca2+/CaM activation (Colbran and Soderling, 1990, Patton 
et al., 1990, Hanson and Schulman, 1992a, Colbran, 1993). These residues are 
particularly interesting as they lie within the CaM binding motif on the 
autoregulatory domain. Thus, when Ca2+/CaM is bound, these residues are 
inaccessible. However, under a basal resting state, autophosphorylation of 
Thr305/Thr306 can occur which prevents Ca2+/CaM activation (Colbran, 1993). 
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Furthermore, Thr305/Thr306 autophosphorylation can reset CaMKII activity 
following CaM dissociation when intracellular Ca2+ resets following stimulation 
(Jama et al., 2009).  
INACTIVATION OF CAMKII 
 A major portion of this dissertation is focused on understanding the 
physiological impact of CaMKII inactivation. Within cells, several mechanisms 
contribute to inactivation. First, as mentioned above, CaMKII is maintained in an 
inactive state in the absence of Ca2+/CaM because basal phosphorylation of 
Thr305/Thr306 prevents Ca2+/CaM binding. Therefore, following Ca2+/CaM 
activation, kinase activity can be effectively reset by phosphorylation of 
Thr305/Thr306 following the dissociation of Ca2+/CaM from the autoregulatory 
domain. Other forms of CaMKII inactivation have also been identified. Unlike 
activation of CaMKII under conditions of saturating Ca2+/CaM and ATP, 
activation of the kinase under limiting ATP quickly induces inactivation (Lou et al., 
1986, Colbran, 1993). The propensity to inactivate under limiting ATP is 
enhanced by elevated temperatures (Hudmon et al., 1996). It was later shown 
that saturating levels of ADP can prevent CaMKII inactivation, suggesting that 
the presence of nucleotides, not just ATP, following Ca2+/CaM stimulation blocks 
inactivation. Interestingly, the presence of a CaMKII substrate that mimics the 
autoregulatory domain, termed Autocamtide (AC2), can prevent the induction of 
this inactivation (Ishida and Fujisawa, 1995). This suggests that the structure of 
the kinase becomes unstable when the catalytic domain is activated and 
autophosphorylation cannot occur which ultimately leads to CaMKII inactivation. 
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Thus, conditions in which Ca2+/CaM is present, nucleotides are limiting, and 
temperature is elevated are maximal for CaMKII inactivation (Lou and Schulman, 
1989, Hudmon et al., 1996). 
 Inactivation of CaMKII is also instigated by the aggregation of kinase 
holoenzymes during periods of cellular distress. This process is an activity-
dependent form of inactivation that is termed self-association as several CaMKII 
holoenzymes associate/aggregate together (Hudmon et al., 1996, Hudmon et al., 
2005). The details entailing the intiation and influence of self-association will be 
discussed later. However, it is important to recognize that several of the 
conditions that prevent CaMKII inactivation (saturating ATP levels/ 
autophosphorylation of Thr286) are known to prevent self-association. Thus, it is 
possible that the inactivation that is observed under these conditions is due to 
self-association/aggregation of the enzyme.  
REGULATORS OF CAMKII SIGNALING 
 Several post-translational modifications of CaMKII have been identified. 
As mentioned above, CaMKII autophosphorylates many residues within the 
catalytic subunit, most recognizably Thr286. Interestingly, other protein kinases, 
such as PKC, have been shown to phosphorylate CaMKII (Waxham and 
Aronowski, 1993). Scansite prediction software suggests that over 15 potential 
modulatory kinase phosphorylation/binding sites may exist in the CaMKII protein; 
however, most of these sites have not been validated experimentally. Several 
protein phosphatases play a key role in dephosphorylating these residues 
(Hashimoto et al., 1987, Fukunaga et al., 1993, Strack et al., 1997a). Recently, 
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several glycosylation sites on CaMKII have been identified (Trinidad et al., 2012). 
The effects of these glycosylation events are not known, as there appears to be 
no change in substrate targeting or enzymatic activity when the glycosylation 
groups are removed (Trinidad et al., 2012). It is interesting, however, that one of 
the residues observed to be glycosylated is Thr306, a residue which is critical for 
maintaining CaMKII in an inactive state in the absence of Ca2+/CaM (Trinidad et 
al., 2012).  
 Oxidation has also been shown to modulate CaMKII activity. In 
lymphocytes and cardiomyocytes, oxidative stress is associated with increased 
autonomous CaMKII activity (Howe et al., 2004, Zhu et al., 2007, Erickson et al., 
2008). Biochemical studies indicated that direct oxidation of Met281/Met282 
results in CaMKII autonomy (Erickson et al., 2008). The initiation of this 
autonomy is still dependent on Ca2+/CaM. However, unlike traditional 
autonomous activity, Thr286 phosphorylation is not required to maintain activity 
when these residues are oxidized, as best highlighted when the Thr286Ala 
mutant exhibited autonomous activity in the presence of oxidizing agents like 
H2O2 (Erickson et al., 2008). This was the first evidence of the generation of 
autonomous activity that bypassed Thr286 autophosphorylation, allowing the 
kinase to maintain activity under cellular distress; an effect which I hypothesize is 
detrimental to neuronal viability.   
CAMKII INHIBITORS 
 Post-translational modifications are not the only avenues of regulating 
CaMKII activity in situ. Yeast two-hybrid screens for CaMKII-interacting proteins 
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identified a novel family of endogenous inhibitory proteins in the brain (Chang et 
al., 1998, 2001). These small 6.5kDa inhibitory proteins, termed CaMKIIN (two 
isoforms CaMKIINα and CaMKIINβ), are high-affinity CaMKII binding proteins. 
They are encoded by two separate genes on chromosome 1 and 3. CaMKIIN is 
capable of inhibiting both autonomous (Ca2+/CaM independent) and total 
(Ca2+/CaM dependent) activity in a dose-dependent manner, with an IC50 of 100-
400 nM (Chang et al., 1998). The inhibitory domain of CaMKIIN was localized to 
27 residues within the carboxy-terminal of the protein (Chang et al., 1998). 
Importantly, these 27 residues were identical between the two CaMKIIN 
isoforms. A peptide encompassing these residues was generated and termed 
CaMKIINtide (Chang et al., 1998). Similar to the parent protein, CaMKIINtide was 
a potent inhibitor of CaMKII activity (Chang et al., 1998). Subsequent 
biochemical studies have shortened this inhibitory peptide to 21 residues (termed 
CN21, (Vest et al., 2007)), and most recently 19 residues (termed CN19, 
(Coultrap and Bayer, 2011)), without significantly affecting the affinity of 
inhibition. Importantly, CaMKIIN and its peptide derivatives are highly-selective 
for CaMKII, with greater than 100-fold potency of CaMKII inhibition over CaMKIV, 
another CaM-dependent kinase family member, as well as PKC, PKA, and MAP-
K1 (Vest et al., 2007).  
While the regulation of CaMKIIN is not fully understood, there appears to 
be differential expression of the two CaMKIIN isoforms in differing brain regions. 
CaMKIINβ is highly expressed in the cerebellum, while CaMKIINα is highly-
expressed in the cortex (Chang et al., 2001). Interestingly, the expression pattern 
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of these isoforms appears to mimic the expression pattern of αCaMKII and 
βCaMKII isoforms. Recent studies suggest that CaMKIIN expression is 
upregulated during the acquisition and consolidation of fear learning (Radwanska 
et al., 2010). Autonomous CaMKII activity has been shown to be critical for this 
form of learning and memory (Frankland et al., 2001, Frankland et al., 2004, 
Easton et al., 2011); thus, the authors propose that the upregulation of CaMKIIN, 
which can turn off this autonomous activity, is critical for the turnover of CaMKII 
activity for proper memory formation.   
Other peptide and small molecule inhibitors of CaMKII have also been 
identified. Autocamtide-2 (AC2) is a high-affinity CaMKII substrate derived to 
mimic the autoregulatory domain surrounding Thr286. Interestingly, mutation of 
the phosphoacceptor site of AC2 to Ala, resulted in a high-affinity peptide 
inhibitor of CaMKII with an IC50 of around 50 nM (Ishida et al., 1995). This 
peptide, termed AIP (AC-2-related inhibitor peptide) is also able to inhibit both 
autonomous (Ca2+/CaM independent) and total (Ca2+/CaM dependent) CaMKII 
activity (Ishida et al., 1995). Because AIP is derived from a substrate peptide, it is 
a competitive inhibitor of substrate phosphorylation with a Ki of 320 nM (with 
respect to parent AC2) (Ishida et al., 1995). However, the autoregulatory domain 
from which AIP is derived is also known to inhibit other CaM-kinase family 
members, PKC and MLCK, at concentrations above 10 μM (Smith et al., 1990). 
KN-62 and KN-93 are allosteric small molecule CaMKII inhibitors (Tokumitsu et 
al., 1990, Sumi et al., 1991). Unlike their peptide inhibitor counterparts, these 
small molecule inhibitors prevent kinase activation and have no effect on 
23 
 
autonomous activity (Tokumitsu et al., 1990, Sumi et al., 1991). The KN drugs 
are competitive inhibitors of CaM binding with a Ki of 900 nM for KN-62 and a Ki 
of 370 nM for KN-93 (Tokumitsu et al., 1990, Sumi et al., 1991). While these 
inhibitors are cell-permeable, there are a variety of off-target effects associated 
with the KN family, including inhibition of other CaM-kinase family members, 
voltage gated calcium channels, and purinergic receptors (Smith et al., 1990, 
Enslen et al., 1994, Ledoux et al., 1999, Gao et al., 2006). However, studies 
using KN-93 can be properly controlled for using the inactive control KN-92.  
Because of off-target effects associated with the small molecule inhibitors, 
focus has shifted towards the use of the high-affinity, highly-selective peptide 
inhibitors such as CN21. While most peptide inhibitors are not inherently cell-
permeable, penetrating motifs and the addition of protein modifications such as 
myristolation can allow for peptide uptake in cells (Nelson et al., 2007). Several 
recent studies have shown that the addition of positively-charged amino acids 
allow for CaMKII inhibitors such as CN21 and AIP to be taken up by neurons 
(Vest et al., 2007, Buard et al., 2010, Vest et al., 2010, Lisman et al., 2012). One 
sequence often used in these studies is a series of subsequent Lys and Arg 
residues found in the HIV-associated coat protein Tat. Inhibitors conjugated to 
the Tat motif exhibit rapid cellular uptake (Vives et al., 1997, Silhol et al., 2002, 
Brooks et al., 2005, Richard et al., 2005). Thus, highly-selective peptide inhibitors 
are easily manipulated to allow for cellular application, thereby affording an 
opportunity to examine the physiological effects of CaMKII signaling within the 
native cell background.  
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TARGETS OF CAMKII IN THE NERVOUS SYSTEM 
My studies are focused on understanding the physiological impact of 
aberrant fluctuations in CaMKII activity. The following section highlights CaMKII-
regulated proteins that are critical for neuronal excitability and cell structure (see 
Figure 1). Understanding the impact that CaMKII regulation can have on the 
activity/stability of these proteins is essential to appreciate how dysregulation of 
CaMKII can affect cellular viability.  
Glutamate Receptors 
Within neurons, CaMKII is activated following increases in cytosolic 
calcium. Neurons express several voltage-gated and ligand-gated calcium 
channels that transduce calcium into the intracellular space. Receptors on 
intracellular stores of calcium can be activated to release calcium into the cytosol 
as well. While various sources of calcium may contribute to CaMKII activation, 
the most characterized pathway for activation is via the N-methyl-D-Aspartate 
receptor (NMDA-R). The NMDA-R is an ionotropic glutamate receptor widely-
expressed in neurons. This receptor is tetrameric with two NR1 subunits and two 
NR2 subunits (NR2A and NR2B), all of which come together to create a pore-
forming ion channel (Behe et al., 1995, Laube et al., 1998, Rosenmund et al., 
1998). Following activation by glutamate and the co-factor glycine, the NMDA-R 
transduces extracellular Ca2+ (and some sodium) into the intracellular cytosol. 
Calcium influx through the NMDA-R has been shown to lead to Thr286 
autophosphorylation, thereby inducing CaMKII autonomy (Shen and Meyer, 
1999). Following this activation, CaMKII then translocates to a variety of cellular 
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compartments, targeting a variety of substrates. Interestingly, one of the 
substrates that CaMKII is shown to target after activation is the NMDA-R (Shen 
and Meyer, 1999, Shen et al., 2000, Strack et al., 2000, Bayer et al., 2001). Once 
the kinase has translocated to the NMDA-R, it is able to both bind and 
phosphorylate this receptor, which has been shown to enhance NMDA-R 
desensitization (Sessoms-Sikes et al., 2005). Thus, there is a reciprocal 
relationship in which NMDA-R leads to CaMKII activation which then causes 
CaMKII translocation back to the NMDA-R to enhance receptor desensitiziation. 
The NR1, NR2A, and the NR2B subunits of the NMDA-R have all been 
shown to interact with CaMKII (Gardoni et al., 1999, Leonard et al., 1999, Bayer 
et al., 2001, Gardoni et al., 2001, Leonard et al., 2002). CaMKII phosphorylates 
both NR2A and NR2B (Gardoni et al., 1999). Furthermore, CaMKII has been 
shown to form a stable interaction with all three subunits (Gardoni et al., 1999, 
Leonard et al., 1999, Bayer et al., 2001, Leonard et al., 2002). Interestingly, the 
binding of CaMKII to the C-terminal portion of the NR2B subunit can affect the 
enzymatic function of CaMKII (Bayer et al., 2001). A peptide encompassing the 
binding region on NR2B has been shown to generate Ca2+/CaM-independent 
CaMKII activity in the absence of Thr286 autophosphorylation (Bayer et al., 
2001). When Ca2+/CaM induces a conformational change in the autoregulatory 
domain, a substrate binding groove on the catalytic surface is exposed (Bayer et 
al., 2006). This groove is separate from the catalytic cleft and the associated 
substrate phosphorylation groove. If Ca2+/CaM has removed the autoregulatory 
domain from the catalytic surface and the binding peptide from the NR2B subunit 
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is able to occupy the substrate binding groove, the catalytic surface is occluded 
and the autoregulatory domain is no longer able to re-bind (Bayer et al., 2006). 
The consequence of this is the generation of autonomous activity even in the 
absence of Thr286 phosphorylation. This is particularly interesting, as it suggests 
that CaMKII substrates can not only provide for feedback for their own regulation, 
they may also provide feed-forward modulation of proteins localized within the 
same subcellular compartment.  
NMDA-Rs can be found within the post-synaptic densities (PSD) and 
extrasynaptic spaces in neurons. The post-synaptic density is a specialized area 
within dendrites that receives signals from pre-synaptic connections. The PSD is 
a tightly-packed subcellular compartment full of CaMKII and CaMKII substrates. 
Nearly 18% of the PSD is composed of CaMKII (Miller and Kennedy, 1985). 
Along with CaMKII, the PSD contains cytoskeletal proteins and an array of 
voltage-gated and ligand-gated channels/receptors. As mentioned, following Ca2+ 
influx via the NMDA-R, CaMKII translocates to NR2B. Because the PSD contains 
NMDA-Rs, CaMKII is recruited to the PSD following activation (Strack et al., 
1997b). This recruitment is critical as a large number of CaMKII substrates are 
found within this small subcellular compartment. To date, over 30 CaMKII 
substrates have been identified in the PSD (Yoshimura et al., 2000, Yoshimura et 
al., 2002). Without proper translocation of the kinase to the PSD, the regulation 
of these substrates would be lost. In fact, in situ studies in HEK293 cells 
indicated that the presence of NR2B at the cell membrane induces translocation 
of CaMKII to the membrane which enhances the phosphorylation of other 
27 
 
membrane-bound proteins (Tsui et al., 2005). Thus, the dynamic interactions 
between CaMKII and the NMDA-R are essential for normal synaptic function.  
Ion Channels and Extracellular Receptors 
 CaMKII has been shown to regulate an array of other voltage-gated and 
ligand-gated ion channels in neurons and astrocytes. Sodium channels, 
potassium channels, calcium channels, and purinergic receptors have all been 
shown to be regulated by CaMKII (Table 1). Connexins are also regulated by 
CaMKII. These hemichannels are particularly interesting as they serve as 
regulators of intracellular ion concentration between connected cells. For 
example, CaMKII has been shown to phosphorylate Connexin43 (found in 
myocytes and astrocytes) which subsequently results in decreased gap junction 
open probability (Dermietzel et al., 1989, Huang et al., 2011, Xu et al., 2012). 
Thus, CaMKII regulation of Connexin43 is critical for turning off the calcium flux 
from one cell to another. The loss of CaMKII activity would then result in 
dispersion of increased cytosolic calcium to nearby, unstimulated astrocytes.  
Several metabotropic receptors, including glutamate and dopamine 
receptors, are also regulated by CaMKII. Table 1 summarizes several ionotropic 
and metabotropic receptors within neurons and astrocytes that CaMKII has been 
shown to regulate. CaMKII has also been shown to regulate several known 
channel/receptor modulators. This includes accessory subunits of these ion 
channels and G-coupled protein receptors as well as other signaling proteins that 
influence channel/receptor function, such as Stargazin, an accessory protein 
essential for AMPA-R insertion (Opazo et al., 2010). While Table 1 summarizes a 
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Ion Channel  Physiological Impact  Reference 
AMPA‐R  Increases current density, targets 
channel to synapse 
Yakel et al., 1995, Tan et 
al., 1994 
ASIC1a  Increases current density  Gao et al., 2005 
BK  Increases open probability  Van Welie and du Lac, 
2011 
Cav1.2  Increases calcium‐dependent 
facilitation 
Hudmon et al., 2005 
Cav2.1  Slows inactivation  Xiang et al., 2007 
Cav3.2  Decreases threshold of activation  Wolfe et al., 2002 
CLC‐3  Activates channel  Cuddapah et al., 2010 
GABA‐A  Increases current density, targets 
channel to membrane 
Houston and Smart, 
2006, Houston et al., 
2007 
GABA‐B1  Prevents internalization  Guetg et al., 2010 
Kv1.4  Slows inactivation  Roeper et al., 1997 
Kv4.2  Increases channel expression  Varga et al., 2004 
Nav1.8  Increases current density   Hudmon et al., 2008 
NMDA‐R  Enhances receptor desensitization  Sessoms‐Sikes et al., 
2005 
P2Y1  Internalizes receptor  Tulapurkar et al., 2006 
TRPV1  Sensitizes receptor  Oh et al, 2004 
 
 
Table 1: Neuronal ion channels and receptors regulated by CaMKII.   
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very small portion of the known CaMKII substrates, it is easy to appreciate that 
CaMKII signaling (or loss of it) can have dramatic effects on neuronal excitability 
and the ability of neurons to respond to external stimulation.  
Cytoskeletal Proteins 
CaMKII has also been shown to regulate a variety of cytoskeletal proteins 
in neurons and astrocytes. Cytoskeletal proteins are often dynamic in nature, 
assembling and disassembling in response to stimulation, allowing cell growth 
and motility. Furthermore, these proteins play a critical role in organelle trafficking 
throughout the cell. CaMKII phosphorylation can inhibit cytoskeleton dynamics. 
For example, CaMKII phosphorylation of α- and β-tubulin not only inhibits tubulin 
assembly, it also inhibits the interaction between tubulin and microtubule-
associated protein II (MAP-2), a key structural component of neurons (Wandosell 
et al., 1986). Similarly, CaMKII phosphorylation of actin also inhibits actin 
polymerization (O'Leary et al., 2006). Furthermore, CaMKII phosphorylation of 
tau, a microtubule-associated protein in neurons, prevents the binding and 
stabilization of tau to microtubules (Singh et al., 1996, Sironi et al., 1998). This is 
particularly interesting as the destabilization of tau within neurons is associated 
with many neurodegenerative diseases such as Alzheimer’s Disease and 
Parkinson’s Disease (as reviewed by (Lee et al., 2001, Morris et al., 2011)).  
CaMKII activity can also decrease cytoskeletal stability by leading to 
protein disassembly. For example, CaMKII phosphorylation of vimentin, a 
cytoskeletal protein in astrocytes, results in the disassembly of vimentin filaments 
in vitro and in situ (Inagaki et al., 1987, Oguri et al., 2006). Thus, in combination 
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with influencing cell excitability, CaMKII phosphorylation of key cytoskeletal 
proteins can greatly impact cell structure, and may ultimately affect processes 
controlled by the cytoskeleton, such as neurotransmitter release and organelle 
transport.   
PHYSIOLOGICAL CAMKII SIGNALING 
Synaptic Plasticity 
CaMKII activity is critical for altering the ability of neurons to strengthen or 
weaken synaptic connections in response to stimulation, a process termed 
synaptic plasticity. Several studies have shown that glutamate stimulation-
induced CaMKII activity can lead to the enhancement of synaptic connections by 
increasing excitatory AMPA-R signaling (reviewed by (Lisman et al., 2012)). 
CaMKII targets both the AMPA-R and a regulatory protein of the AMPA-R to 
directly and indirectly optimize AMPA-R signaling in the synapse. CaMKII 
phosphorylation of Stargazin, a calcium channel accessory subunit shown to 
interact with AMPA-R, results in mobilization of the AMPA-R (Tomita et al., 2005, 
Opazo et al., 2010). Because Stargazin also interacts with PSD-95, a key post-
synaptic density cytoskeletal protein, the AMPA-R is recruited to the PSD (Bats 
et al., 2007). The AMPA-R is an ionotropic glutamate receptor, thus subsequent 
synaptic stimulation can activate both the NMDA-R and the newly-inserted 
AMPA-R. CaMKII also phosphorylates AMPA-R (Tan et al., 1994, Yakel et al., 
1995). This phosphorylation event leads to increased channel conductance in 
response to stimulation (Lledo et al., 1995, Barria et al., 1997a, Barria et al., 
1997b, Derkach et al., 1999). Thus, both the insertion of the AMPA-R at the 
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synapse and the increased ability of the channel to pass ions into the 
extrasynaptic neuron are induced by CaMKII activity. Recently, CaMKII has also 
been shown to downregulate the AMPA-R regulating protein AKAP79/150, which 
is known to decrease AMPA-R current (Nikandrova et al., 2010). By turning off 
the negative feedback, CaMKII activity is able to maintain AMPA-R availability in 
the PSD thereby increasing synaptic strength and initiating long-term 
potentiation.  
The consequence of all of these modulatory events is the strengthening of 
the synaptic connection, a type of synaptic plasticity referred to as long-term 
potentiation (LTP). LTP is the cellular correlate for memory and learning and 
CaMKII activity plays a key role in this process (Malenka et al., 1989, Chen et al., 
2001). Considering that αCaMKII is the predominant isoform of CaMKII within the 
hippocampus, it is not surprising that αCaMKII knock-out animals exhibit both a 
loss of long-term potentiation and severe deficits in memory and learning (Silva 
et al., 1992). 
Not only does CaMKII signaling impact the initiation of LTP, it is also 
critical for its maintenance. Even after initiation, LTP is reversed by the addition 
of AIP and CN27/CN21 (Sanhueza et al., 2007, Sanhueza et al., 2011). It is 
proposed that CaMKII plays a structural role in the synapse. Because the 
maintenance phase of LTP is marked by changes in the structure of the synapse, 
it is possible that disrupting this role of CaMKII ultimately disrupts the 
maintenance of LTP. Recent studies have also identified a role for CaMKII in 
regulating protein turnover within the synapse, a process which is critical for 
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maintenance of LTP. Inhibitors of the ubiquitin proteasome system have been 
shown to reverse LTP (Dong et al., 2008). Following synaptic stimulation, the 
ubiquitin proteasome is recruited to the PSD to ensure proper turnover of 
proteins in this highly-active subcellular compartment. Interestingly, this 
translocation is dependent on CaMKII. CaMKII directly binds one of the 
proteasome subunits and as the kinase becomes activated and begins to 
translocate to NMDA-Rs in the PSD, it pulls the proteasome along with it (Bingol 
et al., 2010). Expression of a CaMKII mutant that does not translocate 
(Iso205Lys) results in a loss of proteasome recruitment to the PSD (Bingol et al., 
2010). Thus, CaMKII may play a direct and indirect role in maintaining synaptic 
strength by contributing to the structure of the PSD as well as by recruiting 
proteins to the synapse that are essential for this maintenance phase.  
Evolutionary Insight 
Genetic manipulations of CaMKII within transgenic mice have alluded to a 
critical need for maintaining CaMKII homeostasis for normal physiology. βCaMKII 
knock-out mice exhibit severe motor deficits and disrupted synaptic plasticity 
within the cerebellum (van Woerden et al., 2009). As mentioned, αCaMKII knock-
out animals display deficits in memory and learning. Furthermore, these mice are 
predisposed to neuronal damage following stroke (Silva et al., 1992). A gene 
dose-dependence of damage was observed when heterozygous and 
homozygous αCaMKII knock-out animals were subjected to middle cerebral 
artery occlusion. Additionally, αCaMKII knock-out mice exhibited increased 
hyperexcitability and were predisposed to epileptic seizures. Interestingly, 
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autoinhibitory-deficient transgenic mice (lacking Thr305/Thr306) also display 
enhanced susceptibility to seizure (Elgersma et al., 2002). Similarly, transgenic 
expression of constitutively-autonomous CaMKII (Thr286Asp) resulted in 
increased epilepsy, which was further associated with decreased life-span in 
males (Mayford et al., 1995). Thus, both a loss of CaMKII and an increase in 
CaMKII activity result in epilepsy and other pathophysiological outcomes, 
including deficits in memory and learning as well as decreased life-spans.  
Many insights into the potential physiological role of CaMKII can also be 
ascertained when we examine the evolutionary homologs and orthologs of 
CaMKII. CaM-dependent kinases are found in nearly all cell types, from single-
celled organisms to higher order multicellular systems. While nomenclature 
varies and there is a wide degree of sequence variability between different cell 
systems, CaMKII signaling proteins can be found from bacteria to plants to 
mammals. Several studies indicate that these CaMKII family members play 
critical roles in maintaining cellular function and viability. For example, 
overexpression of CMK2, the yeast (Schizosaccharomyces pombe) ortholog of 
CaMKII, locks the cell division cycle in the G2 (Gap 2) phase (Alemany et al., 
2002). Ultimately, the consequence of this is the arrest of cell division (Alemany 
et al., 2002). Genetic knockdown of CMK2 sensitizes yeast to oxidative stress 
and the ensuing cell death that can occur from it (Sanchez-Piris et al., 2002). 
This phenomena is particularly interesting because under periods of distress, 
CMK2 becomes activated and phosphorylated at the onset of insult (Sanchez-
Piris et al., 2002), analogous to the activation of CaMKII observed during 
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cerebral ischemia (will be discussed later). Moreover, the enhanced sensitization 
to further stress when CMK2 is inactive is analogous to the predisposition of 
neurons to ischemic death in the αCaMKII knock-out animals (Waxham et al., 
1996). 
Overexpression of CPK32, the thale cress (Arabidopsis thaliana) ortholog 
of CaMKII, is beneficial for plant survival following several insults. An example of 
this is the increased resistance to drought and decreased sensitivity to salt when 
CPK32 is overexpressed (Karve, 2009). Similar to CaMKII in neurons, cellular 
stress in these plants leads to activation and redistribution of CPK32 in the cell 
(Karve, 2009). Osmotic stress, wound formation, and biological stressors such as 
changes in climate all result in increased CPK32 activity (Karve, 2009). Based on 
the protective qualities associated with CPK32, it is inferred that CPK32 
activation is cytoprotective during multiple insults. Interestingly, genetic knock-
down of CPK32 results in an increased sensitivity of these plants to damage 
following insults (Karve, 2009). This is consistent with CMK2 knockdown in yeast 
and αCaMKII knock-out mice, which exhibit predisposition to death following 
excitatory insults (Waxham et al., 1996).  
One of the most radical effects of increased CaMKII activity is observed 
within Drosophila melanogaster. Mutation of CaMKII to a constitutively active 
form leads to Drosophila death as a failure of action potential propogation in the 
insect neurons ultimately induces cardiac failure (Park et al., 2002). Loss-of-
function CaMKII mutations in Drosophila also have profound effects on the 
insects. A loss of CaMKII activity decreases the ability to learn and detect 
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pheromone cues (Joiner Ml and Griffith, 1997, Mehren and Griffith, 2004). There 
is also increased muscle excitability when CaMKII signaling is lost (Wang et al., 
1994). On a cellular level, these changes in muscle excitability are due to 
increased motor neuron branching and increased excitatory synaptic release at 
neuromuscular junctions (Wang et al., 1994). This finding, in combination with 
predisposition to seizure observed in αCaMKII knock-out mice, suggests that a 
loss of CaMKII activity leads to hyperexcitability.  
Neuronal function is also altered in Caenorhabditis elegans when CaMKII, 
or Unc-43, is aberrantly regulated. A gain-of-function mutation results in loss of 
neurotransmitter release, which consequently, impairs the motor system (Reiner 
et al., 1999, Robatzek and Thomas, 2000, Liu et al., 2007). As expected, C 
elegans exhibit a trend in general hyperexcitability when Unc-43 (CaMKII 
homolog) function is decreased (Reiner et al., 1999). Enteric muscle excitability 
is significantly increased with loss-of-function mutations, which results in 
increased defecation. There is also a significant increase in egg laying due to 
hyperexcitability. The most robust effect in C elegans is the increased sensitivity 
to seizure-like convulsions when Unc-43 is knocked down (Reiner et al., 1999, 
Williams et al., 2004). It has been reported that loss-of-function mutants 
spontaneously exhibit repeating muscle bursts akin to seizures. Furthermore, the 
threshold for seizure induction following stimulant treatment is drastically 
decreased in these mutant worms (Williams et al., 2004). This is similar to the 
increased propensity to generate epileptic seizures in the αCaMKII knock-out 
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mice and increased excitability in Drosophila (Wang et al., 1994, Butler et al., 
1995).     
Thus, evolutionary alterations in CaMKII are unfavorable for cellular 
viability. Increased CaMKII signaling in several of these examples is associated 
with cellular death and dramatic decreases in the excitability of neurons. A loss of 
CaMKII function appears to decrease the ability of organisms to respond to 
insults and in higher order systems, this loss of function leads to increased 
cellular excitability. From these evolutionary counterparts, we can begin to 
recognize that a proper balance of CaMKII signaling is required for maintaining 
cellular physiology.   
Insight from other tissue systems 
 Several studies have examined the effects of aberrant CaMKII activity in 
other tissue systems. For example, increased CaMKII activity in cardiomyocytes 
is associated with increased cellular excitability and a predisposition to toxicity. 
The expression of δCaMKII, the predominant cardiac isoform, is significantly 
elevated during heart failure (Hoch et al., 1999, Kirchhefer et al., 1999, Zhang et 
al., 2003). Mechanistic studies have identified that when activated, CaMKII 
aberrantly regulates cardiac ion channels and initiates the transcription of several 
pro-hypertrophic and pro-inflammatory genes (as reviewed by (Singh and 
Anderson, 2011). Thus, inhibition of CaMKII during heart failure affords 
cardioprotection by decreasing these cardio-myopathies. Moreover, the δCaMKII 
knock-out mice are more resistant to heart failure (Backs et al., 2009). No 
changes in morphology or excitation were observed in these knock-outs, 
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indicating that a loss of CaMKII signaling in the heart does not have a detrimental 
effect on cardiac function.  
 Within the immune system, CaMKII signaling is required for cytokine 
production in T lymphocytes, activation of natural killer cells, and initiation of 
macrophage infiltration (Bui et al., 2000, Poggi et al., 2002a, Poggi et al., 2002b, 
Liu et al., 2008). Expression of constitutively-active CaMKII leads to increased 
cytokine production and release, while pharmacological and genetic inhibition of 
CaMKII is associated with a loss of cytokine signaling (Poggi et al., 2002b, Liu et 
al., 2008). Several of the cytokines that appear to be downstream of CaMKII 
signaling are implicated in autoimmune disorders and inflammation. Thus, 
studies suggest that alterations in CaMKII signaling may contribute to the 
pathophysiology of immune diseases. While changes in cellular viability of 
immune cells treated with constitutively-active CaMKII or CaMKII inhibitors has 
not been reported, it is evident that CaMKII signaling plays a key role in immune 
cell function.  
 Homeostatic regulation of CaMKII signaling is also critical within the 
reproductive system. CaMKII inhibition dramatically decreases sperm motility and 
negatively regulates the exocytotic mechanisms required for spermatozoa 
penetration of the ovum. (Schlingmann et al., 2007, Ackermann et al., 2009). 
Within females, a loss of CaMKII activity in Oocytes leads to apoptotic death. 
CaMKII phosphorylation of caspase-2 renders the pro-apoptotic caspase inactive 
to promote oocyte survival. Mutation of the phospho-acceptor site on caspase-2, 
Ser135, results in robust oocyte death within 8 hours (Nutt et al., 2005). Thus, a 
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loss of CaMKII activity in both male and female reproductive machinery can be 
detrimental to fertilization. 
There have also been several studies connecting CaMKII signaling and 
cancer. In general, a loss of CaMKII signaling appears to be toxic for cancer 
cells. Pharmacological CaMKII inhibitors and genetic ablation of CaMKII have 
been shown to induce apoptosis in malignant glioma, melanoma, osteosarcoma, 
and prostate cancer cells (Xiao et al., 2005, Song et al., 2006, Rokhlin et al., 
2007, Yuan et al., 2007). Furthermore, expression of the CaMKIIN inhibitory 
protein has been shown to arrest cell cycling and induce apoptosis in ovarian 
adenoblastomas (Ma et al., 2009). These findings are particularly interesting as 
fluctuations in CaMKIIN protein levels are associated with ovarian 
adenoblastomas (Ma et al., 2009). Robust levels of the CaMKIIN protein has 
been shown to be expressed in normal healthy ovarian tissue; however, 
adenocarcinomas are marked by a significant decrease in CaMKIIN protein (Ma 
et al., 2009). Thus, a reduction in the endogenous regulation of CaMKII may be a 
mechanism underlying how cancer cells evade death. These findings suggest 
that CaMKII activity is essential for the growth and survival of several variants of 
cancer.  
Together, the literature overwhelmingly suggests that dysregulation of 
CaMKII is detrimental to cellular function and viability. Fluctuations in activity are 
correlated with altered excitability, enhanced sensitivity to insults, and increased 
toxicity. From this, we postulate that a proper balance of CaMKII activity is 
essential for maintaining neuronal viability.  
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PATHOLOGICAL CAMKII SIGNALING 
Changes in CaMKII Signaling during Cerebral Ischemia 
Ischemic events within the brain can be devastating to neurons. Neurons 
require oxygen and glucose in order to generate and maintain their excitable 
membrane. Therefore, a loss of blood flow associated with ischemia is 
detrimental to neurons as metabolically-dependent functions such as the 
regulation of ion pumps are no longer able to be maintained. Because ion pumps 
are critical for the maintenance of membrane potential, the loss of pump activity 
during ischemic insult has been shown to lead to an aberrant neuronal 
depolarization from which the neurons are not able to recover (as reviewed by 
(Lipton and Rosenberg, 1994, Aronowski et al., 2000, Mark et al., 2001)). It is 
well-understood that neuronal depolarization can lead to neurotransmitter 
release. Thus, ischemic insults and the resulting periods of decreased energy 
availability are also marked by an increase in neurotransmitter release. While 
several factors can contribute to neuronal death following stroke (such as 
reactive oxygen species generation, mitochondrial dysfunction, lipase activation, 
and macrophage infiltration), the dysregulation of neuronal excitability and 
aberrant neurotransmitter release are key mechanisms underlying ischemic 
neuronal death.  
As mentioned, the terminal depolarization of ischemic neurons results in 
the release of neurotransmitter stores. The most abundant excitatory 
neurotransmitter in the cerebral cortex is the amino acid glutamate. Thus, 
extracellular concentrations of nearly 250 μM glutamate have been observed 
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within the ischemic tissue in a human stroke patient (Bullock et al., 1995). While 
glutamate is critical for excitatory synaptic signaling, the overabundance of 
extracellular glutamate in ischemia is detrimental to neuronal viability. In 1969, 
J.W. Olney first described the neurotoxic effects of increased glutamate in mice 
(Olney, 1969). Over the next 20 years, several groups identified that neuronal 
damage following ischemic stroke was correlated with excess glutamate 
signaling (reviewed by (Choi, 1988)). The hypothesis that excess glutamate 
played a causal role in neurotoxicity was supported by in situ analysis of 
neuronal viability in the hours following exogenous glutamate application. 
Neurons treated with high levels of glutamate exhibited the loss of neuritic 
processes, swollen somas, and increased membrane permeability (Olney et al., 
1986, Choi et al., 1987, Finkbeiner and Stevens, 1988). The process of 
glutamate-induced neuronal death was termed ‘excitotoxicity’; a term which 
highlights the connection between over-excitation and toxicity (Olney, 1969).  
Further work has identified that excitotoxicity is largely induced by 
glutamate activation of the NMDA-R (Choi, 1987, Murphy et al., 1987). While 
neurons express several metabotropic and ionotropic glutamate receptors, 
antagonism of the ionotropic NMDA-R has been shown to prevent excitotoxic 
neuronal death in situ (Choi et al., 1988, Frandsen et al., 1989). Furthermore, 
NMDA-R antagonists have been shown to reduce neuronal damage in animal 
models of stroke (Gotti et al., 1988, Park et al., 1988a, b, Bullock et al., 1990, 
Uematsu et al., 1991). While these findings have been critical for understanding 
the mechanism underlying the initiation of excitotoxicity, the optimism for NMDA-
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R antagonists in therapeutic treatment of ischemic stroke has been dampered by 
the inability of these inhibitors to be effective in clinical trials (as reviewed by 
(Ginsberg, 2008, 2009)). There are large disparities in the findings of these trials 
with some suggesting a neuroprotective effect, others suggesting no effect, and 
others suggesting that the negative side-effects of these drugs outweigh any 
potential benefits. Considering how efficacious these reagents were in animal 
models, the failure of these drugs to be neuroprotective in clinical trials is 
perplexing. As mentioned above, extracellular glutamate levels are significantly 
increased within minutes of insult (Benveniste et al., 1984, Globus et al., 1988, 
Butcher et al., 1990). While this extracellular glutamate has been shown to 
remain elevated for hours to days (Davalos et al., 1997), the therapeutic time 
window for NMDA-R antagonism appears to be much shorter. Because of this, 
recent studies have focused on examining the impact of signaling pathways 
downstream of the NMDA-R (Ginsberg, 2008).  
NMDA-R activation results in Ca2+ influx into neurons. This Ca2+ influx has 
been shown to play a causal role in the neurotoxic effects of glutamate 
stimulation, as buffering of extracellular Ca2+ can prevent excitotoxicty in vitro 
(Choi, 1985). As mentioned earlier, intracellular Ca2+ levels impact numerous 
signaling pathways, including CaMKII which is activated following the onset of 
ischemic insult (Westgate et al., 1994). This excitotoxic-induced activation is 
short-lived as CaMKII enters an inactive state within minutes (Aronowski et al., 
1992, Hanson et al., 1994, Aronowski and Grotta, 1996). This inactivation can 
last for hours to days, depending on the length of ischemic insult. Figure 4 
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summarizes the fluctuations in CaMKII activity in the time surrounding ischemic 
insult (based on previous literature (Aronowski et al., 1992, Hanson et al., 1994, 
Westgate et al., 1994)). 
The Role of CaMKII Inactivation 
These fluctuations in CaMKII activity during ischemic stroke are correlated 
with the extent of neuronal damage. In an animal model of stroke, CaMKII activity 
within the ischemic core was undetectable 24 hours following insult (Hanson et 
al., 1994). For reference, the ischemic core is the tissue that has directly lost 
blood supply. The area surrounding the ischemic core is known as the 
penumbra. This tissue retains partial blood supply; however, signals from the  
core render the penumbra sensitive to the insults that accompany stroke 
(glutamate and reactive oxygen species). Interestingly, CaMKII activity within the 
penumbral region is also decreased 24 hours following stroke (Hanson et al., 
1994). There was a striking pattern between CaMKII activity levels and neuronal 
damage. While the core exhibited the largest extent of CaMKII inactivation, this 
loss of activity radiated from the core into the surrounding penumbra (Hanson et 
al., 1994). This pattern of radiation directly mimicked the pattern of cell death, 
with the largest extent in the core and radiation outward away from insult into the 
penumbra (Hanson et al., 1994). Importantly, proteolytic degradation of the 
kinase does not underlie this decreased activity (Aronowski et al., 1992, 
Westgate et al., 1994, Shackelford et al., 1995). Interestingly, neuroprotective 
strategies that block NMDA-R function have been shown to prevent the loss of 
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Figure 4: Schematic of CaMKII activity in the time surrounding 
excitotoxic insult. 
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CaMKII activity, further supporting the correlation between CaMKII inactivation 
and the extent of neuronal death (Aronowski et al., 1993).  
The concept that CaMKII inactivation is detrimental to neuronal survival 
following stroke is also supported by studies in the αCaMKII knock-out mouse. 
Interestingly, αCaMKII knock-out mice displayed greater infarct size than their 
wild-type littermates (Waxham et al., 1996). Moreover, there was gene-dosage 
sensitivity to stroke damage, with the greatest damage in homozygous knock-out 
mice and moderate damage in heterozygous αCaMKII animals (Waxham et al., 
1996). Together, these data suggest that a loss of CaMKII activity could play a 
detrimental role in the ability of neurons to survive an ischemic/excitotoxic insult. 
The Role of Aberrant CaMKII Activation 
While inactivation of CaMKII correlates with neuronal death, an increase in 
CaMKII activity precedes this inactivation. Several studies have attempted to 
better understand the influence of CaMKII activation during periods of cellular 
distress. Application of small molecule inhibitor KN-93 prior to excitotoxic insult 
has been shown to afford neuroprotection to cortical, hippocampal, and retinal 
neurons (Hajimohammadreza et al., 1995, Takano et al., 2003, Vest et al., 2010). 
Peptide inhibitors of CaMKII, such as tat-CN21 and tat-AIP, have also been 
shown to be efficacious at reducing excitotoxicity (Laabich and Cooper, 2000, 
Fan et al., 2006, Goebel, 2009, Vest et al., 2010). However, these studies have 
been limited to inhibition of CaMKII prior to insult. Thus, our studies are focused 
on understanding the impact of CaMKII signaling in the time surrounding insult, 
by applying inhibitors at various time points before and after glutamate 
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stimulation. During the completion of our studies for Chapter 2, the Bayer lab 
indicated that injection of tat-CN21 an hour after the induction of middle cerebral 
artery occlusion in mice reduced infarct size 24 hours following insult (Vest et al., 
2010). These findings indicated that targeting CaMKII during ischemic stroke 
may be therapeutically advantageous. As will be discussed in Chapter 2, we 
have expanded on their findings to better address enzymatic changes in CaMKII 
that occur when the inhibitors are applied in the time surrounding insult.  
Self-Association 
How can both aberrant activation and inactivation of CaMKII play a role in 
excitotoxic neuronal death? The answer may lie in the functional consequences 
that activation of CaMKII during periods of cellular distress has on CaMKII 
stability and activity. Nearly 20 years ago, differential centrifugation of whole 
brain lysates taken from animals subjected to cerebral ischemia indicated that 
CaMKII transitioned from soluble to sedimentable fractions following insult 
(Aronowski et al., 1992, Yamamoto et al., 1992, Kolb et al., 1995, Shackelford et 
al., 1995). This transition occurs rapidly, and directly correlates with a loss of 
CaMKII activity (Aronowski et al., 1992, Kolb et al., 1995, Shackelford et al., 
1995). This translocation was consistent in hippocampal slices subject to 
ischemic insult in vitro (Kolb et al., 1995). Electron microscopy studies identified 
that ischemic-like insults induced the translocation of CaMKII to aggregate-like 
clusters in neurons (Dosemeci et al., 2000, Tao-Cheng et al., 2001, Tao-Cheng 
et al., 2002). These clusters were purified and mass spectrometry revealed that 
they were primarily composed of αCaMKII protein (Dosemeci et al., 2000). 
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Utilization of GFP-tagged αCaMKII allowed for real-time analysis of this CaMKII 
aggregation within neurons following excitotoxic glutamate stimulation (Hudmon 
et al., 2005). Interestingly, αCaMKII began to cluster within minutes of glutamate 
application, suggesting that excitotoxic insults rapidly cause CaMKII aggregation 
(Hudmon et al., 2005). To further understand this, purified αCaMKII was 
observed in ischemic-like conditions in vitro (limiting ATP, reduced pH; discussed 
below) (Hudmon et al., 1996, Hudmon et al., 2001, Hudmon et al., 2005). Light 
scattering analysis indicated that the shape and size of αCaMKII in solution was 
drastically different when the kinase was added to ‘ischemic-like’ solution 
compared to physiologically normal solution (pH 7.4 with saturating levels of 
ATP) (Hudmon et al., 2001). Transmission electron microscopy indicated that the 
size and shape difference between these two conditions was due to the 
formation of grape-like clusters of CaMKII holoenzymes (Hudmon et al., 2001). 
Because this process is an interholoenzyme association (ie multiple CaMKII 
holoenzymes cluster together) the process was termed ‘self-association’. 
Much work has gone into trying to understand the mechanism of CaMKII 
self-association. It is known that this process is activity-dependent in that it 
requires Ca2+/CaM activation (Hudmon et al., 1996). However, Ca2+/CaM binding 
is not sufficient to induce self-association, as under physiological conditions little 
CaMKII is self-associated. A role for ATP concentration has been established; 
self-association does not occur when free ATP levels are within 2-4 mM 
(Hudmon et al., 1996). However, when CaMKII is activated in limiting ATP, self-
association is observed (Hudmon et al., 1996). Interestingly, the kinase is unable 
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to self-associate when ATP is completely absent, suggesting a requirement for 
the presence of some nucleotides. Indeed, ADP and the ATP analog AMP-PNP 
are able to substitute for ATP and induce self-association when ATP is 
completely depleted (Vest et al., 2009). These data suggest that under periods of 
cellular distress that decrease ATP availability, CaMKII is sensitive to self-
association. During ischemic stroke in vivo, ATP concentration has been shown 
to plummet within minutes of insult (Kobayashi et al., 1977, Onodera et al., 1986, 
Eleff et al., 1991). Along with this loss in ATP, an increase in AMP levels has 
been observed (Kobayashi et al., 1977, Onodera et al., 1986) as well as a 
transient increase in ADP levels (Kobayashi et al., 1977). In situ excitotoxic 
insults show a similar effect with significant decreases in intracellular ATP levels 
following insult (Mattson et al., 1993, Budd et al., 2000). Thus, ischemic events 
create an environment that fosters CaMKII self-association.   
Another hallmark of ischemia that has been shown to regulate CaMKII 
self-association is a reduction in pH. Under physiological pH (7.3-7.4), αCaMKII 
does not self-associate, even when ATP levels are depleted (Hudmon et al., 
1996, Hudmon et al., 2001); however, as the pH decreases towards pH 7.0 or pH 
6.0, the sensitivity of the kinase to self-associate increases (Hudmon et al., 
2001). Because intracellular pH within neurons is maintained by proper 
oxygen/glucose availability, ischemic insults result in rapid decreases in pH; in 
vivo stroke models have shown that pH can reach levels as low as pH 6.2 in 
minutes (Silver and Erecinska, 1992). Decreased ATP and decreased pH 
additively affect the sensitivity of αCaMKII self-association. As mentioned, high 
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levels of ATP ( >1 mM) prevent self-association even when pH is significantly 
reduced (Hudmon et al., 1996). Furthermore, higher pH (pH 7.4) can prevent this 
aggregation from occurring even when ATP is depleted (Hudmon et al., 2001). 
While self-association is prevented at higher pH, the limiting levels of ATP still 
induce CaMKII inactivation (Hudmon et al., 1996, Hudmon et al., 2001). 
Together, a decrease in pH and a decrease in ATP lead to enhanced 
susceptibility to self-association.  
Interestingly, autophosphorylation of Thr286 prevents self-association 
even under periods of decreased ATP and pH. While phosphorylation of this 
residue is most often recognized as being essential to rendering CaMKII 
autonomous, Thr286 phosphorylation also appears to provide stability to the 
kinase by preventing this aggregation (Hudmon et al., 2005). It is thought that 
this protection that autophosphorylation affords may explain the ability of high 
levels of ATP to prevent self-association; increased ATP availability will result in 
increased Thr286 phosphorylation. The concept that the autophosphorylation 
state of Thr286 determines the sensitivity to self-association is supported by in 
situ studies with Thr286 mutants. Overexpression of autophosphorylation 
deficient Thr286Ala resulted in significantly higher levels of self-association in 
neurons and HEK293 cells subjected to ischemic-like insults, compared to wild-
type αCaMKII (Hudmon et al., 2005). The constitutively-autophosphorylated 
mutant Thr286Asp is more resistant to self-association than wild-type αCaMKII 
(Hudmon et al., 2005). Many theories exist as to how this residue may influence 
the stability/structure of the kinase; however, there is currently no crystal 
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structure available for autophosphorylated CaMKII. AC-2, the peptide mimetic of 
the autoregulatory domain, can prevent self-association (Hudmon et al., 2001). 
While the mechanism underlying self-association is not fully-understood, it has 
been hypothesized that the autoregulatory domain interacts with the surface of 
another holoenzyme causing the interholoenzyme aggregation (Hudmon et al., 
2001).  
Despite these speculations, the connection between self-association and 
CaMKII inactivation is apparent. Self-association results in the inactivation of 
CaMKII. It is important to point out that inactive kinase does not self-associate, 
rather self-association leads to inactivation. Phosphorylation of Thr305/Thr306 
results in inactivation (see CaMKII Inactivation section). Phosphomimetics at 
these residues (Thr305Asp/Thr306Asp) have been shown to be resistant to self-
association in situ (Hudmon et al., 2005). This is because CaMKII self-
association is dependent on Ca2+/CaM binding, which cannot occur when 
Thr305/Thr306 are phosphorylated. Thus, the loss of enzyme activity under 
ischemic-like conditions is likely due to inactivation subsequent to self-
association. The impact of self-association/inactivation on neuronal viability is still 
poorly-understood.  
RESEARCH GOALS 
Ultimately, a better understanding of how CaMKII activity contributes to 
neuronal physiology is essential in order to fully-appreciate the role of CaMKII in 
normal and diseased states. Neurodegenerative diseases such as cerebral 
ischemia destabilize CaMKII activity while inducing cellular death. It is apparent 
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that CaMKII signaling is correlated with excitotoxic neuronal death; however, 
whether CaMKII plays a causal role, rather than a correlative one, is still 
unknown. The purpose of this dissertation is to address this knowledge gap and 
solidify the role of CaMKII signaling in regulating/maintaining neuronal viability.   
I hypothesize that the large fluctuations in CaMKII activity- both the 
transient increase and prolonged inactivation observed following excitotoxic 
insult- play a causal role in the induction of neurotoxicity observed in the hours 
and days following insult. To address this, I will modulate CaMKII in the time 
surrounding excitotoxic insult to fully understand what impact overactivation of 
the kinase has on both neuronal viability and subsequent functional changes in 
CaMKII itself. Furthermore, we will also analyze the consequence of a rapid, yet 
prolonged decrease in neuronal CaMKII activity. Finally, we will examine the 
effect of CaMKII inhibition in astrocytes to identify how these cells can influence 
neuronal survival when CaMKII activity is decreased. These experiments will 
allow us to solidify a role for CaMKII activity as an important director of neuronal 
function and will highlight potential avenues for therapeutic targeting of CaMKII in 
neurodegenerative diseases.  
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PART I: EXCITOTOXIC NEUROPROTECTION AND VULNERABILITY WITH 
CAMKII INHIBITION 
SUMMARY 
Aberrant calcium signaling is a common feature of ischemia and multiple 
neurodegenerative diseases. While activation of Ca2+/CaM-dependent protein 
kinase II (CaMKII) is a key event in calcium signaling, its role in excitotoxicity is 
controversial. Our findings demonstrate neuroprotection in neuronal cultures 
treated with the small molecule (KN-93) and peptide (tat-AIP and tat-CN21) 
inhibitors of CaMKII immediately prior to excitotoxic glutamate/glycine insult. 
Unlike KN-93 which blocks CaMKII activation, but not constitutively active forms 
of CaMKII, tat-CN21 and tat-AIP significantly reduced excitotoxicity in cultured 
neurons when applied post-insult. We observed that the neuroprotective effects 
of tat-CN21 are greatest when applied before the toxic glutamate challenge and 
diminish with time, with the neuroprotection associated with CaMKII inhibition 
diminishing back to control 3 hours post glutamate insult. Mechanistically, tat-
CN21 inhibition of CaMKII resulted in an increase in CaMKII activity and the 
percentage of soluble αCaMKII observed in neuronal lysates 24 hours following 
glutamate stimulation. To address the impact of prolonged CaMKII inhibition prior 
to excitotoxic insult, neuronal cultures were treated with CaMKII inhibitors 
overnight and then subjected to a sub-maximal excitotoxic insult. In this model, 
CaMKII inhibition prior to insult exacerbated neuronal death, suggesting that a 
loss of CaMKII enhances neuronal vulnerability to glutamate. Although changes 
in αCaMKII or NR2B protein levels are not responsible for this enhanced 
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glutamate vulnerability, this process is blocked the protein translation inhibitor 
cycloheximide. Thus, the neuroprotection afforded by CaMKII inhibition can be 
seen as neuroprotective immediately surrounding the excitotoxic insult, whereas 
sustained CaMKII inhibition produced by excitotoxicity leads to neuronal death by 
enhancing neuronal vulnerability to glutamate.  
INTRODUCTION 
Finely-tuned transient increases in intracellular calcium are essential for 
neuronal development, communication and plasticity. However, dysregulated 
calcium signaling can produce neuronal death via necrotic and programmed cell 
death mechanisms (Portera-Cailliau et al., 1997, Dirnagl et al., 1999, Snider et 
al., 1999). Excitotoxicity is a hallmark of most neurodegenerative diseases; a 
process that leads to excessive accumulation of intracellular calcium via the 
over-activation of excitatory glutamate receptors. Because of its prominent role in 
neuronal calcium signaling, calcium/calmodulin-dependent protein kinase II 
(CaMKII) may contribute to excitotoxic neurodegeneration for the following 
reasons, 1) CaMKII is activated and autophosphorylated in stroke, brain trauma 
and epilepsy (Perlin et al., 1992, Churn et al., 1995, Morioka et al., 1995, 
Zalewska and Domanska-Janik, 1996), 2) the calmodulin inhibitor calmidazolium 
is a neuroprotective agent in ischemia (Pohorecki et al., 1990), and 3) ischemia 
induces CaMKII translocation (Aronowski et al., 1992, Morioka et al., 1995, 
Aronowski and Grotta, 1996, Hu et al., 1998, Dosemeci et al., 2001) and 
phosphorylation of key post-synaptic substrates (i.e. post-synaptic density) 
(Meng and Zhang, 2002, Takagi et al., 2003, Fu et al., 2004, Hao et al., 2005). 
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Previous studies using small molecule and peptide inhibitors of CaMKII such as 
KN-93 and autocamtide-2 inhibitory protein (AIP) have been shown to be 
neuroprotective when applied before an excitotoxic insult in vitro 
(Hajimohammadreza et al., 1995, Laabich and Cooper, 2000, Takano et al., 
2003, Fan et al., 2006, Goebel, 2009, Vest et al., 2010). However, because 
CaMKII also regulates substrates involved in neuronal survival (e.g. L-type 
calcium channels, CREB and BCL-2 etc.), it is also possible that inhibiting 
CaMKII may exacerbate excitotoxic neuronal death (Dash et al., 1991, Bok et al., 
2007, Wheeler et al., 2008). In support of this, an ischemic insult in αCaMKII 
knock-out mice leads to much greater neuronal death than in wild-type litter 
mates, suggesting that CaMKII activity is important for neuronal survival to 
excitotoxicity (Waxham et al., 1996).  
To date, the discrepancies found between the in vivo knock-out model and 
in situ small molecule and peptide inhibitor experiments are not understood. 
While it possible that differences could be due to model systems (genetic knock-
out versus pharmacological manipulation), the impact that both short-term and 
sustained CaMKII inhibition prior to excitotoxic insult have on neuronal survival 
has not been explored in one system concurrently. Furthermore, the small 
molecule and peptide inhibitors of CaMKII used in previous experiments have 
been shown to have a variety of off-target effectors. The family of KN-drugs has 
been shown to inhibit a variety of CaM-kinase family members as well as 
voltage-gated potassium and calcium channels (Enslen et al., 1994, Ledoux et 
al., 1999, Gao et al., 2006). AIP, which mimics the autoregulatory domain of 
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CaMKII, has also been shown to inhibit other CaM-kinase family members (Smith 
et al., 1990).  
In order to determine whether CaMKII inhibition is neuroprotective, a 
battery of CaMKII inhibitors including those presented in earlier studies (KN-93 
and AIP) as well as the highly-specific CaMKIINtide peptide inhibitor, CN21 (Vest 
et al., 2007), were applied either immediately before or after the onset of 
excitotoxic insult. KN-93, AIP, and CN21 all afforded neuroprotection when 
applied prior to the onset of an excitotoxic insult. Interestingly, only AIP and 
CN21, which inhibit the autonomous form of CaMKII (Ishida et al., 1995, Chang 
et al., 1998, Rose and Hargreaves, 2003), afforded neuroprotection when applied 
after insult. The translocation and loss of CaMKII activity observed 24 hours after 
glutamate excitotoxicity was prevented in a time-dependent manner by CaMKII 
inhibition. To examine the effect that prolonged loss of CaMKII activity has on 
neuronal sensitivity to excitotoxicity, neuronal cultures were treated with CaMKII 
inhibitors and were then subjected to a sub-maximal glutamate/glycine insult. 
Prolonged CaMKII inhibition (>8 hours) exacerbates neuronal death following an 
excitotoxic challenge; a process that requires protein synthesis. Taken together, 
these data indicate that acute inhibition of CaMKII is neuroprotective when 
applied immediately surrounding an excitotoxic insult, whereas prolonged 
inhibition enhances neuronal death to an excitotoxic challenge.  
EXPERIMENTAL PROCEDURES 
 Materials. CN21 (KRPPKLGQIGRSKRVVIEDDR), CN21c 
(GQIGRSKVVIEDDRIDDVLK), CN21Ala (KAPAKAAWAAASKRVVIEDDR), AIP 
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(RKKLRRQEAFDAL) as well as tat (YGRKKRRQRR)-conjugated peptides and 
Fam-labeled peptides were synthesized and HPLC purified by Biopeptide Co, 
Inc. San Diego, CA, USA. KN-93 and KN-92 were purchased from Calbiochem, 
EMD Biosciences, La Jolla, CA. Culture-grade glutamate, glycine, and 
cycloheximide was purchased from Sigma, St. Louis, MO.  
Embryonic cortical neuron culture. Cortical tissue from E18-E19 Sprague-Dawley 
rat pups was harvested according to approved IACUC guidelines as previously 
described (Hudmon et al., 2005) with the following modifications. Pelleted cortical 
cells were resuspended in neuronal growth media (Neurobasal media containing 
2% NuSerum (BD Biosciences, San Jose, CA), 2%NS21 (Chen et al., 2008), and 
penicillin (10 units/mL), streptomycin (10 µg/mL), and L-glutamine (29.2 µg/mL) 
at a density of 2.5 million cells/mL and seeded on poly-D-lysine (50 µg/mL) 
coated 15mm coverslips (German glass Number 0) or 60mm dishes. Forty-eight 
hours after plating, cultures are treated with 5-fluor-2’-deoxyuridine(1.5 µg/mL) 
(Sigma) and Uridine (3.5 mg/mL) to kill mitotically active cells. Neurons were fed 
every 48 hours, with half of the conditioned media replaced with fresh media.   
Immunocytochemistry of neuronal cultures. Neurons 7-8 days in vitro (DIV) were 
fixed in 4% paraformaldehyde (0.1 M phosphate buffer, pH 7.4) for 10 minutes 
and washed in phosphate buffered saline (PBS) three times. Cells were 
permeabilized in 0.5% Triton X-100 in PBS for 10 minutes at room temperature, 
washed in PBS three times, blocked for 1 hour in 2% BSA Fraction V, 20% 
normal goat serum, 0.1% Triton X-100 in PBS at room temperature, washed an 
additional three times in PBS. Cells were then incubated in primary antibodies, 
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monoclonal MAP-2 (1:1000 Sigma, St. Louis, MO), polyclonal GFAP (1:1000 
Sigma), mouse monoclonal anti-αCaMKII antibody (CBα2; 1:5000), or polyclonal 
pan CaMKII (1:1000 Cell Signaling, Danvers, MA) for 2 hours at room 
temperature. After three washes, secondary antibodies (goat anti-mouse 
DyLight800, 1:5000 or anti-rabbit Alexa594, 1:5000 (Molecular Probes, Eugene, 
OR)) were incubated PBS for one hour at room temperature. Coverslips were 
mounted in Prolong Gold Antifade with DAPI mounting media (Molecular Probes) 
and neurons imaged using a Nikon Ti-E inverted microscope. 
Excitotoxic stimulation. Neurons (7-8 or 14 DIV) were stimulated with varying 
amounts of glutamate/glycine as described in results. The standard excitotoxic 
condition used was 200 µM glutamate/20 µM glycine for 1 hour at 37oC. Half of 
the conditioned media is removed and fresh growth media containing 2x 
glutamate/glycine is added to each dish. Peptide inhibitors were diluted in fresh 
neuronal growth media from a 10 mM stock. When pretreatment with inhibitors is 
performed, media containing 2x peptide was added and allowed to incubate at 
37oC for 20 minutes at concentrations described in results. Half of this media is 
removed and stimulation media containing 2x glutamate/glycine supplemented 
with 1x peptide is then added for stimulation. When inhibitors are added during 
the excitotoxic insult, half of the excitation media is removed and fresh neuronal 
growth media containing 1x glutamate/glycine and 2x peptide is added. For 
application of peptide following the excitotoxic insult, stimulation media was 
washed and replaced with fresh neuronal growth media. At the time of 
application, half of this media is removed and 2x peptide is added for 1 hours at 
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37oC. Following all treatments, stimulation media is washed with fresh neuronal 
growth media three times. Half of the media is removed and conditioned media is 
added back to the wells at the end of stimulation or drug treatment. Cultures are 
incubated at 37oC 24 hours following stimulation. Manipulation of the neuronal 
cultures (multiple washes consistent with experimental manipulations) produces 
roughly 10-20% cell death compared to the percentage of dying cells measured 
in the absence of manipulation.  
Cell death assay. Twenty-four hours following glutamate/glycine stimulation, the 
coverslips were washed in PBS and stained using Live/Dead Cytotoxicity/Viability 
kit (Molecular Probes, Eugene, OR). Coverslips are incubated as directed by the 
manufacturer for 40 mins at room temperature, washed in PBS and immediately 
imaged on Nikon Ti-E inverted microscope (100x magnification). Each coverslip 
is imaged in three different fields using a Texas Red filter to detect cytotoxic cells 
and a FITC filter to detect viable cells. Cells were quantified using the automated 
counting software Nikon Elements 3.0. A threshold of cytotoxic nuclei was set to 
>20 µm2, as determined with DAPI co-staining. A viability threshold was set at 
>50 µm2, and anything smaller was disregarded as debris. Total cell number was 
determined by addition of cytotoxic and viable cells. Total cell number was not 
significantly different between experimental groups for each assay. Propidium 
iodide was also applied for a series of experiments to determine the rate of 
excitotoxic neuronal injury. Co-staining with DAPI allowed for the calculation of 
total cell number in these experiments. In some assays, cell death is normalized 
to excitotoxic stimulation control as indicated. 
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CaMKII activity assay. Recombinant αCaMKII was expressed in insect cells 
using baculovirus and purified as described previously (Bradshaw et al., 2002). 
CaMKII (25ngs) was incubated with 50 mM Hepes pH 7.4, 100 mM NaCl, 10 mM 
MgCl2, 100 µM ATP, 2 mM CaCl2, 5 µM CaM, 50 µM Syntide2 
(PLARTLSVAGLPGKK), and [γP32 ]-ATP (3 µCi per reaction) for 1 minute at 
30oC. The solution was then transferred to P81 filter papers (Whatman, GE 
Healthcare, Piscataway, NJ), washed with 75 mM phosphoric acid 3 times for 5 
minutes each, and counted in Beckman Beta Counter as described previously 
(Hudmon et al., 1996). The purified CaMKII routinely had a specific activity of 4-
15 µmols/min/mg. For activity assays performed with neuronal lysates, cells were 
lysed in lysis buffer containing ( 50 mM Hepes pH 7.4, 4 mM EGTA, 10 mM 
EDTA, 15 mM Na4P2O7-10H20, 100 mM β-glycerophosphate, 25 mM NaF, and 
protease inhibitor cocktail (#539137,Calbiochem)(Kolb et al., 1995)), sonicated, 
and incubated with 50 mM Hepes pH 7.4, 100 mM NaCl, 10 mM MgCl2, 100 µM 
ATP, 2 mM CaCl2, 5 µM CaM, 50 µM AC2 (KKALRRQETVDAL), and [γP32 ]-ATP 
(3 µCi per reaction) for 3 minutes at 30oC. Preliminary experiments indicated the 
linear range of the reaction extended from 30 seconds to 4 minutes. Protein 
levels were assessed and activity was normalized to total protein using a DC 
protein assay kit (Biorad, Hercules, CA).  
Peptide SPOTS arrays. Peptide arrays are constructed using the SPOTS-
synthesis method (Frank and Overwin, 1996, Frank, 2002). Standard 9-
fluorenylmethoxy carbonyl (Fmoc) chemistry is used to synthesize peptides on 
cellulose membranes prederivatized with a polyethylene glycerol spacer (Intavis 
59 
 
AG, Cologne, Germany). Fmoc protected and activated amino acids (Anaspec, 
Fremont, CA) are spotted in 20x30 arrays on 150 mm by 100 mm cellulose 
membranes using an Intavis robot (Intavis AG, Cologne, Germany). Peptides 
consist of CN21c (GQIGRSKVVIEDDRIDDVLK) and CN21Ala 
(KAPAKAAWAAASKRVVIEDDR) as well as a scanning mutagenesis (stepwise 
single amino acid replacement) of CN21 (KRPPKLGQIGRSKRVVIEDDR) with 
alanine. The ethanol dried membrane was stained in 0.1% bromophenol blue, 
washed, ethanol dried, and labeled for annotation. After imaging, the blot was 
deprotected in a solution of 49.9% trifluoroacetic acid, 49.9% dichloromethane, 
0.03% triisopropylsilane, and 0.02% water for one hour at room temperature. 
Followed by 4 X 25 mL washes with dichloromethane, 4 X 25 mL washes with 
dimethylformamide, and 2 X 25 mL washes with ethanol. The peptide membrane 
is blocked at room temperature for 1 hour in binding buffer (20 mM Tris, pH 7.4, 
200 mM NaCl, 1 mM EDTA, and 0.1% Tween-20) plus 5% BSA. Alexa800-labeled 
CaMKII is activated in a pre-reaction mixture as described previously (Hudmon et 
al., 1996). Autophosphorylated CaMKII was diluted in binding buffer plus 1% 
BSA and added to the membrane for 5 minutes at room temperature. After 5 
minutes, the blot was washed 3 times in binding buffer for 5 minutes each. 
CaMKII binding is visualized using a Licor imaging station. Intensity of binding is 
analyzed using Odyssey v1.2. CaMKII binding to blank areas (non-peptide 
containing spots) of the membrane were used to normalize for background and 
non-specific binding of CaMKII.   
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Measuring CaMKII translocation. Neurons were lysed in lysis Buffer (see above), 
sonicated, and protein concentration was quantified. Equal protein levels were 
centrifuged for 30 mins, 4 degrees, 15,000xg. The supernatant and pellet were 
resuspended in LDS/BME (final volume 250 μLs for all samples) and SDS-PAGE 
separation was performed. Western blotting was done using primary monoclonal 
αCaMKII (CBα2 1:1000) and βCaMKII (CBβ1 1:1000) antibodies followed by 
secondary DyLight800-labeled antibody. Immunostaining was quantified using a 
Licor imaging station and Odyssey v1.2 was used for analysis.  
Anisotropy. Fluorescent anisotropy was monitored in real-time using an AB-2 
fluorimeter with a λexcitation of 500 nm, λemission of 525 nm, and slit widths of 4 nm. 
An increase in anisotropic value indicates binding to the fluorescent-labeled 
NR2B peptide (Fam-MKAQKKNRNKLRRQHSYDTFDVDL). Baseline was 
attained for 30 seconds with anisotropy buffer (50 mM Tris pH 7.6 and 100 mM 
KCL), 100 nM Fam-NR2B, 10 mM MgCl2, 1 mM ADP, 5 µM CaM, and 2 mM 
CaCl2 (+/- inhibitor peptide), 1 µg purified αCaMKII was added, and 30 seconds 
later 5 mM EGTA was added to induce CaM-dissociation and reverse peptide 
binding.  
Immunoblotting. Neurons were lysed in lysis buffer (see above), sonicated, and 
protein concentration was determined using a DC kit (Biorad). Protein lysate 
levels were normalized and suspended in LDS-PAGE buffer (Invitrogen). 
Monoclonal αCaMKII (1:1000), monoclonal NR2B (1:1000), and monoclonal 
GAPDH (1:1000) antibodies were used along with secondary goat anti-mouse 
DyLight800-labeled and goat anti-rabbit Alexa680-labeled (1:10,000) antibodies. 
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Detection and quantification were peformed using a Licor imaging station 
(Odyssey v1.2).   
Fluorescent uptake assays. tat-CN21-Fam (KRPPKLGQIGRSKRVVIEDDR–
Fam) and tat-CN21Ala-Fam (KAPAKAAWAAASKRVVIEDDR –Fam) peptides 
were diluted in fresh neuronal growth media and applied at a final concentration 
of 10 µM for varying lengths of time to 96-well plates containing neurons 7-8 DIV. 
After treatment, neurons were washed with PBS 3 times, all media was removed 
and WallacV3 microplate reader used to detect total fluorescence in each well. 
Fam-labeled peptides were only used to examine uptake.   
Data analysis. One-way ANOVA with a subsequent Dunnett’s Test was 
conducted to compare differences between the means of each group (p<0.05, 
SEM) in all in situ cell death assays as well as many in vitro catalytic assays. 
Student t-test was also used when appropriate. Statistical analyses were 
performed using SigmaPlot 11 and statistical significance was accepted at 
p<0.05. 
RESULTS 
Characterization of Neuronal Cultures and Their Death Following 
Glutamate-Glycine Application in Cortical Neurons 
After 7-8 days in vitro (DIV), 97% of the cultured cortical cells are MAP2 
positive. Less than 2% of the remaining cells stained with the astrocyte marker 
GFAP, indicating that these cultures are predominantly neurons (Figure 5A-5B). 
Over 90% of the cultured cells were also CaMKII positive, as detected by both a 
monoclonal αCaMKII and polyclonal pan-CaMKII antibody (Figure 5B). Neuronal 
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viability was assessed using a differential calcein-AM (FITC green) to label vital 
cells and ethidium homodimer to label cytotoxic cells (Texas Red) (Figure 5C-D). 
Dose-dependent applications of glutamate/glycine indicated that 200 μM 
glutamate/20 μM glycine for one hour at 37oC is sufficient to induce maximal 
cytotoxicity (Figure 5E). Time-dependent application of 200 μM glutamate/20 μM 
glycine indicated that maximal death is achieved by one hour of stimulation 
(Figure 6A). Under these conditions, neuronal death did not exceed 40%-50% of 
total cell number. The inability to kill 100% of neurons in culture may be attributed 
the composition of NMDA receptors and the subsequent sensitivity of the NMDA 
receptors at this stage of neuronal development (Sinor et al., 2000). For 
normalization, cell death is expressed as a percentage of the maximal death 
observed 24 hrs following 200 μM glutamate/20 μM glycine for one hour, unless 
noted otherwise. Pre-treatment with 20 µM MK-801, an NMDA-receptor 
antagonist, completely prevents glutamate/glycine excitoxicity in this assay, 
indicative of classical NMDA-dependent excitotoxicity (Figure 5E inset). 
Morphologically, the neurons appear in brightfield as round and  
swollen immediately following glutamate/glycine treatment and visible 
degeneration of neuronal processes is observed within 4 hours (data not shown). 
A time course of propidium iodide staining indicated that by 4 hours following 
glutamate/glycine insult, 40-50% of cells have compromised membranes (Figure 
6B). Similarly, 40-50% of cells are cytotoxic 24 hours following stimulation, as 
detected by LIVE/DEAD staining. Consistent with necrotic death, cycloheximide 
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Figure 5: Glutamate-glycine induced excitotoxicity in cortical neuron 
cultures. A, Primary cortical neurons 7 DIV, stained with MAP-2 (green), 
GFAP (red), DAPI (blue). B, Average number of cells (±SD, n=3) stained 
for the neuronal marker (MAP-2), astrocyte marker (GFAP), αCaMKII, and 
pan-CaMKII at 7 DIV. C-D, Representative images of control cultures, C, 
and cultures treated with 200 μM glutamate/20 μM glycine for one hour, D, 
stained with LIVE/DEAD Viability/Cytotoxicity kit (Molecular probes) 24 
hours following treatment. This differentially stains viable cells (green) and 
cytotoxic cells (red). E, Average cell death (normalized to maximal death, 
±SEM, n=5-8) in control cultures and cultures treated with varying 
concentrations of glutamate. Inset, average cell death (±SEM, n=5-8) in 
control cultures, cultures stimulated with 200 μM glutamate/20 μM glycine, 
and cultures pretreated with 20 μM MK-801 followed by glutamate 
stimulation (*p<0.05; One-way ANOVA, post-hoc Dunnett’s test). 
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Figure 6: Characterization of glutamate/glycine induced excitotoxicity 
in 7-8 DIV cortical neurons. A, Average cell death (±SEM; n=5-12) with 
application of 200 µM glutamate/ 20 µM glycine for varying amounts of 
time as measured by Live/Dead Cytotoxicity/Viability kit. B, Average 
percentage of cells (±SEM; n=4-5) labeled with propidium iodide at varying 
times following 200 µM glutamate/20 µM glycine stimulation for 1 hour. The 
asterisk indicates a significant difference compared to control, no 
stimulation (*p<0.05; One-way ANOVA, post-hoc Dunnett’s test). C, 
Average cell death (±SEM, n=5) following glutamate stimulation with and 
without co-treatment with 0.5 mg/mL cycloheximide as measured by 
Live/Dead Cytotoxicity/Viability kit (*p<0.05; One-way ANOVA, post-hoc 
Dunnett’s test). 
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pretreatment did not prevent glutamate/glycine-triggered neuronal death (Figure 
6C) (Deshpande et al., 1992, Lipton, 1999, Bredesen, 2007).  
Validation of CaMKII Inhibitors and Controls 
The role of CaMKII in neuronal excitotoxicity was characterized using 
small molecule and peptide inhibitors. KN-93 is a membrane-permeable small 
molecule that inhibits CaMKII activation with a Ki of 370 nM (Sumi et al., 1991). A 
peptide derived from the autoregulatory domain of CaMKII, termed AIP, has also 
been established as a highly-potent CaMKII inhibitor with an IC50 of 40 nM 
(Ishida et al., 1995). However, like the KN-family of inhibitors, AIP has also been 
shown to inhibit multiple members of the CaM-kinase family (Smith et al., 1990, 
Enslen et al., 1994). We also examined the potential of peptides derived from the 
endogenous CaMKII inhibitor, CaMKII-Ntide (Chang et al., 1998). The 21 amino 
acid version of CaMKII-Ntide, termed CN21, has an IC50 of 100 nM (Vest et al., 
2007). A control for CN21, termed CN21c, had also been previously established 
(Vest et al., 2007). CN21c is a 21 amino acid peptide that was produced by a C-
terminal shift of 5 residues from the CN21 peptide on the CaMKIIN protein. In 
order to import these peptides into cells, we fused the cellular import sequence 
from Tat (tat) to the N-terminus of the CN21 peptide, as described previously 
(Vest et al., 2007), as well as the control CN21c peptide and the AIP peptide. We 
first verified the effects of the unconjugated and tat-conjugated CN21 and control 
CN21c in an in vitro CaMKII activity assay. Unconjugated tat alone did not have a 
significant impact on CaMKII (Figure 7A). Consistent with previous literature 
(Vest et al., 2007), CN21 effectively inhibited CaMKII phosphorylation of 
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Syntide2, a known substrate of CaMKII, in our in vitro catalytic assay (Figure 7A). 
Similarly, tat-CN21 also inhibited phosphorylation of Syntide2 (Figure 7A). 
CaMKII was not inhibited with unconjugated control CN21c, consistent the 
previous report (Vest et al., 2007). Surprisingly, unlike unconjugated CN21c, tat-
CN21c significantly reduced CaMKII activity by 80% compared to control (Figure 
7A). A full dose-response curve shows that while tat-CN21 exhibited a lower IC50 
of CaMKII inhibition (0.0772 ± 0.012 µM), tat-CN21c also inhibited CaMKII 
activity at low doses, IC50 2.5574 ± .138 µM (Figure 7B). Sequence analysis of 
CN21, CN21c and tat-CN21c indicated that the addition of the highly charged tat 
sequence restores 3 of the 5 residues removed in the development of CN21c 
(Figure 7C). In support of this observation, addition of the tat motif resulted in an 
increase in CaMKII binding to immobilized peptides of CN21c (Figure 8A). Thus, 
when CN21c is conjugated to tat, the highly-charged cell-penetrant motif partially 
restores inhibitory efficacy.  
To develop a new control peptide for CN21, alanine (Ala) scanning 
mutagenesis was performed on the CN21 sequence to examine the impact that 
changes in amino acid size, charge and hydrophobicity has on CaMKII/CN21 
interaction. Activated Alexa800-labeled CaMKII was used to measure CaMKII 
binding to the immobilized peptide array (Figure 7D). The binding intensity of 
each peptide spot was compared to wild-type peptide; variance for the wild-type 
CN21 (n=3) is shown for comparison (black bar in Figure 7E). Analysis of the 
Alanine (Ala) scanning indicated seven residues in CN21 (Arg2, Pro4, Leu6, 
Gly7, Iso9, Gly10, Arg11) that reduced CaMKII binding by >40% (Figure 7E, 
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Figure 7: Effects of tat-conjugated inhibitory and control peptides on 
CaMKII substrate phosphorylation and identification of critical amino 
acids in CN21 required for CaMKII binding. A, Effects of 10 µM 
unconjugated and tat-conjugated inhibitory peptide CN21 as well as control 
CN21c on CaMKII phosphorylation of Syntide2 (±SD; n=3; *p<0.05; One-
way ANOVA, post-hoc Dunnett’s test). B, Dose-responses for tat-CN21 
and tat-CN21c inhibition of CaMKII phosphorylation of Syntide2 (±SD; 
n=3). C, Clustal alignment of CN21, CN21c, and tat-CN21c. * indicates 
identical residues and : indicates conserved residues. D, Image of 
Alexa800-labeled CaMKII bound to an immobilized peptide array of the 
CN21 peptide (wild-type) followed by Alanine (Ala) scanning. E, 
Quantification of Alexa800-labeled CaMKII binding to CN21 and Ala 
mutants. The hatched bars represents residues with greater than 40 
percent reduction of CaMKII binding when mutated, compared to wild-type 
(black bar). * indicates residues that were replaced to Ala in the CN21Ala 
control peptide. F, CaMKII phosphorylation of Syntide2 in the presence of 
control (DMSO), tat, or tat-CN21Ala (±SD; n=3; *p<0.05; One-way ANOVA, 
post-hoc Dunnett’s test).  
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Figure 8: Characterization of tat-CN21, tat-CN21c and tat-CN21Ala 
binding to CaMKII. A, Image (top) of Alexa800-labeled CaMKII bound to an 
immobilized peptide array containing CN21c, the first ten residues of 
CN21c (10merCN21c), and tat-10merCN21c, as indicated above. Bar 
graph indicates quantification of average fluorescent intensity (±SD; n=6). 
The asterisk indicates significant difference compared to CN21c (*p<0.05; 
One-way ANOVA, post-hoc Dunnett’s test). B, Average fluorescent 
intensity (±SD; n=5) of Alexa800-labeled CaMKII binding to immobilized 
CN21 or CN21Ala (*p<0.05; t-test). C, Fluorescent anisotropy of Fam-
NR2Bs binding to CaMKII in real time in the presence and absence of 10 
µM tat-CN21 and tat-CN21Ala. Baseline was determined (0-30 seconds) in 
the presence of Mg2+/ATP and Ca2+/CaM. 1 µg CaMKII was added (30-60 
seconds) and the binding reaction was reversed with the addition of 5 mM 
EGTA (60-90 seconds). D, Average changes in anisotropic value (±SD; 
n=3) from Supplemental Figure 2C. The asterisk indicates significant 
difference compared to control (*p<0.05, One-way ANOVA, post-hoc 
Dunnett’s test). 
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hatched boxes). Additional scanning with residues that would add variations in 
residue charge (Aspartate) and size/hydrophobicity (Phenylalanine) also 
indicated that mutation of these seven residues blocked CaMKII binding (data not 
shown). In development of the CN21c, Bayer and colleagues reported that 
multiple residues on the C-terminus of CN21 may also be important for binding to 
CaMKII (Vest et al., 2007). Our data indicate that the large pocket of charged 
amino acids in the C-terminus of CN21 (Glu-Asp-Asp-Arg) cannot be disrupted 
using single Ala replacements. A recent crystal structure of CN21 bound to 
CaMKII (PDB#3KL8) revealed that many of the residues identified by our 
biochemical/functional approach are in the appropriate orientation and position to 
interact with the catalytic surface of CaMKII (Chao et al., 2010). Accordingly, a 
new peptide containing Ala replacement of multiple key residues (Arg2Ala, 
Pro4Ala, Leu6Ala, Gly7Ala, Iso9Ala, Gly10Ala, Arg11Ala- marked with an 
asterisk in 7E) was synthesized and termed CN21Ala. CN21Ala reduced CaMKII 
binding to ~5% of wild-type CN21 (Figure 8B).  
We then tested whether tat-CN21Ala inhibited CaMKII substrate 
phosphorylation in an in vitro kinase assay. Unlike, tat-CN21c, tat-CN21Ala did 
not significantly decrease CaMKII activity under similar conditions (Figure 7F). 
Similarly, tat-CN21, and not tat-CN21Ala, inhibited CaMKII binding to a peptide 
derived from the NMDA-receptor subunit, a known targeting substrate (Figure 
8C-D). To verify that tat-CN21 and tat-CN21Ala were both taken up to a similar 
extent by neurons, we generated a C-terminal carboxyfluorescein-tagged (Fam) 
version of both peptides (termed tat-CN21-Fam and tat-CN21Ala-Fam) and 
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measured fluorescent uptake in a fluorescent microplate reader (Figure 8). 
Fluorescent labeling could be detected as early as 2 minutes and was maximal 
by 20 minutes in both tat-CN21-Fam and tat-CN21Ala-Fam groups (Figure 8), 
with no significant difference in peptide uptake detected.  
Pretreatment with CaMKII Inhibitors Affords Neuroprotection from 
Excitotoxicity 
We next examined if inhibition of CaMKII with tat-CN21 application prior to 
an excitotoxic insult is neuroprotective. Because uptake of tat-conjugated 
peptides was maximal by 20 minutes (Figure 9), neuronal cultures were pre-
treated with varying doses of tat-CN21 for 20 minutes before application of 
glutamate/glycine (200 μM glutamate/20 μM glycine at 37oC for one hour). tat-
CN21 afforded neuroprotection from the excitotoxic insult in a dose-dependent 
manner. The dose-response curve revealed that the optimal concentration of tat-
CN21 for neuroprotection is approximately 2-10 µM (Figure 10A). Doses 
exceeding 10 µM were less efficacious, which may be attributed to inhibition of 
CaMKIV with high levels of tat-CN21 (Vest et al., 2007). We also examined cell 
death levels 48 hours following insult to see if cultures treated with tat-CN21 
exhibited delayed degeneration compared to control cultures. Yet, even 48 hours 
later, neurotoxicity levels were no different than control (Figure 11A). Having 
determined that tat-CN21 is neuroprotective, we examined the impact of 
pretreatment with control peptides, tat-AIP, and the KN-drugs. Consistent with 
previous studies (Vaslin et al., 2009), 10 µM unconjugated tat provides slight, yet 
significant neuroprotection from excitotoxicity (Figure 10B). tat-CN21Ala (10 µM ) 
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Figure 9: Characterization of tat-CN21-Fam and tat-CN21Ala-Fam 
uptake in neurons. Average fluorescent uptake (±SD; n=3) was measured 
using Wallac3V multiplate reader following incubations with 10 µM tat-
CN21-Fam or tat-CN21Ala-Fam for varying times (0-25 minutes). The 
asterisk indicates significant difference compared to tat-CN21Ala-Fam 
(*p<0.05; t-test). 
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Figure 10: Neuroprotection from excitotoxicity using CaMKII 
inhibitors. A, Average cell death (±SEM; n=6-10) with application of 
varying concentrations of tat-CN21 prior to stimulation. Death is normalized 
to glutamate/glycine stimulation. The asterisk indicates significant 
difference compared to control, 0 µM (*p<0.05; One-way ANOVA, post-hoc 
Dunnett’s test). B, Average cell death (±SEM; n=7-14) 24 hours following 
glutamate/glycine stimulation with and without pretreatment with various 
CaMKII inhibitors, as indicated. Death is normalized to glutamate/glycine 
stimulation. Experimental groups were treated with 10 µM tat-CN21, tat-
CN21Ala, tat, and tat-AIP, as well as 1 µM KN-93 and KN-92. The pound 
symbol indicates significant difference compared to glutamate/glycine 
stimulation (#p<0.05, One-way ANOVA, post-hoc Dunnett’s test). The 
asterisk indicates significant difference compared to non-stimulated control 
(*p<0.05; One-way ANOVA, post-hoc Dunnett’s test).  
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Figure 11: tat-CN21 neuroprotection at 14 DIV and 48 hours following 
stimulation. A, Average cell death (±SEM, n=4-5) in neuronal cultures 24 
hours (gray bars) and 48 hours (white bars) following treatment as 
indicated. The asterisk indicates significant difference compared to the 
control of that time-point (*p<0.05, One-way ANOVA, post-hoc Dunnett’s 
test). B, Average cell death (±SEM, n=4) in 14 DIV cortical cultures 
exposed to glutamate stimulation with/without 10 µM tat-CN21 or 10 µM 
control tat-CN21Ala. The asterisk indicates significant difference compared 
to non-stimulated control. (*p<0.05, One-way ANOVA, post-hoc Dunnett’s 
test).  
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did not afford neuroprotection beyond that observed with unconjugated tat 
indicating that unlike tat-CN21, tat-CN21Ala is not neuroprotective (Figure 10B). 
The neuroprotective property of tat-CN21 pretreatment was also examined in 
older cultures (14 DIV). Despite an increase in excitotoxic vulnerability, neuronal 
cultures treated with tat-CN21, and not tat-CN21Ala, exhibited significantly 
reduced cell death, bringing cellular toxicity back to control levels (Figure 11B). 
Consistent with the in vitro kinase assay, tat-CN21c which maintained CaMKII 
inhibitory potency, also significantly reduced glutamate/glycine stimulated 
neuronal death to control levels (data not shown). Similar to tat-CN21, 
pretreatment with 10 µM tat-AIP completely abolished glutamate/glycine-induced 
excitotoxic neuronal death (Figure 10B). Pretreatment with 1 µM KN-93 
significantly decreases neuronal death when applied 20 minutes prior to 
glutamate/glycine stimulation (Figure 10B). Unexpectedly, the inactive analog 
KN-92 also reduced glutamate/glycine toxicity in this assay (Figure 10B), which 
may be consistent with off-target effects previously ascribed (Enslen et al., 1994, 
Ledoux et al., 1999, Gao et al., 2006). Peptide inhibitors AIP and CN21 were also 
tethered to another cell-penetrating motif, antennepedia. However, these 
peptides proved to be toxic when applied for 80 minutes (time of pretreatment 
and stimulation) and were omitted from further use (data not shown).  
CaMKII inhibitors Afford Neuroprotection when Applied Following an 
Excitotoxic Insult 
CaMKII undergoes an autophosphorylation reaction that bestows a unique 
form of activity (i.e. autonomous) that no longer requires its activator, 
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calcium/CaM (Saitoh and Schwartz, 1985, Miller and Kennedy, 1986). Thus, 
sustained intracellular calcium potentiates CaMKII signaling to support both 
aberrant phosphorylation of CaMKII substrates as well as autonomous activity, 
which together may be detrimental to neuronal survival. Although CN21 is not a 
potent inhibitor of autophosphorylation (Vest et al., 2007), it does inhibit activity of 
both the calcium/CaM dependent and autonomous forms of CaMKII (Chang et 
al., 1998). In contrast, the KN-family of drugs (KN-62 and KN-93) only blocks 
CaMKII activation and therefore does not inhibit CaMKII autonomous activity 
(Sumi et al., 1991). Thus, we hypothesized that KN-93 would not be 
neuroprotective when applied after an excitotoxic insult, whereas CN21 would be 
neuroprotective after the insult. Application of tat-CN21 at different time points 
during or after the glutamate/glycine challenge (Figure 12A) revealed a 
significant decrease in cell death even when applied 2 hours following the 
excitotoxic insult (Figure 12B). However, the protection afforded by tat-CN21 
under these conditions was lost when applied 3 hours after the onset of the 
excitotoxic insult. Although KN-93 pre-treatment is neuroprotective (Figure 10B), 
application of this drug one hour after the excitotoxic insult is not (Figure 12B) as 
cell death levels were equal to the glutamate/glycine challenge in the absence of 
any inhibitors. Like tat-CN21, tat-AIP, which also inhibits CaMKII in the presence     
or absence of calcium/calmodulin (Ishida et al., 1995, Rose and Hargreaves, 
2003), was also neuroprotective when applied one hour after the excitotoxic 
insult (Figure 12B). The levels of tat-CN21 and tat-AIP neuroprotection seen at 
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Figure 12: Time-dependent neuroprotection of tat-CN21 from 
excitotoxicity. A, Schematic timeline of inhibitor application and glutamate 
stimulation. B, Average cell death (±SEM; n=10-14) with varying time-
points of 10 µM tat-CN21 application as well as 1 µM KN-93 and 10 µM tat-
AIP at one hour following stimulation. All inhibitors were applied for one 
hour. The asterisk indicates significant difference compared to stimulation 
control (*p<0.05; One-way ANOVA, post-hoc Dunnett’s test). C, Average 
CaMKII activity (±SD; n=3) in neuronal lysates 24 hours following 
glutamate stimulation and application of 10 µM tat-CN21 at various time-
points after glutamate application. Activity was first normalized for equal 
protein amounts and then normalized to control, or non-treated cultures. 
The asterisk indicates significant difference compared to control, while the 
pound sign indicates significant difference compared to stimulation 
(*#p<0.05; One-way ANOVA, post-hoc Dunnett’s test). D, Western blots 
(top) of αCaMKII and βCaMKII in the supernatant (S) and particulate (P) 
fractions 24 hours following stimulation and application of 10 µM tat-CN21 
at various time points. Summary data (bottom) for particulate aMKII (±SD; 
n=3). The asterisk indicates a significant difference compared to control 
while the pound sign indicates a significant difference compared to 
stimulation (*#p<0.05, One-way ANOVA, post-hoc Dunnett’s test).  
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one hour were not significantly different (t-test, *p>0.05). Thus, only inhibitors of 
activated CaMKII are neuroprotective following an excitotoxic glutamate insult.  
Following cerebral ischemia, CaMKII has been shown to undergo periods 
of prolonged inactivation and the length of CaMKII inactivation has been 
correlated with extent neuronal death (Hanson et al., 1994). Therefore, we 
examined CaMKII activity within our neuronal cultures 24 hours after excitotoxic 
insult when tat-CN21 was applied at various points before and after the onset of 
stimulation. As expected, CaMKII activity was reduced 70% in stimulated cultures 
compared to control cultures (Figure 12C). However, CaMKII activity was 
significantly higher in cultures that tat-CN21 was applied to before and after the 
onset of insult. A time-dependent decrease in CaMKII activity correlates with the 
time-dependent increase in neuronal death (Figure 12B-C). Translocation of 
CaMKII from the supernatant to the particulate fraction is one key event that may 
result in prolonged inactivation of the kinase, a process that has been shown to 
occur under excitotoxic conditions (Aronowski et al., 1992, Kolb et al., 1995, 
Hudmon et al., 1996, Tao-Cheng et al., 2002) and may be due to self-association 
(Hudmon et al., 1996, Dosemeci et al., 2000, Hudmon et al., 2005). We 
hypothesized that tat-CN21 application was able to avert the induction of 
prolonged CaMKII inactivation, by preventing translocation of CaMKII. Compared 
to control conditions, glutamate stimulated cultures exhibited significantly more 
αCaMKII in the particulate fraction 24 hours following treatment (Figure 12D). At 
this stage of neuronal development, βCaMKII expression is predicted to be 
higher than αCaMKII (Burgin et al., 1990b, Fink et al., 2003); however, there was 
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no statistical change in levels of βCaMKII in the supernatant or particulate 
fractions (quantification not shown). Application of tat-CN21 prior to stimulation 
as well as up to 30 minutes after the onset of stimulation resulted in a significant 
decrease in the amount of αCaMKII found in the sedimentable, pelleted fraction 
(Figure 12D). Importantly, despite changes in activity and transitions to the 
particulate fraction, total αCaMKII levels were not changed in any treatment 
group (Figure 13). Thus, tat-CN21 decreased the levels of αCaMKII translocation 
and CaMKII inactivation. Together, this suggests that while inhibition of the 
transient increase in CaMKII activity may be neuroprotective, preventing a long-
term loss of activity is also beneficial for neuronal viability.  
CaMKII inhibition Predisposes Neurons to Excitotoxicity 
While small molecule and peptide inhibitors have neuroprotective effects 
when applied immediately surrounding the excitotoxic insult, knock-out studies 
indicated that the loss of αCaMKII resulted in increased infarct size following 
arterial occlusion in knock-out animals compared to wild-type littermates 
(Waxham et al., 1996). Thus, a loss of CaMKII predisposed neurons to ischemic 
death. This, along with the correlation between the levels of activatable CaMKII 
and neuronal viability, led us examine what impact prolonged loss of CaMKII 
prior to an excitotoxic insult has on neuronal survival. Treatment with a sub-
maximal excitotoxic insult (200 µM glutamate/20 µM glycine for 15 minutes) 
resulted in approximately 18% cell death after 48 hours (Figure 14B). Application 
of tat-CN21 for 24 hours, followed by wash and then further incubation for 24 
hours resulted in approximately 18% cell death (Figure 14B). Combination of 
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Figure 13: tat-CN21 application following onset of excitotoxic insult 
does not affect αCaMKII protein levels. A, Western blots of αCaMKII 
and loading control GAPDH in neuronal lysates 24 hours following 
stimulation with application of 10 µM tat-CN21 at various time-points 
surrounding glutamate/glycine stimulation. B, Summary data for 
normalized protein levels of αCaMKII quantified and plotted relative to 
GAPDH control (p>0.05, One-way ANOVA). 
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prolonged tat-CN21 application (24 hours) followed by sub-maximal 
glutamate/glycine stimulation synergistically increased neuronal toxicity to >50% 
which was significantly higher than glutamate/glycine alone or tat-CN21 
treatment alone (Figure 14B). This exacerbation of neuronal death was not seen 
in cultures treated with control tat-CN21Ala for 24 hours prior to 
glutamate/glycine stimulation (Figure 14B). Interestingly, the application of sub-
maximal glutamate followed by tat-CN21 overnight enhanced death compared to 
either treatment alone (Figure 14B), suggesting that CaMKII activity may be 
important for neuronal survival following excitotoxic insult.  
The time-frame in which CaMKII inhibition prior to excitotoxic insult 
predisposes cells to excitotoxicity was examined by applying tat-CN21 for varying 
lengths of time prior to insult. Interestingly inhibition for 4 hours or less had no 
impact on neuronal sensitivity to glutamate (Figure 14C). However, tat-CN21 
application for 8 or more hours resulted in a significant increase in neuronal 
death compared to glutamate/glycine stimulation alone (Figure 14C). Because 
this time frame would allow for potential changes in protein translation, we co-
applied cycloheximide with tat-CN21. This co-treatment prior to stimulation 
significantly reduced neurotoxicity levels compared to 24 hour tat-CN21 alone 
(Figure 14D). This suggests that protein translation plays a key role in the switch 
to increased glutamate sensitivity. We examined the levels of CaMKII and the 
NR2B subunit of the NMDA receptor to determine whether these key players are 
upregulated following prolonged CaMKII inhibition, however there was no change 
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Figure 14: tat-CN21 enhances neuronal vulnerability to excitotoxicity. 
A, Schematic indicating treatment protocols (A-E) used to characterize the 
effect of prolonged CaMKII inhibition prior to and before a sub-maximal 
glutamate stimulation (200 µM glutamate/glycine for 15 mins signified by 
black box E). B, Average cell death (±SEM; n=5-10) of neuronal cultures 
treated with tat-CN21 and tat-CN21Ala overnight before or after a sub-
maximal glutamate/glycine insult, (A-E). The asterisk indicates significant 
difference compared to tat-CN21 treatment alone (*p<0.05, One-Way 
ANOVA, post-hoc Dunnett’s test). The pound sign indicates significant 
difference between tat-CN21/glutamate vs glutamate/tat-CN21 (#p<0.05, t-
test). C, Average cell death (±SEM, n=5-6) in cultures exposed to 10 µM tat-
CN21 for varying amounts of time prior to a submaximal glutamate/glyine 
stimulation. Cell death is visualized 24 hours following stimulation. The 
asterisk indicates significant difference compared to control cultures (0 
hours) which received submaximal stimulation alone with no inhibitor 
application. (*p<0.05, One-way ANOVA, post-hoc Dunnett’s test). D, 
Average cell death (±SEM, n=5-6) in cultures exposed to 0.5mg/mL 
cycloheximide, 10 µM tat-CN21, or co-treatment with both 24 hours prior to 
submaximal stimulation. Cell death is visualized 24 hours following 
glutamate/glycine stimulation. The asterisk indicates significant difference 
compared to control while the pound sign indicates significant difference 
between co-treatment and tat-CN21 treatment alone. (*p<0.05, One-way 
ANOVA, post-hoc Dunnett’s test; #p<0.05, t-test). 
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in the levels of either protein (Figure 15). The protein(s) responsible for this 
switch have yet to be determined. 
DISCUSSION 
Aberrant release of the excitatory neurotransmitter L-glutamate has long 
been hypothesized to contribute to neuronal death in stroke and 
neurodegenerative disorders via over-excitation and calcium accumulation 
(Olney, 1969, Olney and Sharpe, 1969, Olney, 1971, Choi, 1985). Based on the 
success of in vitro and animal models (Foster et al., 1987, Omae et al., 1996, 
Suzuki et al., 2003, Hoyte et al., 2004), many were disappointed to discover that 
drug therapies designed solely to block or reduce glutamate receptor activation 
did not prevent neurodegeneration in clinical trials (Albers et al., 1999, Morris et 
al., 1999, Davis et al., 2000, Hoyte et al., 2004). Thus, focus now lays on 
searching for new mechanisms to modulate calcium entry or the downstream 
targets activated by aberrant calcium signaling (Szydlowska and Tymianski, 
2010). A key mediator of glutamate-induced calcium signaling is the 
multifunctional CaMKII; a Ser/Thr protein kinase implicated in synaptic plasticity 
(Hudmon and Schulman, 2002, Lisman et al., 2002). CaMKII is activated by 
excitotoxic calcium signaling (Westgate et al., 1994, Zalewska and Domanska-
Janik, 1996) and has been implicated in regulating a number of different 
substrates linked to excitotoxic calcium signaling as well as neuronal survival.   
Earlier studies have shown that pre-incubation with the small molecule CaMKII 
inhibitors KN-62 or KN-93 produce neuroprotection when given before an 
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Figure 15: Prolonged tat-CN21 treatment does not affect αCaMKII or 
NR2B protein levels. A, Western blots of NR2B, αCaMKII and GAPDH in 
neuronal lysates 24 hours following application of 10 µM tat-CN21 or tat-
CN21Ala. Summary data for normalized protein levels of NR2B, B, and 
αCaMKII, C, quantified and plotted relative to control (p>0.05).  
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excitotoxic challenge (Hajimohammadreza et al., 1995, Takano et al., 2003, Vest 
et al., 2010 ). We also observed neuroprotection with KN-93 pretreatment (Figure 
10B), however, it was difficult to interpret that the neuroprotection was due to 
CaMKII inhibition because the inactive analog, KN-92, was also protective in our 
assays (Figure 10B). The myristoylated CaMKII peptide inhibitor AIP (Ishida et 
al., 1995) has also been shown to display neuroprotective activity in vivo and in 
cultured neurons exposed to toxic levels of NMDA (Laabich and Cooper, 2000, 
Fan et al., 2006, Goebel, 2009). We observed potent neuroprotection using the 
AIP peptide as well as a peptide derived from the endogenous CaMKII inhibitor, 
CN21, when tagged with the tat cellular import sequence to enhance membrane 
permeability (Figure 10B). Because recent data indicates that cellular import 
sequences can inhibit neurotoxicity to glutamate (Vaslin et al., 2009), we also 
validated the specificity of these peptide inhibitors to control peptides. We relied 
on tat alone to serve as a control for AIP yet optimized a control peptide for CN21 
by identifying and mutating critical residues responsible for binding to CaMKII. 
Compared to the active peptides (tat-CN21 and tat-AIP), very little inhibition was 
observed for tat-CN21Ala or the tat peptide in either in vitro or cell based assays, 
suggesting that the neuroprotection observed with the active peptides is not due 
to the cellular import sequence nor to peptide sequences that do not interact with 
CaMKII. In total, our data favor the hypothesis that excitotoxic calcium signaling 
induces neurotoxic CaMKII activity. Interestingly, both tat-AIP and tat-CN21, 
which inhibit activated and/or autophosphorylated CaMKII (Ishida et al., 1995, 
Chang et al., 1998, Rose and Hargreaves, 2003), were also neuroprotective 
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when applied after the excitotoxic challenge (Figure 12B). These data are 
intriguing as KN-93, which can only inhibit CaMKII activation, was not 
neuroprotective when applied after an excitotoxic insult (Figure 12B); a result that 
suggests that only inhibitors of activated/autophosphorylated CaMKII are 
efficacious following the onset of excitotoxic calcium signaling.  
During the preparation of this manuscript, it was reported that tat-CN21 
was neuroprotective in vitro as well as in an animal model of stroke (Vest et al., 
2010). However, in these studies, the neuroprotection afforded by tat-CN21 in 
cultured hippocampal neurons was not diminished even after 6 hours following 
the excitotoxic glutamate insult, the longest time-point reported in their study 
(Vest et al., 2010). We observed that the neuroprotective effects of tat-CN21 are 
greatest when applied before the toxic glutamate challenge and diminish with 
time (Figure 12B), with the neuroprotection associated with CaMKII inhibition 
diminishing back to control after 3 hours post glutamate insult. We found that this 
time window of neuroprotection correlates to changes in neuronal membrane 
integrity (see Figure 6B). Thus, our data favor a model whereby the pathological 
contributions of CaMKII to excitotoxic damage may be limited to a 2-3 hour 
period post excitotoxic injury. Potential reasons for different outcomes between 
our study and that of Vest et al., include differences in the glutamate stimulation 
protocol (200 µM for 1 hour versus 400 µM for 5 mins) as well as the type of 
culture (7-8 DIV cortical neurons versus 7 DIV hippocampal neurons obtained 
from embryonic (highly pure) versus post-natal (mixed), respectively). However, it 
should be noted that the in vivo experiment performed by Bayer and colleagues 
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was, in fact, performed at one hour post-ischemia (Vest et al., 2010); a time point 
our study finds to be neuroprotective in cultured neurons. 
The potential therapeutic utility of inhibiting CaMKII to enhance neuronal 
survival following an excitotoxic glutamate exposure is intriguing, as following 
activation in excitotoxic conditions (Westgate et al., 1994, Zalewska and 
Domanska-Janik, 1996), CaMKII undergoes functional changes that at face-
value would appear to be designed to limit aberrant CaMKII activity. We 
observed a significant decrease in CaMKII activity 24 hours following an 
excitotoxic glutamate insult (Figure 12C). In addition, unlike βCaMKII, excitotoxic 
calcium signaling induces αCaMKII to translocate form the soluble to the 
particulate fraction (Figure 12D). Soluble to particulate accumulation of CaMKII 
may be due to activity-dependent translocation of CaMKII to specific subcellular 
compartments, like the post-synaptic density (Aronowski et al., 1992, Suzuki et 
al., 1994) and/or the formation of CaMKII aggregates (Dosemeci et al., 2000, 
Tao-Cheng et al., 2002, Hudmon et al., 2005). These functional changes in 
CaMKII activity and localization are not limited to our neuronal culture model, as 
both CaMKII inactivation and soluble to particulate translocations are observed in 
vivo and in slice models of ischemia (Aronowski et al., 1992, Hanson et al., 1994, 
Kolb et al., 1995, Aronowski and Grotta, 1996, Zalewska et al., 1996). 
Importantly, the glutamate-induced translocation and loss of CaMKII activity are 
reduced by tat-CN21 application in a time-dependent fashion (Figure 12C and 
12D), suggesting that maintaining a soluble and activatable pool of CaMKII for 24 
hours after an excitotoxic insult enhances neuronal survival (Hanson et al., 
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1994). These data are consistent with a functional switch from CaMKII playing a 
neurotoxic role with the induction of the excitotoxic insult to a neuroprotective role 
2-3 hours after the insult. One might envision that sustained loss of CaMKII 
activity induced by excitotoxic calcium signaling could be detrimental for neuronal 
survival, as a number of CaMKII substrates are pro-survival (e.g. CREB and L-
type channels) (Dash et al., 1991, Wheeler et al., 2008). CaMKII regulation of 
substrates that limit neuronal excitability and glutamate signaling could function 
as a “brake” for subsequent excitotoxic calcium signaling. For example, CaMKII 
phosphorylation of NMDA-receptors leads to desensitization (Sessoms-Sikes et 
al., 2005) whereas CaMKII upregulation of GABA-receptors could be a form of 
feed-forward inhibition that could limit the activity of neuronal circuits (Houston 
and Smart, 2006). In these scenarios, sustained loss of CaMKII could be 
maladaptive for future recovery or susceptibility to excitotoxicity. In support of this 
model, we observed that inhibition of CaMKII for 8-24 hours prior to a sub-
maximal glutamate/glycine challenge exacerbates neuronal death (Figure 14B-
C). This enhanced neuronal vulnerability to an excitotoxic insult is also seen in 
vivo, as genetic knockdown of αCaMKII doubles the size of the infarct volume in 
knockout mice exposed to focal ischemia compared to wild-type littermates 
(Waxham et al., 1996). Changes in neither αCaMKII nor NR2B protein levels 
appear to be responsible for this enhanced glutamate vulnerability (Figure 15A-
C), although this process does require protein synthesis (Figure 14D). Although 
the mechanism(s) of this shift from neuroprotection to enhanced neuronal 
vulnerability to glutamate following CaMKII inhibition warrants further 
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investigation, our data suggests that inhibition of CaMKII via tat-CN21/AIP prior 
to or immediately after an excitotoxic insult functions to limit aberrant CaMKII 
activity and reduce the long-term inactivation of CaMKII following aberrant 
calcium signaling (Figure 12C and 12D). Thus, the neuroprotection afforded by 
CaMKII inhibition can be seen as neuroprotective immediately surrounding the 
excitotoxic insult, whereas sustained CaMKII inhibition produced by excitotoxicity 
leads to neuronal death by enhancing neuronal vulnerability to glutamate.  
In summary, our data supports the hypothesis that inhibition of CaMKII 
activity either at the onset or soon after an excitotoxic insult is neuroprotective. 
CaMKII activated by excitotoxic calcium signaling is neurotoxic and therefore, 
inhibition of this activity within a limited time-window around the excitotoxic insult 
enhances neuronal survival. However, these data also support a model whereby 
sustained loss of CaMKII activity predisposes neurons to glutamate excitotoxicity. 
The role of CaMKII in promoting neuronal survival and recovery from an 
excitotoxic challenge must be taken into consideration when pursuing CaMKII 
inhibition as a therapeutic intervention to ischemic stroke or other 
neurodegenerative diseases.  
 
*This manuscript was published in Molecular and Cellular Neuroscience* 
Ashpole NM and Hudmon A (2011) Excitotoxic neuroprotection and vulnerability 
with CaMKII inhibition. Mol Cell Neurosci. 46(4):720-30.   
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PART II: CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II 
INHIBITION INDUCES NEUROTOXICITY VIA DYSREGULATION OF 
GLUTAMATE/CALCIUM SIGNALING AND HYPEREXCITABILITY 
SUMMARY 
Aberrant glutamate and calcium signaling are neurotoxic to specific 
neuronal populations. Calcium/calmodulin-dependent kinase II (CaMKII), a 
multifunctional serine/threonine protein kinase in neurons, is believed to regulate 
neurotransmission and synaptic plasticity in response to calcium signaling 
produced by neuronal activity. Importantly, several CaMKII substrates control 
neuronal structure, excitability, and plasticity. Here, we demonstrate that CaMKII 
inhibition for >4 hours using small molecule and peptide inhibitors induces 
apoptosis in cultured cortical neurons. The neuronal death produced by 
prolonged CaMKII inhibition is associated with an increase in TUNEL staining, 
caspase-3 cleavage, and is blocked with translation inhibitor cycloheximide. 
Thus, this neurotoxicity is consistent with apoptotic mechanisms, a conclusion 
that is further supported by dysregulated calcium signaling with CaMKII inhibition. 
CaMKII inhibitory peptides also enhance the number of action potentials 
generated by a ramp depolarization, suggesting increased neuronal excitability 
with a loss of CaMKII activity. Extracellular glutamate concentrations are 
augmented with prolonged inhibition of CaMKII. Enzymatic buffering of 
extracellular glutamate and antagonism of the NMDA subtype of glutamate 
receptors prevent the calcium dysregulation and neurotoxicity associated with 
prolonged CaMKII inhibition. However, in the absence of CaMKII inhibition, 
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elevated glutamate levels do not induce neurotoxicity, suggesting that a 
combination of CaMKII inhibition and elevated extracellular glutamate levels 
results in neuronal death. In sum, the loss of CaMKII observed with multiple 
pathological states in the central nervous system, including epilepsy, brain 
trauma, and ischemia, likely exacerbates programmed cell death by sensitizing 
vulnerable neuronal populations to excitotoxic glutamate signaling and inducing 
an excitotoxic insult itself.  
INTRODUCTION 
Precisely-regulated calcium signaling is essential for normal neuronal 
growth and survival. While slight fluctuations in intracellular calcium 
concentration are tolerated by neurons, and necessary for a variety of 
physiological processes, dysregulation of intracellular calcium leads to neuronal 
death. Intracellular calcium overload can lead to mitochondrial depolarization and 
the over-activation of the downstream signaling pathways regulated by calcium. 
One important signaling pathway that is activated by calcium signaling is 
calcium/calmodulin (CaM)-dependent protein kinase II (CaMKII). Following 
activation with calcium-bound calmodulin, CaMKII targets to and phosphorylates 
a number of substrates in neurons, including voltage- and ligand-gated calcium 
channels, CREB, ERK, and voltage-gated sodium channels (as previously 
reviewed (Hudmon and Schulman, 2002, Colbran, 2004, Coultrap et al., 2011)).  
Fluctuations in CaMKII activity have been associated with neuronal 
disease states that exhibit excitotoxic calcium dysregulation, such as stroke, 
epilepsy, and traumatic brain injury (Aronowski et al., 1992, Perlin et al., 1992, 
91 
 
Hanson et al., 1994, Westgate et al., 1994, Churn et al., 1995, Zalewska and 
Domanska-Janik, 1996, Schwarzbach et al., 2006, Folkerts et al., 2007). 
Immediately following the onset of excitotoxic stimulation, CaMKII is activated 
(Westgate et al., 1994, Zalewska and Domanska-Janik, 1996) and inhibition of 
CaMKII prior to excitotoxic insult prevents neuronal damage both in vitro and in 
vivo (Hajimohammadreza et al., 1995, Laabich and Cooper, 2000, Fan et al., 
2006, Goebel, 2009, Vest et al., 2010, Ashpole and Hudmon, 2011). However, 
αCaMKII knock-out animals paradoxically exhibit a significant increase in 
neuronal damage following stroke compared to wild-type littermates (Waxham et 
al., 1996). Moreover, we recently showed that prolonged pharmacological 
inhibition of CaMKII actually exacerbated excitotoxicity following a submaximal 
glutamate challenge (Ashpole and Hudmon, 2011). Thus, while an acute loss of 
CaMKII may protect neurons from excitotoxic insult, a prolonged loss of CaMKII 
activity sensitizes neurons to glutamate toxicity; an observation we hypothesize 
contributes to programmed cell death in the penumbral region associated with 
ischemia and brain trauma. In support of this hypothesis, a loss of CaMKII 
activity has been shown to be spatially correlated with the extent of neuronal 
damage following focal ischemia (Hanson et al., 1994). The region immediately 
surrounding the infarct not only displays the greatest damage but also the 
greatest loss in CaMKII activity (Hanson et al., 1994). However, the ischemic 
environment is associated with complex biochemical changes that are associated 
with aberrant glutamate signaling, including enhanced ROS activity, acidosis, 
and a decrease in energy availability. Thus, we choose to investigate neuronal 
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survival, calcium signaling, and excitability following a loss of CaMKII activity 
induced by a broad spectrum of CaMKII inhibitors in the absence of an 
exogenous glutamate challenge. Our data supports a model whereby prolonged 
inhibition of CaMKII produces apoptosis in cortical neurons by a feed-forward 
process associated with neuronal hyperexcitabilty and dysregulated calcium and 
glutamate signaling.   
EXPERIMENTAL PROCEDURES 
Materials. Unconjugated tat (YGRKKRRQRR), CN21 
(KRPPKLGQIGRSKRVVIEDDR), CN21Ala (KAPAKAAWAAASKRVVIEDDR), 
CN21C (GQIGRSKRVVIEDDRIDDVLK), tat-AIP (YGRKKRRQRR-
RKKLRRQEAFDAL), tat-CN21, tat-CN21Ala, as well as Fam-labeled versions of 
these peptides were synthesized and HPLC purified by Biopeptide Co, Inc. San 
Diego, CA, USA. Myristolated AIP (myr-AIP; 64929) was purchased from 
Anaspec, Fremont, CA. KN-93 (422708) and KN-92 (422709) were purchased 
from Calbiochem, EMD Biosciences, La Jolla, CA. STO-609 (1551) was 
purchased from Tocris Bioscience, Ellisville, MO. MK-801 (M107), Nifedipine 
(N7634), Nimodipine (N149), Tetrodotoxin (T8024), Omega-Conotoxin (C9915), 
Ifenprodil (I2892), and Memantine (M9292) were purchased from Sigma Aldrich, 
St. Louis, MO.  
Neuronal cultures. Cortical neurons were harvested from E18-E19 Sprague-
Dawley rat pups according to approved IACUC guidelines as previously 
described (Ashpole and Hudmon, 2011). Primary hippocampal neurons were 
prepared from postnatal day 1 Sprague-Dawley rat pups as previously described 
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(Dubinsky, 1993, Brustovetsky et al., 2009). For most experiments, cortical 
neurons were seeded at a density of 2.5 million cells/mL and seeded on poly-D-
lysine (50 µg/mL) coated 15 mm coverslips (German glass Number 0) or 60 mm 
dishes. For experiments looking at neuronal viability at different stages of culture 
development, neurons were seeded at 1.25 million cells/mL. Cultures were 
treated with 5-fluor-2’-deoxyuridine (15 mg/mL) (Sigma, F0503) and Uridine (35 
mg/mL) (Sigma, U3750) to kill mitotically active cells on day 2-4. Co-cultures of 
neurons and astrocytes were not treated with these mitotic inhibitors. 
Cell death assay. Following treatment, the coverslips were washed in PBS and 
stained using Live/Dead Cytotoxicity/Viability kit (Molecular Probes, Eugene, OR) 
as previously described (Ashpole and Hudmon, 2011). Each coverslip is imaged 
in three different fields using a Texas Red filter to detect cytotoxic cells and a 
FITC filter to detect viable cells on a Nikon Ti-E inverted microscope (100x 
magnification). Cells were quantified using the automated counting software 
Nikon Elements 3.0 as previously described (Ashpole and Hudmon, 2011). Total 
cell number was determined by addition of cytotoxic and viable cells. Complete 
media exchanges and washing conditions routinely induced cytotoxicity in about 
5-10% of cultured neurons. 
Immunocytochemistry of neuronal cultures. Neurons (8-9 DIV) treated with 
CaMKII inhibitors were fixed in 4% paraformaldehyde (0.1 M phosphate buffer, 
pH 7.4) for 10 minutes and washed in phosphate buffered saline (PBS) three 
times. For labeling, cells were permeabilized in 0.5% Triton X-100 in PBS for 10 
minutes at room temperature, washed in PBS three times, blocked for 1 hour in 
94 
 
2% BSA Fraction V, 20% normal goat serum, 0.1% Triton X-100 in PBS at room 
temperature, washed an additional three times in PBS. Cells were then incubated 
in primary polyclonal cleaved caspase 3 antibody (1:500, Cell Signaling (#9661), 
Beverly, MA) for 2 hours at room temperature. After three washes, secondary 
antibodies (anti-rabbit Alexa594, 1:5000 (Molecular Probes, Eugene, OR)) were 
applied for one hour at room temperature. Coverslips were washed in PBS three 
times and were subsequently mounted in Prolong Gold Antifade with DAPI 
mounting media (Molecular Probes) and cells were imaged using a Zeiss Axio 
ObserverZ1 and processed with Axiovision 4. 
CaMKII activity assay. Neuronal cultures were lysed in lysis buffer containing (50 
mM HEPES pH 7.4, 4 mM EGTA, 10 mM EDTA, 15 mM Na4P2O7-10H20, 100 
mM β-glycerophosphate, 25 mM NaF, 1% Triton-X 100, and protease inhibitor 
cocktail (Calbiochem, 539137) as described previously (Kolb et al., 1995), 
sonicated, and incubated with 50 mM HEPES pH 7.4, 100 mM NaCl, 10 mM 
MgCl2, 100 µM ATP, 2 mM CaCl2, 5 µM CaM, 50 µM AC2 (KKALRRQETVDAL), 
and [γP32 ]-ATP (3µCi per reaction) for 3 minutes at 30oC. The linear range of the 
reaction extended from 30 seconds to 4 minutes. Protein levels were assessed 
and activity was normalized to total protein using DC protein assay kit (Biorad, 
Hercules, CA).  
Calcium imaging. Hippocampal neurons 10-12 DIV were loaded with 2.6 M 
Fura-2FF-AM (Molecular Probes, Invitrogen) and 1.7 M Rhodamine 123 and 
subsequently imaged as previously described (Brustovetsky et al., 2009, 
Brustovetsky et al., 2011). During imaging, the neurons were maintained in a 
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bath solution containing 10 mM HEPES, pH 7.4, 139 mM NaCl, 3 mM KCl, 0.8 
mM MgCl2, 1.8 mM CaCl2, 5 mM glucose and 65 mM sucrose. For Fluo-4 
experiments, cortical neurons were incubated with 5 µM Fluo-4-AM (Molecular 
Probes, Invitrogen) diluted in rat physiological saline (138 mM NaCl, 2.7 mM KCl, 
1.8 mM CaCl2, 1.06 mM MgCl2, 12.4 mM HEPES pH 7.4, 5.6 mM glucose; final 
pH adjusted to 7.3) for 30 minutes at 37oC. Following incubation cells were 
washed with rat physiological saline 3 times for 5 minutes each. A Nikon Ti-E 
inverted microscope with a FITC filter was employed to monitor Fluo-4 levels 
once every thirty seconds. Baseline was monitored for 5 minutes. In all 
experiments with CaMKII inhibitor application, the inhibitor was added 10 minutes 
after start of imaging, some experiments called for the addition of other inhibitors 
as indicated. For these, the drugs were applied at the 5 minute mark in order to 
identify whether the drug itself had an impact on calcium levels prior to CaMKII 
inhibitor application at minute 10. Analysis was performed using Nikon Elements 
v3.0 in which Fluo-4 levels were measured in ~20 cells per field and 3 fields per 
coverslip. Neurons were identified at the start of the experiment with a 20 mM 
KCl depolarization with a subsequent wash. The fluorescent intensity of each cell 
was normalized to time 0, as the drug was applied. 
Electrophysiology. Action potential studies were carried out using the whole cell 
patch-clamp technique under the current clamp mode. Whole cell voltages were 
recorded with HEKA software (HEKA electronic). The neuronal growth media on 
the cortical neurons (8-10 DIV) was gradually replaced by the extracellular 
recording solution before the patch clamp recording. The extracellular solution 
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consisted of rat physiological saline (as previously described). The intracellular 
solution contains 140 mM potassium gluconate, 2 mM KCl, 3 mM MgCl2, 10 mM 
HEPES, 5 mM phosphocreatine, 2 mM K-ATP, 0.2 mM Na-GTP; final pH 
adjusted to 7.4. Pipette resistance was 2-4 MΩ when filled with the internal 
solution. Data were acquired and analyzed using the Pulsefit software following 
previously established protocols (Wang et al., 2005, Zhang et al., 2008). Cortical 
neurons were held at their resting potentials by injection of steady current 
throughout the experiment. To determine the current threshold for action 
potential initiation, neurons were injected with a series of depolarizing currents 
with variable amplitudes for 200 ms. The sampling frequency was 10 kHz. 
Following identification of the current threshold for action potential generation, 
the neurons were injected with a 1 second depolarizing ramp current that 
subsequently elicited one to two action potentials. Neurons that maintain initial 
resting membrane potentials more negative than -50 mV after whole cell 
configuration and had less than 3 action potentials at the starting point were 
included in this study. We compared the change in the number of APs obtained 
10 minutes after establishing the whole cell configuration to the number obtained 
at the initial starting time point when the peptide had not diffused into the 
intracellular environment. The current clamp studies were performed at room 
temperature (~21oC).  
Glutamate measurements. Glutamate concentrations in the neuronal media were 
assessed using Amplex Red Glutamatic Acid/Glutamate Oxidase Assay per 
manufacturer protocol (Molecular Probes, Invitrogen). The glutamate detection 
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assay standard curve was linear from 180 nM to >6 µM glutamate. For high high-
performance liquid chromatography quantification, glutamate was measured by 
HPLC separation and electrochemical detection of an OPA-mercaptoethanol 
derivative using modifications of the method of Donzanti and Yamamoto 
(Donzanti and Yamamoto, 1988). See Supplemental Figure 4 for more detail.   
Data analysis. Electrophysiology data are presented as the mean ± S.E.M. 
Statistical significance between groups was determined using one-way ANOVA 
with a post-hoc Bonferroni’s test. One-way ANOVA with a subsequent Dunnett’s 
Test was conducted to compare differences between the means of each group in 
all in situ cell death assays, in vitro catalytic assays, and calcium imaging 
experiments. Student t-test was also used when appropriate. Statistical 
significance was accepted at p<0.05. Analysis was performed using SigmaPlot 
11 software. 
RESULTS 
Neurotoxicity with CaMKII Inhibition 
To test the hypothesis that CaMKII inhibition induces neuronal death, we 
subjected cortical neurons (8 DIV) to acute (1 hour) and prolonged (24 hours) 
pharmacological inhibition of CaMKII using multiple inhibitors. Peptides derived 
from the endogenous inhibitor of CaMKII, termed CN21, and the autoinhibitory 
domain of CaMKII itself (AIP) were used because of their high specificity to inhibit 
CaMKII (Ishida et al., 1995, Chang et al., 1998, Vest et al., 2007). As previously 
described (Vest et al., 2007, Vest et al., 2010, Ashpole and Hudmon, 2011), 
conjugation of peptide inhibitors to the cell-penetrant motif, tat, affords the ability 
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to examine the effects of CaMKII inhibition with cell penetrating peptides in both 
cultures and in vivo. In addition to the peptide inhibitors, we also utilized the 
allosteric CaMKII inhibitor KN-93 (Sumi et al., 1991, Ishida et al., 1995, Vest et 
al., 2007, Ashpole and Hudmon, 2011). We applied 10 µM tat-CN21, tat-AIP, and 
1 µM KN-93 to cortical neuronal cultures for 1 or 24 hours and subsequently 
examined viability/cytotoxicity levels 24 hours following the start of treatment 
(Ashpole and Hudmon, 2011). To compensate for the decreased bioavailability 
associated with tat-based peptides accumulating in non-cytoplasmic 
compartments (Tunnemann et al., 2006), the concentrations of the peptide 
inhibitors used in this study are roughly 100 fold above the in vitro IC50 for CN21 
(77-100 nM) (Vest et al., 2007, Ashpole and Hudmon, 2011). To control for 
potential off target effects, we applied KN-92, the inactive control for KN-93, or a 
peptide control, tat-CN21-Ala (Ashpole and Hudmon, 2011). For each neuronal 
death experiment, data was normalized by subtracting average neuronal death 
observed in control cultures. The control cultures in each experimental group 
consistently exhibited 5-10% toxicity. Cortical neuron viability was no different 
than control cultures (DMSO treated) when CaMKII inhibitors were applied for 
one hour (Figure 16A, gray bars). In contrast, all three CaMKII inhibitors (KN93, 
tat-CN21, tat-AIP) significantly increased neuronal death 12-18% when applied 
for 24 hours (Figure 16A, black bars). Compared to control cultures, lower 
concentrations of tat-CN21 also induced neurotoxicity when applied overnight (1 
µM tat-CN21 5.3% ± 2.4%; p<0.05). Importantly, cultures treated with the 
inactivecontrols, tat-CN21Ala and KN-92, for 24 hours did not exhibit significant 
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changes in neuronal viability (Figure 16A), suggesting that the neurotoxic effects 
are specific to the application of active small molecule and peptide CaMKII 
inhibitors. Furthermore, the tat motif, itself, was not toxic when applied for 24 
hours (0.533 ± 1.6%; p>0.5). Utilization of a myristolated-AIP peptide inhibitor of 
CaMKII also induced neurotoxicity (29.6 ± 4.2%; p<0.05). Thus, CaMKII inhibition 
using both small molecule and peptide inhibitors conjugated to tat and 
myristolated cell-penetrating motifs induce neuronal death when applied for 24 
hours.  
While a significant increase in neurotoxicity was observed within our 
neuronal cultures when CaMKII was inhibited at 8 DIV, we tested whether the 
age of the culture affected this neuronal death. While no differences were 
observed in neuronal viability between control groups at 8 DIV, 14 DIV and 21 
DIV, 24 hour inhibition of CaMKII with tat-CN21 significantly enhanced 
neurotoxicity with respect to time in culture (Figure 16B). Compared to cultures 8 
DIV, 14 DIV cultures exhibited nearly 25% toxicity while nearly 75% of cells were 
compromised when CaMKII was inhibited at 21 DIV. The cell death observed 
with CaMKII inhibition is not limited to highly enriched cortical cultures (>95% 
MAP-2 immunopositive (Ashpole and Hudmon, 2011), as a similar level of 
toxicity was observed in neurons cultured with glia (Figure 16C). In these co-
cultures, a monolayer of GFAP positive astrocytes underlying MAP2 positive 
cortical neurons represent an astrocytes to neurons ratio of 3:2 (Figure 17). 
Thus, the toxicity produced by CaMKII inhibition is enhanced by culture age and 
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Figure 16: Neurotoxicity with CaMKII inhibition. A, Neuronal death 
(mean ± SEM, n=3-15) normalized to control when CaMKII inhibitors (10 
µM peptide inhibitors and 1 µM small molecule inhibitors) were applied to 
neuronal cultures (8 DIV) for 1 hr (gray bars) or 24 hrs (black bars). 
*p<0.05 compared to control (One-Way ANOVA, post-hoc Dunnett’s test). 
B, Neuronal death (mean ± SEM, n=4-17) normalized to control when 10 
µM tat-CN21 or tat-CN21Ala was applied to neuronal cultures for 24 hours 
at 8, 14, and 21 DIV. *p<0.05 compared to control at that time point, 
#p<0.05 compared to 8 DIV tat-CN21 treatment (One-Way ANOVA, post-
hoc Dunnett’s test). @p<0.05 for 14 DIV tat-CN21 treatment vs 21 DIV tat-
CN21 treatment (t-test). C, Neuronal death (mean ± SEM, n=4) normalized 
to control when 10 µM tat-CN21 or tat-CN21Ala was applied to co-cultures 
for 24 hours. *p<0.05 compared to control (One-Way ANOVA, post-hoc 
Dunnett’s test). 
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Figure 17: Characterization of co-cultures of neurons and astrocytes. 
Representative image of immunostained co-cultures with MAP2 positive 
neurons (green) and GFAP positive glia (red). The inset indicates average 
percentage of cells (± SEM; n=4) that are MAP2 positive.  
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observed in both highly pure cultures of cortical neurons as well as cortical 
neurons cultured with astrocytes.     
In Figure 16A we report that CaMKII inhibition for acute (1 hour) versus 
prolonged (24 hours) differentially affects neuronal death. To determine the 
minimal time where CaMKII inhibition-induced cell death, we applied tat-CN21 for 
various times between 1 and 24 hours. In addition, we explored exposure times 
longer than 24 hours to determine if neurotoxicity was saturated. Once again, a 1 
hour exposure of neurons to tat-CN21 failed to produce cell death (Figure 18A). 
CaMKII inhibition for 4 hours or less was also not toxic to neurons (Figure 18A). 
Progressively increasing neuronal death as a function of CaMKII inhibition time 
was observed up to 12 hours. However, longer incubation times (24 or 48 hrs) 
did not produce additional neurotoxicity (Figure 18A), suggesting that events 
occurring within the first 12 hours largely determine the neuronal death 
associated with CaMKII inhibition.    
The extent of CaMKII inactivation produced by focal ischemia in vivo was 
previously shown to correlate with the extent of neuronal damage (Hanson et al., 
1994). Because we observed a time-dependence in the neurotoxicity produced 
by CaMKII inhibition, we determined if neuronal death in cortical cultures is 
correlated with functional changes in CaMKII. We observed a time-dependent 
loss in the activatable pool of CaMKII that correlated with exposure time of the 
CaMKII inhibitor. Application of tat-CN21 for ≥4 hours resulted in a significant 
decrease in activatable CaMKII compared to vehicle-treated control neurons 
(Figure 18B). A maximal 50% loss of activity occurred when tat-CN21 was 
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Figure 18: Time-dependence of neurotoxicity and CaMKII inactivation 
with CaMKII inhibition. A, Neuronal death (mean ± SEM, n=7-12) 
normalized to control when 10 µM tat-CN21 was applied to neuronal 
cultures for varying lengths of time. *p<0.05 compared to control (One-Way 
ANOVA, post-hoc Dunnett’s test). B, Kinase activity (mean ± S.D., n=3-4) 
in neuronal lysates subjected to an in vitro CaMKII assay in the presence 
of calcium/calmodulin after 10 µM tat-CN21 (or tat-CN21Ala) was applied 
to cortical neurons for varying lengths of time. *p<0.05 compared to control 
(One-Way ANOVA, post-hoc Dunnett’s test).   
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applied for 24 hours. Importantly, neurons treated with inactive tat-CN21Ala for 
24 hours did not exhibit a decrease in activatable CaMKII (Figure 18B).  
We previously showed that neuronal uptake of fluorescent 
carboxyfluorescein (Fam) labeled tat-CN21 and control tat-CN21Ala (Fam 
conjugated to the C-terminus) were similar in our cortical cultures (Ashpole and 
Hudmon, 2011). Using these Fam-labeled peptides, we measured peptide 
uptake and neuronal death in order to identify whether fluorescently labeled 
neurons are preferentially dying in our assay. Using fluorescent microscopy, we 
observed that ~25% of cells display substantial tat-CN21-Fam or tat-CN21Ala-
Fam uptake (Figure 19). However, a large proportion of cells exhibit low, but still 
above background levels of fluorescent peptide, suggesting that CaMKII activity 
may be reduced in more than the 25% of cells (Figure 19). It is noteworthy that 
peptide uptake (~25%) correlates with neuronal death (~25%). The disconnect 
between maximal cell death (~25%) and the 50% decrease in CaMKII activity 
could be explained by the observation that not all cells exhibit the same levels of 
peptide uptake, suggesting that low levels of CaMKII inhibition may not reach a 
threshold that is required for neurotoxicity. While the mechanism behind the 
differential peptide uptake and loss of CaMKII activity is not known, there is a 
clear correlation with cytotoxicity and CaMKII inhibitor uptake as nearly 80% of 
cytotoxic cells exhibit tat-CN21-Fam co-localization (Figure 19).  
CaMKII Inhibition Induces Apoptosis 
The time-dependence of CaMKII inhibition (>4 hours) leading to toxicity is 
consistent with apoptosis. To test if neurons were undergoing apoptosis in 
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Figure 19: Neurotoxicity is predominantly found in neurons that have 
CaMKII inhibitor uptake. A, Representative image of neurons treated with 
tat-CN21-Fam (green) for 24 hours and stained with ethidium homodimer 
(red) and Hoescht staining (blue). B, Average number of cytotoxic cells (± 
SEM; n=8) per field found to co-localize or not co-localize with tat-CN21-
Fam.  
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response to prolonged CaMKII inhibition, cultures were co-treated with tat-CN21 
and the protein translation inhibitor cycloheximide. Co-application of 0.5 mg/mL 
cycloheximide blocked tat-CN21-induced neurotoxicity (Figure 20A). Similarly, 
co-treatment of tat-AIP and cycloheximide abolished the tat-AIP-induced toxicity 
(Figure 21). In further support of apoptosis, there was a significant increase in 
TUNEL staining of cultures treated with tat-CN21 for 24 hours compared to 
control and cultures co-treated with 0.5 mg/mL cycloheximide (Figure 20B). To 
confirm that the apoptosis occurred within cells that took up the CaMKII 
inhibitors, we next examined levels of activated caspase-3, a neuronal marker for 
apoptosis. Overnight application of tat-CN21-Fam was used in order to identify 
neuron uptake of the CaMKII inhibitor. Activated caspase-3 labeling was limited 
to cells that contained tat-CN21-Fam (Figure 20C). Not all neurons that were tat-
CN21-Fam positive displayed caspase-3 activation. However, nearly all of the 
neurons that contained tat-CN21-Fam had pyknotic and fragmented nuclei, 
indicating that the neurons were compromised (Figure 20C). Thus, while some 
necrotic cell death may not be ruled out, CaMKII inhibition does lead to 
apoptosis. 
Calcium Dysregulation with CaMKII Inhibition 
One prominent mechanism underlying neurodegeneration is dysregulated 
calcium signaling (as reviewed by (Orrenius et al., 2003)). Cultured hippocampal 
neurons (DIV 14) were loaded with Fura-2FF-AM and intracellular calcium levels 
were measured using ratiometric fluorescent imaging. While tat-CN21Ala or tat 
did not alter intracellular calcium levels, tat-CN21 led to a gradual rise in 
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Figure 20: Neuronal apoptosis with CaMKII inhibition. Neuronal death 
(mean ± SEM, n=5-10) following treatment with tat-CN21 with or without 
0.5 mg/mL cycloheximide as measured by A, ethidium homodimer 
membrane permeability dye, or B, TUNEL staining. *p<0.05 compared to 
control while #p<0.05 compared to tat-CN21 alone (One-Way ANOVA, 
post-hoc Dunnett’s test). C, Representative image of a field of neurons 
treated with 10 µM tat-CN21-Fam for 24 hours (top left) immunostained for 
cleaved caspase-3 (top right), nuclear marker Hoechst (bottom left), and a 
merge of all three channels (bottom right). Arrows indicate fragmented or 
pyknotic nuclei.  
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Figure 21: CaMKII inhibitor tat-AIP also induces apoptosis. Neuronal 
death (mean ± SEM; n=5-7) following 24 hour treatment with 10 µM tat-AIP 
in the absence or presence of 0.5 mg/mL cycloheximide. *p<0.05 
compared to control (One-Way ANOVA, post-hoc Dunnett’s test). 
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intracellular calcium (Figure 22B-D), suggesting that CaMKII inhibition leads to a 
slow, tonic increase in intracellular calcium. This calcium dysregulation is also 
observed in cortical neurons loaded with Fluo-4AM. Using this high affinity 
calcium indictor, we observed significantly elevated intracellular calcium levels 
occurring within 10 minutes exposure to tat-CN21 application (Figure 22E-F). 
Again, no changes in intracellular calcium were observed with tatCN21-Ala 
(Figure 22E). Similar to tat-CN21, 10 µM tat-AIP (data not shown) and 10 µM 
myristolated-AIP (Figure 22F) induced a significant increase in intracellular 
calcium concentration. In contrast, inhibition of the CaMKK pathway (CaMKI and 
CaMKIV (Tokumitsu et al., 2002, Schmitt et al., 2005)), using STO-609, does not 
induce calcium dysregulation (Figure 22F). Thus, acute CaMKII inhibition leads a 
slow increase in intracellular calcium levels. 
Low extracellular calcium largely prevented the tat-CN21-induced calcium 
influx (Figure 22F), indicating that calcium is likely derived from extracellular 
sources. L-type voltage-gated calcium channels do not appear to contribute to 
this process because pretreatment with 10 µM nimodipine had no effect on tat-
CN21 induced calcium dysregulation (Figure 22F). However, synaptic 
transmission may contribute to the increase in intracellular calcium, as 1 µM N-
type calcium channel blocker omega-conotoxin abolished calcium dysregulation 
prior to tat-CN21 treatment. Because N-type calcium channels play a prominent 
role in synaptic activity, we tested if neuronal activity was essential for this 
process by inhibiting AMPA receptors. Indeed, inhibition of AMPA receptors, 
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Figure 22: Calcium dysregulation with CaMKII inhibition in neurons. 
A, Representative bright-field and, B-C, fluorescent images of Fura-2FF-
loaded hippocampal neurons, B, before and, C, after treatment with 10 µM 
tat-CN21. D, Cytoplasmic calcium levels, [Ca2+]C, (mean ± SEM) before 
and after application of 10 µM tat-CN21, tat-CN21Ala, or tat. E, Neuronal 
intracellular calcium levels (mean ± SEM) before (-300 to 0 seconds) and 
after (0 to 1200 seconds) application of 10 µM tat-CN21, tat-CN21Ala, or 
tat, as measured by Fluo-4 (n=4). F, Average integral of fluorescent 
intensity from 0-1200 seconds in E (mean ± SEM, n=3-6) with application 
of CaMKII inhibitors with and without pharmacological blockers of neuronal 
excitability. The integral was normalized to the calcium influx observed with 
application of 10 µM tat-CN21. *p<0.05 compared to tat-CN21 alone (One-
Way ANOVA, post-hoc Dunnett’s test).  
FURA Imaging Courtesy of the Brustovetsky Lab 
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using 10 µM CNQX, blocked calcium dysregulation following CaMKII inhibition. In 
further support for neuronal activity being essential for the tonic increase in 
intracelluar calcium observed with CaMKII inhibition, inhibition of voltage-gated 
sodium channels using TTX (1 µM) prior to tat-CN21 treatment completely 
abolished the calcium influx (Figure 22F). These data are consistent with 
neuronal activity being essential for the calcium influx associated with inhibition 
of CaMKII.   
Enhanced Neuronal Excitability with CaMKII Inhibition 
To address the potential for CaMKII inhibition to alter neuronal excitability, 
we employed whole cell current-clamp to measure action potential firing in 
response to a depolarizing voltage ramp. In these experiments we used lower 
peptide concentration (1 µM) because the patch pipette provides direct access to 
the cytosol. We used inhibitory peptides without the cell-penetrating tat motif to 
affect only the cell from which we were recording. Each cell served as its own 
control by determining the number of action potentials generated immediately 
after establishing whole-cell configuration versus 10 minutes later when the 
peptide inhibitors have had the opportunity to diffuse from the pipette to inhibit 
CaMKII. Cortical neurons exposed to 1 µM CN21 for 10 minutes exhibited a 
three-fold increase in the number of action potentials compared to neurons 
treated with 1 µM inactive peptide CN21Ala (Figure 23A-B). CN21C, another 
previously established control for CN21 (Vest et al., 2010, Ashpole and Hudmon, 
2011), did not result in a significant increase in action potential number compared 
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Figure 23: CaMKII inhibition augments neuronal excitability. A, 
Representative traces from cortical neurons at time 0 and 10 minutes 
following diffusion of either 1 µM CN21 or 1 µM CN21Ala. Neurons were 
held at their resting membrane potentials and injected with 1 second 
depolarizing current ramps to evoke action potentials. B, Number of action 
potentials (mean ± SD) evoked at time 0 or 10 minutes after whole cell 
configuration in the presence of CN21 or control CN21Ala or CN21C. 
*p<0.01 between the number of action potentials between time 0 and 10 
minutes (One-Way ANOVA, post-hoc Bonferroni).  
Courtesy of Weihua Song 
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to baseline. Overall, these data support the hypothesis that CaMKII inhibition 
enhances neuronal excitability. 
CaMKII Inhibition Predisposes Neurons to Excitotoxic Insults 
Our observed increase in neuronal excitability with a loss of CaMKII 
activity supports previous reports indicating that genetic αCaMKII knock-out 
animals are predisposed to epilepsy (Butler et al., 1995). We hypothesize that 
this increased excitability not only underlies the observed neurotoxicity, but also 
mechanistically underlies the decreased ability of the neurons to handle 
excitatory insults. As mentioned, αCaMKII knock-out animals also exhibit greater 
neuronal damage following middle cerebral artery occlusion than their wild-type 
littermates (Waxham et al., 1996). Similarly, overnight inhibition of CaMKII with 
tat-CN21 exacerbated cortical cell death following application of exogenous 
glutamate in an in vitro model of excitotoxicity (Ashpole and Hudmon, 2011). To 
further explore the role of CaMKII inhibition in sensitizing neurons to excitotoxic-
related insults, we sought to identify whether prolonged CaMKII inhibition 
predisposed neurons specifically to NMDA-R activation and/or sensitized 
neurons to the deleterious effect of reactive oxygen species. Thus, 10 µM tat-
CN21 was applied to cortical neurons for 24 hours. Following overnight inhibition 
of CaMKII, the neurons were subjected to submaximal levels of 100 µM 
NMDA/10 µM glycine or H2O2 for 5 minutes, washed, and 24 hours later cell 
viability assessed. Compared to cultures that were treated with NMDA for 5 
minutes alone, cultures subjected to CaMKII inhibition prior to NMDA-R 
stimulation exhibited significantly increased neuronal death (15% vs 45%) 
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(Figure 24). Similarly, neurons treated with tat-CN21 also exhibited significantly 
higher levels of toxicity when treated with H2O2, compared to H2O2 alone (Figure 
24). Neuronal sensitivity to Microcystin-LR, a cell-permeable protein phosphatase 
1 and 2A inhibitor, was also assessed as CaMKII activity has been shown to be 
necessary for microcystin-induced apoptosis (35). Interestingly, prolonged 
CaMKII inhibition was not synergistic nor additive with microcystin toxicity (Figure 
24), suggesting that CaMKII inhibition via tat-CN21 blocks neurotoxicity produced 
by microcystin treatment and that the neuronal death induced by CaMKII 
inhibition is not obstructed by protein phosphatase inhibitors. Together these 
data suggest that a prolonged loss of CaMKII sensitizes neurons to ROS and 
NMDA-R mediated excitotoxicity. Thus, CaMKII inhibition appears toxic to 
neurons both directly via inducing calcium dysregulation and hyperexcitabilty and 
indirectly through predisposing neurons to glutamate excitotoxicity.  
Glutamate Dysregulation with CaMKII Inhibition 
Because a loss of CaMKII predisposes neurons to glutamate 
excitotoxicity, we questioned whether CaMKII inhibition itself affected glutamate 
levels within our cultures. To address this question, cultures were treated with 
tat-CN21 for varying lengths of time and glutamate concentration in the media 
was assessed using a glutamate oxidase assay. There was a significant increase 
in glutamate concentration in the media as early as 20 minutes following tat-
CN21 application (Figure 25A). Twenty-four hours following tat-CN21 application 
the concentration of glutamate in the bath solution was 4-5 µM while tat-CN21Ala 
failed to raise glutamate levels compared to control without treatment (0.5-1 µM). 
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Figure 24: Prolonged CaMKII inhibition sensitizes neurons to 
excitotoxic-related insults. Neuronal death (mean ± SEM, n=3-7) 
following treatment with various combinations of tat-CN21, NMDA, H2O2, or 
microcystin-LR. All cell death measurements were made 48 hours from the 
start of treatments. Cultures were treated with NMDA, H2O2, or 
microcystin-LR independently or in combination with a 24 hour pre-
treatment of 10 µM tat-CN21. The clear boxes highlight the potential levels 
of cytotoxicity if the average death induced by tat-CN21 treatment alone 
would be additive. *p<0.05 compared to control (One-Way ANOVA, post-
hoc Dunnett’s test). #p<0.05 compared to NMDA treatment alone (t-test). 
@p<0.05 compared to H2O2 alone (t-test).  
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Figure 25: CaMKII inhibition results in increased glutamate in 
conditioned neuronal media. Glutamate concentration (mean ± SD, n=3-
6) in neuronal media following incubation with 10 µM tat-CN21 or tat-
CN21Ala for varying lengths of time, as measured by a glutamate oxidase 
assay. *p<0.05 compared to vehicle control (DMSO) (One-Way ANOVA, 
post-hoc Dunnett’s test).  
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Similarly, HPLC analysis of glutamate concentration in the media also indicated 
that 24 hour application of tat-CN21 resulted in more than a two-fold elevation in 
glutamate concentration compared to inactive tat-CN21Ala (Figure 26).  
To determine whether this slight elevation in glutamate is important for 
calcium dysregulation and cell death, we sought to attenuate the glutamate rise 
enzymatically to dissociate CaMKII inhibition with the increased extracellular 
glutamate. Glutamate pyruvate transaminase (GPT), in the presence of pyruvate, 
catalyzes the conversion of glutamate to -ketoglutarate and alanine (Beaton et 
al., 1957). Thus, we added 0.25 mg/mL GPT and 2 mM pyruvate in combination 
with the CaMKII inhibitory peptide tat-CN21 to the cortical neurons and measured 
extracellular glutamate levels using the oxidase assay. Twenty-four hour 
application of tat-CN21 resulted in a significant increase in glutamate in the 
media of the cultured cortical neurons (Figure 27A). Co-application of GPT and 
pyruvate with tat-CN21 brought glutamate levels back to control. When pyruvate 
was omitted from the treatment, a significant increase in glutamate concentration 
was seen with tat-CN21 (Figure 27A). Furthermore, when GPT was boiled prior 
to application, GPT and pyruvate failed to bring tat-CN21-induced glutamate 
release back to control levels (Figure 27A).  
Having successfully buffered the prolonged rise in extracellular glutamate 
when CaMKII was inhibited, we measured acute changes in intracellular calcium 
concentrations with Fluo-4AM when GPT and pyruvate was present. As before, 
10 µM tat-CN21 induced significant dysregulation of intracellular calcium 
concentrations within minutes of application (Figure 27B). Interestingly, 
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Figure 26: CaMKII inhibition results in increased glutamate in the 
media. Average concentration of glutamate in the media (± SEM, n=3) 
following treatment with CaMKII inhibitor tat-CN21 or control tat-CN21Ala, 
as measured by HPLC. *p<0.05 between the groups (t-test). For 
calculation of concentration, 5 µl of sample was transferred to assay tubes 
and placed in an autosampler tray at 8°C. Internal standard (20 µl 
homoserine) was added to each sample, then the sample was derivatized 
by the addition and mixing of 20 µl of the OPA/β-mercaptoethanol reagent. 
One minute and thirty seconds after the addition of the reagent 10 µl of the 
sample-reagent mixture was injected onto an HPLC column (HR-80; ESA, 
Chelmsford, MA). Separations were carried out isocratically with a mobile 
phase containing 0.1 M sodium phosphate dibasic (pH 6.75), and 25% 
methanol at a flow rate of 410 µl/minutes and a column temperature of 
40°C. Electrochemical detection was performed by an ESA (Chelmsford, 
MA) Coulochem II detection system with a guard cell set at 700 mV, and 
dual electrodes set at 300 mV (E1), and 600 mV (E2) for oxidization of the 
glutamate derivative. Peak areas were calculated based on standard 
curves and adjusted for the value of the internal standard.  
Courtesy of Dr. Eric Engleman 
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Figure 27: Enzymatic catalysis of glutamate prevents acute and 
prolonged effects of CaMKII inhibition. A, Glutamate concentration 
(mean ± S.D., n=4-8) in neuronal media following incubation with 10 µM 
tat-CN21 for 24 hours with and without co-application of glutamate 
pyruvate transaminase (GPT)/pyruvate, GPT alone, or boiled 
GPT/pyruvate. *p<0.05 compared to control while #p<0.05 compared to 
tat-CN21/GPT/pyruvate treatment (One-Way ANOVA, post-hoc Dunnett’s 
test). B, Neuronal intracellular calcium levels (mean ± SEM, n=3) following 
application of tat-CN21 in the presence or absence of GPT/pyruvate. Bar 
graph inset indicates the average integral from 0-1200 seconds (mean ± 
SEM, n=3) for these treatment groups. C, Neuronal death (mean ± SEM, 
n=3-6) after 24 hour treatment with 10 µM tat-CN21 alone or co-application 
with GPT/pyruvate, GPT alone, or boiled GPT/pyruvate. *p<0.05 compared 
to control while #p<0.05 compared to tat-CN21/GPT/pyruvate treatment 
(One-Way ANOVA, post-hoc Dunnett’s test).  
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application of GPT and pyruvate prevented tat-CN21-induced calcium influx 
(Figure 27B). Co-application of tat-CN21 with pyruvate alone did not alter calcium 
influx with CaMKII inhibition (0.85 ± .24, normalized to tat-CN21).  
Neuronal viability following CaMKII inhibition was also assessed with 
extracellular glutamate buffering. Consistent with the glutamate experiments, the 
tat-CN21-induced neurotoxicity was abolished by co-treatment with GPT and 
pyruvate (Figure 27C). Cultures treated with GPT/tat-CN21 exhibited a statistical 
increase in neuronal death, similar to cultures treated with tat-CN21 alone 
(Figure 27C). Significant neurotoxicity was also observed when cultures were 
treated with pyruvate and tat-CN21 (19.077 ±1.876%). Once more, both omission 
of pyruvate and boiling of GPT prior to application resulted in a failure in 
preventing tat-CN21-induced neurotoxicity (Figure 27C). Together, these data 
indicate that enzymatically degrading the glutamate released after CaMKII 
inhibition prevents calcium dysregulation and neuronal death.    
We next examined if calcium entering through glutamate receptors, 
specifically the NMDA receptors contributes to the observed calcium influx. 
Application of 20 µM MK-801 reduced tat-CN21-induced calcium influx by ~80% 
(Figure 28A). As mentioned earlier, the calcium influx induced by CaMKII 
inhibition was also blocked by pharmacological antagonism of synaptic activity 
(via blockade of VGSCs, AMPA-Rs, and VGCCs). To determine the contribution 
of synaptic NMDA receptors in this calcium dysregulation, cortical neurons were 
treated with bicuculline to induce synaptic activity by inhibiting GABAergic 
signaling as described previously (Hardingham et al., 2002, Ivanov et al., 2006). 
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Figure 28: Pharmacological antagonism of the NMDA receptor 
prevents acute and prolonged effects of CaMKII inhibition. A, Average 
integral of fluorescent intensity from 0-1200 seconds (mean ± SEM, n=3-6) 
reflecting calcium influx in control neurons, or neurons subjected to 
treatment with tat-CN21 alone or in combination with 20 µM MK-801 or in 
combination with a prior synaptic NMDA-R blockade. To block synaptic 
NMDA-Rs before tat-CN21 treatment, 10 µM bicuculline was applied to 
allow synaptic activity, followed by the addition of 20 µM MK-801 to inhibit 
the synaptic NMDA-Rs opened as a result of this synaptic activity. *p<0.05 
compared to control while #p<0.05 compared to tat-CN21 (One-Way 
ANOVA, post-hoc Dunnett’s test). B, Neuronal death (mean ± SEM, n=4-
24) after 24 hour treatment with 10 µM tat-CN21 alone or in the presence 
of 20 µM MK-801, 10 µM ifenprodil, 1 µM memantine, or 200 nM TTX. 
*p<0.05 compared to control while #p<0.05 compared to tat-CN21 (One-
Way ANOVA, post-hoc Dunnett’s test).  
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Rapid increases in cytoplasmic calcium were observed with bicuculline 
treatment. MK-801 was added immediately following exposure to bicuculline to 
block the open NMDA-Rs (Huettner and Bean, 1988) (Figure 29). The CaMKII 
inhibitor, tat-CN21, was then applied and subsequent changes in intracellular 
calcium concentration were monitored. Interestingly, this blockade of synaptic 
NMDA-Rs significantly blunted tat-CN21-induced calcium influx (Figure 28A). 
However, this treatment did not maintain levels of intracellular calcium to those 
observed in control, indicating that while much of the calcium influx observed with 
CaMKII inhibition was via the synaptic NMDA receptors, calcium entering through 
extrasynaptic NMDA-Rs may also contribute to this process. 
Because antagonism of the NMDA receptor successfully blunted the acute 
increase in calcium influx, we hypothesized that MK-801 would also reduce the 
neurotoxicity induced by CaMKII inhibition. Compared to cultures treated with tat-
CN21 alone, neurotoxicity was reduced nearly 80% when tat-CN21 was co-
applied with 20 µM MK-801 (Figure 28B). We next attempted to block 
extrasynaptic NMDA-Rs to determine the influence of extrasynaptic versus 
synaptic NMDA-Rs to the neurotoxicity induced by CaMKII inhibition. Low levels 
of ifenprodil and memantine have been shown to be preferential antagonists to 
the NR2B-containing extrasynaptic NMDA-Rs (Thomas et al., 2006, Xia et al., 
2010). There was still a significant increase in the observed neurotoxicity when 
tat-CN21 was co-applied with 10 µM ifenprodil or 1 µM memantine, with neither 
drug affecting viability alone (Figure 9B). However, ifenprodil does reduce the 
levels of toxicity below that observed with tat-CN21 alone (Figure 28B), 
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Figure 29: Calcium influx with CaMKII inhibition is blunted by 
synaptic blockade. Representative traces of intracellular calcium levels in 
a field of control cortical neurons or a field treated with tat-CN21 
with/without prior synaptic blockade. To induce synaptic blockade (dark 
gray trace), 10 µM bicuculline was applied to the bath (see arrow). When 
intracellular calcium levels became elevated, 20 µM MK-801 was applied 
(see arrow). At -300 seconds, control and antagonist-treated cultures were 
washed with physiological saline before application of 10 µM tat-CN21 at 
time 0.   
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suggesting that extrasynaptic NMDA-Rs may play a partial role in the toxicity 
associated with the loss of CaMKII signaling. Increasing the dose of memantine 
to 10 µM, a level that inhibits not only extrasynaptic NMDA-Rs but also partially 
inhibits synaptic NMDA-Rs, does significantly reduce neuronal death (13.6 ± 
4.6%). When cultures were treated with low levels of TTX (200 nM) to block 
action potential-induced synaptic activity, tat-CN21-induced toxicity was brought 
back to baseline (Figure 28B). Thus, while extrasynaptic NMDA-Rs cannot be 
ruled out, it is quite convincing that synaptic activity is necessary for both the 
calcium dysregulation and neurotoxicity associated with a loss of CaMKII 
signaling (Thomas et al., 2006, Xia et al., 2010). In total, these data suggest that 
CaMKII inhibition induces a slow-tonic excitotoxic event via calcium 
dysregulation, enhanced neuronal excitability, and augmented extracellular 
glutamate levels.  
Finally, to determine if the accumulation of glutamate in the bath solution 
was solely responsible for this neurotoxicity, cortical neurons were treated for 24 
hours with 10 µM tat-CN21. Then, the conditioned media was removed from 
these cultures and directly applied to naïve cortical neurons. Neurons treated 
with the conditioned media did not display a significant difference in viability 
compared to non-treated control cultures (Figure 30). We also did not observe 
significant neuronal death when 4 µM glutamate was applied to our cortical 
cultures for 24 hours (6.9 ± 3.1% vs control 5.8 ± 2.2%), suggesting that this 
glutamate concentration in the media is not sufficient to induce neuronal death in 
the absence of CaMKII inhibition. Thus, while the increased extracellular 
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Figure 30: Conditioned media from neurons treated with CaMKII 
inhibitors does not induce neurotoxicity. Neuronal death (mean ± SEM, 
n=3-9) in neurons treated with 10 µM tat-CN21 for 24 hours or naïve 
neurons treated for 24 hours with media removed from tat-CN21-treated 
neurons. *p<0.05 compared to control (One-Way ANOVA, post-hoc 
Dunnett’s test). 
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glutamate resulting from CaMKII inhibition is necessary for the observed 
neurotoxicity, it is not sufficient to produce the toxicity itself. Together, these data 
indicate that the combination of elevated glutamate with the loss of CaMKII 
activity induces toxicity. Thus, the mechanism underlying the neurotoxicity with 
CaMKII inhibition is the decreased ability of neurons to tolerate glutamate 
stimulation, including the stimulation resulting from the low levels of glutamate 
associated with the neuronal hyperactivity directly resulting from CaMKII 
inhibition.  
DISCUSSION 
Prolonged CaMKII inhibition using both small molecule (KN-93) and 
peptide (tat-AIP, myr-AIP, and tat-CN21) inhibitors is toxic to cultured neurons in 
the presence and absence of astrocytes. Although an acute one hour exposure is 
not toxic, all of these inhibitors produced neuronal death after 24 hours. We 
elected to use pharmacological approaches over genetic knockdown of CaMKII 
in order to better mimic the time-course of CaMKII inactivation associated with 
ischemic brain trauma and other diseases associated with aberrant neuronal 
activity. Pharmacological inhibitors afford the opportunity to determine acute 
changes in neuronal activity and calcium homeostasis with CaMKII inhibition. 
Plus, the CaMKII inhibitors used are not thought to display any isoform 
specificity, avoiding potential complications associated with isoform 
compensation associated with genetic knockdown. Multiple pharmacological 
inhibitors (small molecule and peptide) employing different methodologies for cell 
uptake (cell permeable small molecule versus tat and myristolated peptide import 
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strategies) were used to limit the possibility of off-target effects confounding our 
conclusions.  
The concentration of tat-CN21 (10 µM) used throughout this study is 
similar previous studies using this CaMKII inhibitor to explore neurite extension 
(Vest et al., 2007) and neuroprotection to a glutamate-insult (Vest et al., 2010, 
Ashpole and Hudmon, 2011). Although these values are ~100 fold over the IC50 
for CN21 in vitro (Vest et al., 2007, Ashpole and Hudmon, 2011), cell uptake and 
bioavailability can be limiting for intracellular peptide inhibitors (Tunnemann et al., 
2006), making the peptide concentrations used in this and other studies 
reasonable pharmacological concentrations. Finally, previously established 
inactive controls for KN-93 (KN-92) (Sumi et al, 1991) and tat-CN21 (tat-
CN21Ala) (Ashpole and Hudmon, 2011) did not induce neuronal death at the 
concentration of the active inhibitors that clearly produced toxicity, suggesting 
that the neuronal toxicity observed is due to CaMKII inactivation.  
Prolonged CaMKII inhibition is consistent with features of both necrotic 
and apoptotic cell death. Apoptotic cell death is supported by the following 
observations: 1) application of the inhibitors required an incubation period of >8 
hours to induce toxicity, 2) inhibitor application led to an increase in TUNEL 
staining, 3) colocalization between neurons that take up fluorescent tat-CN21 
and cleaved caspase-3 was observed, and 4) cell death was prevented by the 
protein translation inhibitor, cycloheximide. The pro-apoptotic Bcl-2-associated 
death promoter (BAD) protein is inactivated by CaMKII phosphorylation. Thus, it 
is possible that the prolonged inhibition of CaMKII activity dysinhibits the BAD 
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cascade, leading to apoptosis (Bok et al., 2007). A population of neurons 
containing the CaMKII inhibitor did not exhibit caspase-3 staining, yet these 
neurons consistently exhibited morphological changes in the nucleus 
(condensation and fragmentation). It is unclear whether these neurons represent 
a continuum between necrosis and apoptosis, or whether this could be 
specifically related to apoptosis with secondary necrosis (Bonfoco et al., 1995).  
CaMKII inhibition results in a slow sustained increase in intracellular 
calcium levels that is accompanied by elevated glutamate and enhanced 
neuronal excitability. Calcium dysregulation occurs within 10-20 minutes of 
exposure to tat-CN21; a time-course that correlates with maximal fluorescent 
uptake of tat-based peptides in our cortical cultures (Ashpole and Hudmon, 
2011). Although L-type voltage-gated calcium channels do not appear to 
contribute to calcium dysregulation following CaMKII inhibition, ion channels 
regulating neuronal activity (voltage-gated sodium channels and N-type voltage-
gated calcium channel) are critical for this process. Consistent with synaptic 
coupling required for calcium dysregulation, we observed that functional 
glutamate receptors (AMPA- and NMDA-subtypes) as well as elevated glutamate 
to be necessary for this process. While synaptic NMDA-Rs appeared to largely 
dictate calcium dysregulation and neuronal toxicity to CaMKII inhibition, we 
cannot rule out a contribution played by extrasynaptic NMDA-Rs in these 
processes. The involvement of both synaptic and extrasynaptic NMDA-Rs in 
calcium dysregulation and toxicity is reasonable considering that elevated levels 
of glutamate appear to accumulate in the media over time, with enhanced 
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extracellular glutamate levels observed as early as 20 minutes following 
exposure to CaMKII inhibitors. Thus, while increased synaptic transmission may 
be necessary, it is possible that once glutamate accumulates in the milieu, it can 
also activate receptors outside of the synaptic cleft. Interestingly, exposure to 
elevated glutamate using conditioned media or exogenous glutamate is not toxic 
in the absence of CaMKII inhibition, suggesting that glutamate by itself is not 
sufficient for neurotoxicity in the absence of CaMKII inhibition. However, the 
elevated extracellular glutamate in conjunction with CaMKII inhibition appears to 
be essential to both calcium dysregulation and neurotoxicity, as enzymatic 
buffering of extracellular glutamate or pharmacological inhibition of the AMPA or 
NMDA receptors prevents calcium dysregulation. The fact that media exchange 
after 4 hours prevents neuronal toxicity to CaMKII inhibition is consistent with 
these observations, further supporting an important functional and temporal 
association between CaMKII inhibition and neuronal activity in this form of 
neurotoxicity.  
Although our data does not rule out the possibility that elevated 
extracellular glutamate is produced by cell lysis, the observation that an increase 
in the number of action potentials induced by a depolarizing current following 
CaMKII inhibition by localized delivery of the CN21 inhibitor to individual cortical 
neurons supports the hypothesis that CaMKII inhibition directly enhances 
neuronal excitability. This acute response in neuronal excitability to CaMKII 
inhibition is novel. However, genetic knock down of αCaMKII in mice (Butler et 
al., 1995) or neuronal cultures by siRNA (Carter et al., 2006) support these 
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findings. Thus, results from experiments examining the effect of CaMKII inhibition 
via pharmacological (this study) or genetic approaches (Butler et al., 1995, Carter 
et al., 2006) support the hypothesis that CaMKII is a major regulator of neuronal 
excitability.  
Our experiments favor a model whereby the sustained inhibition of CaMKII 
activity instigated a vicious cycle of sustained increases in intracellular calcium 
due to sustained glutamate release. In essence, CaMKII inhibition initiates an 
excitotoxic cycle by increasing neuronal excitability which subsequently supports 
enhanced glutamate levels in the media; a feed forward cycle that can be broken 
by preventing neuronal activity, blocking calcium dysregulation or by removing 
extracellular glutamate. These data suggest that CaMKII may be viewed to 
function in neurons as a brake for glutamate-excitation and/or as a master 
regulator of neuronal excitability and calcium homeostasis. Finally, the observed 
results do not appear to be limited to highly purified cortical cultures, as co-
cultures of cortical neurons with astrocytes also display neuronal death following 
CaMKII inhibition. We cannot rule out the potential of glial function or viability 
being altered following CaMKII inhibition in mixed cultures, as glial cells also 
express CaMKII (δCaMKII (Takeuchi et al., 2000)), thus on-going experiments 
will need to examine consequences of CaMKII inhibition in astrocyte function and 
survival.  
How could CaMKII inhibition impact calcium-induced neuronal death 
during ischemia and other excitotoxic stimuli? CaMKII has been shown to 
inactivate in the core of an ischemic insult in vivo as well as in the surrounding 
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penumbral tissue (Hanson et al., 1994); a phenomena also observed following 
aberrant neuronal activity in epilepsy (Yamagata et al., 2006). The mechanism of 
CaMKII inactivation in these diseases is not well understood, but it is known that 
CaMKII proteolysis is preceeded by post-translational modifications (Churn et al., 
1992a), including a soluble to particulate transition consistent with CaMKII 
aggregation following ischemia (Aronowski et al., 1992, Hanson et al., 1994, Tao-
Cheng et al., 2002). Inactivation associated with aggregation is consistent with 
CaMKII self-association; a form of catalytic aggregation that requires calcium-
CaM activation and is maximized under ischemic conditions (i.e. reduced energy) 
(Hudmon et al., 1996, Hudmon et al., 2005). In the current study, we have 
attempted to mimic one consequence of CaMKII self-association via 
pharmacological inhibition of enzymatic activity. Similar to in vivo studies 
characterizing functional changes in CaMKII associated with aberrant neuronal 
activity, we have observed a sustained loss of activatable CaMKII with long-term 
tat-CN21 exposure in cultured cortical neurons. This sustained inactivation and 
transition of αCaMKII from the soluble to particulate fractions has been previously 
shown to also accompany excitotoxic glutamate-glycine insults in neuronal 
cultures (Hudmon et al., 2005, Ashpole and Hudmon, 2011). An intriguing 
hypothesis is that the neuroprotection produced by acute exposure to CaMKII 
inhibitors may be limiting neurotoxicity to excitotoxic glutamate/glycine 
challenges by paradoxically preventing excitotoxic-induced CaMKII inactivation-
aggregation.  
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Independent of this speculation, the present results indicate that sustained 
inactivation of CaMKII leads to neuronal cell death through engagement of 
apoptotic/necrotic pathways induced by calcium dysregulation and 
hyperexcitability, which contributes to the decreased capacity of neurons to cope 
with excitatory insults. These data may provide further mechanistic insight into 
the increased infarct size observed within αCaMKII knock-out animals (Waxham 
et al., 1996), and moreover, to the phenomenon of expanding neuronal damage 
in the ischemic penumbra. Peri-infarct depolarizations have been shown to 
underlie the progression of neuronal damage from the core throughout the 
penumbra (Mies et al., 1993, Ohta et al., 2001, Fujioka et al., 2004). Interestingly, 
these depolarizations have been shown to be calcium dependent and are 
significantly reduced by NMDA receptor antagonism (Ohta et al., 2001). These 
findings are consistent with the functional consequences of CaMKII inactivation 
highlighted in this study. Thus, our working hypothesis is that the extent of 
neuronal damage in the penumbral region is governed by the loss of CaMKII, 
which increases neuronal activity and heightens susceptibility to excitotoxic-
related insults, such as glutamate and ROS activity. 
 
*This manuscript was published in the Journal of Biological Chemistry* 
Ashpole NM, Song W, Brustovetsky T, Engleman EA, Brustovetsky N, Cummins 
TR, Hudmon A. (2012) Calcium/calmodulin-dependent protein kinase II (CaMKII) 
inhibition induces neurotoxicity via dysregulation of glutamate/calcium signaling 
and hyperexcitability. 287(11):8495-506.  
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Part III: LOSS OF CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE 
II ACTIVITY IN CORTICAL ASTROCYTES INDUCES NEUROTOXIC ATP 
RELEASE 
SUMMARY 
The extent of calcium/calmodulin-dependent protein kinase II (CaMKII) 
inactivation in the brain following ischemia directly correlates with the extent of 
damage. We have previously shown that a loss of CaMKII in neurons is 
detrimental to neuronal viability. In the current study, we detail functional 
changes in cortical astrocytes with CaMKII inhibition along with examining how 
these changes impact neurons. CaMKII inhibition in cultured astrocytes using 
either a small molecule (KN-93) or a peptide inhibitor (tat-CN21) is associated 
with calcium oscillations and dysregulated intracellular calcium levels. 
Surprisingly, this calcium influx could be blocked by the N-type calcium channel 
antagonist, omega-conotoxin. While the function of N-type calcium channels 
within astrocytes is controversial, these voltage-gated calcium channels have 
been linked to calcium-dependent vesicular gliotransmitter release. When 
extracellular glutamate and ATP levels were measured following CaMKII 
inhibition, we observed glutamate levels were not altered, whereas ATP levels in 
the extracellular environment increased with CaMKII inhibition. Extracellular ATP 
accumulation associated with CaMKII inhibition contributes both to calcium 
dysregulation within astrocytes and cortical neuron toxicity. Thus, CaMKII 
inhibition within astrocytes dysregulates calcium signaling supporting ATP 
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release – a process that fuels calcium oscillations and dysregulation in astrocytes 
along with toxic gliotransmitter activity in neurons.  
INTRODUCTION 
Astrocytes play a critical role in regulating neuronal function and plasticity 
by providing structural support, releasing neurotrophic factors, tuning synaptic 
transmission, and buffering neurotoxic ions/neurotransmitters produced by 
normal/aberrant neuronal activity (Banker, 1980, Rosenberg and Aizenman, 
1989, Pfrieger and Barres, 1997, Barres, 2008, Ransom and Ransom, 2012). 
The excitatory neurotransmitter glutamate is essential for normal synaptic activity 
amongst a majority of neuronal synapses; however, the aberrant neuronal 
activity and damage that accompanies ischemia and traumatic brain injury lead 
to toxic levels of extracellular glutamate – a process classically defined as 
excitotoxicity. Importantly, astrocytes have been shown to decrease the 
sensitivity of neurons to glutamate excitotoxicity 100-fold in culture systems, 
presumably by their ability to take-up and buffer extracellular glutamate 
(Rosenberg and Aizenman, 1989). We have previously shown that inhibition of 
calcium/calmodulin-dependent protein kinase II (CaMKII) within cultured cortical 
neurons leads to the induction of excitotoxic glutamate release. Inclusion of 
astrocytes in these neuronal cultures did not alleviate neuronal toxicity, 
suggesting that astrocyte-neuronal communication is compromised when CaMKII 
is inhibited.  
A significant decrease in CaMKII is seen within the core and penumbral 
tissue regions following a stroke (Hanson et al., 1994). The extent in the loss of 
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CaMKII signaling directly correlates with the extent of tissue damage, supporting 
the hypothesis that CaMKII inhibition may be detrimental to neuronal survival 
(Hanson et al., 1994). This model is further supported by data showing that 
pharmacological and genetic CaMKII inhibition compromises neuronal survival to 
excitotoxic insults (Waxham et al., 1996, Ashpole and Hudmon, 2011, Ashpole et 
al., 2012). However, what role or contribution that CaMKII inhibition plays in 
astrocytes and other support cells to glial-neuronal function and communication 
is unknown.  
Although CaMKII is best known for its function in neurons, CaMKII is 
expressed throughout several cell types in the brain, including glial and 
endothelial cells (Fukunaga et al., 1988, Takeuchi et al., 2000). For example, 
while αCaMKII is the predominant isoform in neurons (Ouimet et al., 1984), the 
δCaMKII variant appears to be the predominant isoform within astrocytes 
(Takeuchi et al., 2000). Within astrocytes, CaMKII signaling regulates 
cytoskeletal networks (Yano et al., 1994, Ogawara et al., 1995), gene expression 
(Yano et al., 1996), and apoptosis (Kubes et al., 1998, Song et al., 2006). Thus, it 
is conceivable that the loss of CaMKII activity within ischemic tissue represents 
CaMKII inactivation in neurons as wells as astrocytes and other supporting cells. 
In the current study, we used acute and chronic application of CaMKII inhibitors 
to investigate calcium signaling and gliotransmitter release in cultured cortical 
astrocytes. These data support a feed-forward model by which CaMKII inhibition 
in astrocytes compromises astrocyte calcium homeostasis and ultimately 
neuronal survival via ATP release. Thus, we propose a model whereby a loss 
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CaMKII activity in astrocytes further compromises neuronal survival to aberrant 
glutamate signaling through extracellular accumulation of ATP; a process that 
could greatly impact the spread and severity of the neuronal death in the 
penumbral and border zones of an ischemic insult.  
EXPERIMENTAL PROCEDURES 
Materials. Peptide inhibitors including tat-CN21 (YGRKKRRQRR-
KRPPKLGQIGRSKRVVIEDDR) and tat-CN21Ala (YGRKKRRQRR-
KAPAKAAQAAASKRVVIEDDR) as well as Fam-labeled versions of these 
peptides were synthesized by Biopeptide Co. Inc, San Diego, CA. KN-93 
(422708) and KN-92 (422709) were purchased from Calbiochem. Myristolated 
AIP (64929) was purchased from Anaspec, Fremont, CA. MRS 2179 (0900), A 
740003 (3701), and ARL 67156 (1283) were purchased from Tocris. MK-801 
(M107), CNQX (C239), nifedipine (N7634), omega-conotoxin (C9915), and 
suramin (S2671) were purchased from Sigma.  
Neuron and astrocyte cultures. Mixed co-cultures of neurons (both cortical and 
hippocampal) and astrocytes were derived from E18 to E19 Sprague-Dawley rat 
pups according to approved IACUC guidelines as described previously (Ashpole 
et al., 2012). Pure astrocytes were derived from postnatal day 1-3 Sprague-
Dawley rat pups following methods established by McCarthy and de Vellis 
(McCarthy and de Vellis, 1980). Following dissociation, digestion, and titruation, 
cortical cells were resuspended in growth media (DMEM containing 2% 
NuSerum, penicillin (10 units/mL), streptomycin (10 μg/mL), and L-glutamine 
(29.2 μg/mL)) at a density of 2.5 million cells/mL and seeded on poly-d-lysine 
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(50 μg/mL) coated 10 cm dishes. Cells were feed every 3-4 days, with half of the 
conditioned media being replaced with fresh growth media. When the cultures 
became confluent (7-8 DIV), the plates were shaken to remove oligodendrocytes. 
Following a wash, the astrocytes were then split (using trypsin), and seeded on 
12 mm or 15 mm coverslips coated in poly-d-lysine. The cultures were then 
grown in neuronal growth media (Neurobasal containing 2% NuSerum, 2% 
NS21, penicillin (10 units/mL), streptomycin (10 μg/mL), and L-glutamine 
(29.2 μg/mL) until treatment (following an additional 3-4 DIV). Pure cortical 
neurons were grown on 12 mm or 15 mm poly-d-lysine coverslips as previously 
described (Ashpole et al., 2012) for 8-10 DIV until treatment.  
Calcium imaging. Co-cultures of neurons and astrocytes (10-12 DIV) as well as 
cultures of pure astrocytes were loaded with Fluo-4AM or 2.6 μm Fura-2FF-AM 
and subsequently imaged as described previously (Ashpole et al., 2012). The 
use of Fluo-4AM or Fura-2FF-AM is highlighted in the Results. During imaging, 
the cultures were incubated in rat physiological saline (138 mM NaCl, 2.7 mM 
KCl, 1.8 mM CaCl2, 1.06 mM MgCl2, 12.4 mM HEPES, pH 7.4, 5.6 mM glucose; 
final pH adjusted to 7.3) as described (Ashpole et al., 2012). A Nikon Ti-E 
inverted fluorescent microscope was utilized to monitor fluorescent intensity once 
every 5-10 seconds. Baseline was monitored for 2-5 minutes. To identify neurons 
in the co-culture experiments, a 20mM KCl depolarization at the start of the 
imaging was employed. Neurons were identified as cells that immediately 
responded to KCl with a robust increase in calcium. In all experiments with 
CaMKII inhibitor application, the inhibitor was added 5 minutes after start of 
138 
 
imaging. For experiments requiring various receptor/channel antagonists, the 
drugs were applied at the 2 minute mark to identify whether the drug itself had an 
impact on calcium levels prior to CaMKII inhibitor application. Analysis was 
performed using Nikon Elements v3.0 in which fluorescent intensity measured in 
at least 10 cells per field. The fluorescent intensity of each cell was normalized to 
time 0 (or the 5 minute mark), as the CaMKII inhibitor was applied.   
Glutamate uptake. Glial cultures (3-4 DIV following split unto coverslips) were 
treated with CaMKII inhibitors in combination with 1.5 µCi/mL H3-glutamate and 
0.5 µM unlabeled glutamate for various lengths of time, as indicated. Cultures 
were then washed in cold PBS and lysed in 20 mM Tris, pH 7.4, 200 mM NaCl, 
0.1 mM EDTA, and 2X protease inhibitor mixture (Calbiochem, 539137) as 
described previously (Ashpole and Hudmon, 2011, Ashpole et al., 2012). The 
lysate was then diluted in Ready Safe liquid scintillation cocktail (Beckman 
Coulter), vortexed, and H3 was measured using a liquid scintillation β-counter.  
Immunocytochemistry of astrocyte cultures. Glial cultures (3-4 DIV following split 
unto coverslips) were immunostained as previously described (Ashpole and 
Hudmon, 2011, Ashpole et al., 2012). Following fixation, permeabilization, and 
blocking, the cultures were incubated in polyclonal anti-GFAP, monoclonal anti-
OX-42, polyclonal anti-pan-CaMKII, or monoclonal anti-vimentin overnight at 4 
degrees. After three washes, secondary antibodies (anti-rabbit Alexa680 or anti-
mouse Alexa594, 1:5000 (Molecular Probes)) were applied for 1 h at room 
temperature. Coverslips were washed in PBS three times and were subsequently 
mounted in Prolong Gold Antifade with DAPI mounting media (Molecular 
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Probes), and cells were imaged using a Zeiss Axio ObserverZ1 and processed 
with Axiovision 4.  
CaMKII activity assay. Astrocyte cultures were lysed in 20mM Tris, pH 7.4, 200 
mM NaCl, 0.1 mM EDTA, and 2X protease inhibitor mixture (Calbiochem, 
539137) as described previously (Ashpole and Hudmon, 2011, Ashpole et al., 
2012), sonicated, and incubated with 0.1% Triton-X-100 for 5 minutes. To 
measure total CaMKII activity, a portion of the lysate was then incubated with 50 
mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl2, 100 μM ATP, 2 mM CaCl2, 5 
μM CaM, 50 μm AC-2 (KKALRRQETVDAL), and [γ-32P]ATP (3 μCi per reaction) 
for 3 minutes at 30oC. To measure autonomous CaMKII activity, a portion of the 
lysate was incubated in 50 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl2, 
100 μM ATP, 5 mM EGTA, 50 μm AC-2, and [γ-32P]ATP (3 μCi per reaction) for 3 
minutes at 30oC. The linear range of the phosphorylation reactions extended 
from 1 to 10 minutes. Protein levels were assessed using the DC protein assay 
kit (Bio-RAD) and activity was normalized to total protein.  
Inhibitor uptake analysis. Fluorescently conjugated peptides (tat-CN21-Fam and 
tat-CN21Ala-Fam) were diluted in fresh neuronal growth media and applied to 
astrocyte cultures at a final concentration of 10 μM for varying lengths of time (0-
2 min). After treatment, coverslips were washed 3 times in PBS before blotting 
and were then mounted in Prolong Gold Antifade with DAPI mounting media. 
Coverslips were then imaged in three different fields with a Zeiss Axio Observer 
Z1 and processed with Axiovision 4. The total cell number (DAPI staining) and 
the total number of cells containing the fluorescent peptides (FITC detection) 
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were then quantified. No fluorescence was detected in cultures that were not 
treated with the fluorescent peptides.   
ATP measurements. ATP concentrations in the media were assessed using the 
Enlighten ATP Assay System per manufacturer's protocol (Promega). The 
luciferase was detected and quantified using a Victor V3 plate reader. The ATP 
detection assay standard curve was linear from 0.001 nM to 0.1 μM.  
Cell death measurements. Neuronal coverslips were stained using Live/Dead 
Cytotoxicity/Viability kit (Molecular Probes) as previously described (Ashpole and 
Hudmon, 2011, Ashpole et al., 2012). The cells were imaged using a Zeiss Axio 
Observer Z1 and processed with Axiovision 4 (x100 magnification). Each 
coverslip was imaged in three different fields. The images were exported and 
automated cell counting software (Nikon Elements v3.0) was used to quantify 
cytotoxic cells (Texas red filter), viable cells (FITC filter), or total cell number 
(DAPI filter).  
Data analysis. Statistical analysis was performed using SigmaPlot v11 software. 
One-way ANOVA with a subsequent Dunnett's test was used to compare 
differences between the means of each group in the in situ calcium imaging 
experiments, in vitro catalytic assays, and in situ cell death assays. When 
appropriate, a Student's t test was also performed. 
RESULTS 
Calcium Dysregulation with CaMKII inhibition in Neuronal/Glial Cultures 
The degree of CaMKII inactivation within the brain following stroke directly 
correlates with the extent of neuronal damage (Hanson et al., 1994). We have 
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previously shown that inhibition of CaMKII in cultured cortical neurons induced an 
excitotoxic neuronal death cascade (Ashpole et al., 2012). This neuronal death 
was also observed in co-cultures of neurons and astrocytes, suggesting that 
perhaps the neuroprotective function of astrocytes was compromised when 
CaMKII was inhibited (Ashpole et al., 2012). Because aberrant neuronal calcium 
influx contributed to the neurotoxicity induced by CaMKII inhibition, we first 
examined whether similar patterns of calcium dysregulation were observed in the 
co-cultures of neurons and astrocytes following application of CaMKII inhibitors 
as previously observed in our pure neuronal cultures. For this, we optically 
monitored intracellular calcium levels using Fluo-4AM in our co-cultures of 
neurons and astrocytes. Previously, we characterized the cellular content of 
these co-cultures and identified that roughly 40% of cells in these cultures were 
MAP-2 positive neurons and nearly 60% were GFAP-positive astrocytes 
(Ashpole et al., 2012). To inhibit CaMKII, we used the specific CaMKII inhibitor, 
tat-CN21 (Vest et al., 2007, Ashpole and Hudmon, 2011, Ashpole et al., 2012). 
CN21 is a peptide inhibitor derived from the endogenous CaMKII inhibitory 
protein in the brain originally termed CAMKII-N (Chang et al., 1998). Because the 
peptide inhibitor is not membrane permeable, it was conjugated to the cell-
penetrant motif, tat, for intracellular delivery of the peptide inhibitor as described 
previously (Vest et al., 2010, Ashpole and Hudmon, 2011, Ashpole et al., 2012). 
As shown previously in highly enriched neuronal cultures (Ashpole et al., 2012), 
we observed that application of tat-CN21 peptide resulted in increased 
intracellular calcium levels (Figure 1A); however, the kinetics of this increase in 
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intracellular calcium appeared markedly different than the slow-onset previously 
observed in our enriched cortical cultures. The increase in intracellular calcium 
levels seen with the active CaMKII inhibitor tat-CN21 were not seen using our 
control peptide, tat-CN21Ala (Ashpole and Hudmon, 2011). To tease apart the 
contribution of changes in Fluo-4AM fluorescence within the mixed culture 
system, a KCl depolarization stimulation was used to identify the fluorescent 
calcium signatures of neurons. Because nearly all of the cells that were not MAP-
2 positive in these co-cultures were GFAP-positive (Ashpole et al., 2012), the 
cells that did not immediately respond to the KCl were considered astrocytes. 
Using this method to deconvolute the calcium signatures of neurons versus glial 
cells, we found that as we described previously (Ashpole et al., 2012), neurons 
undergo a characteristic delayed calcium dysregulation (Figure 31B). Astrocytes 
appear quite different in both the time of onset and oscillatory nature of the 
kinetics for changes in intracellular calcium levels (Figure 31B-C). In addition, 
unlike the dysregulated calcium levels seen in neurons, the dysregulated 
intracellular calcium levels did not appear to keep increasing over time in the glial 
cells (Figure 31C). These findings in mixed cortical cultures were consistent 
when co-cultures of hippocampal neurons and astrocytes were loaded with Fura-
2FF as the calcium indicator and subjected to CaMKII inhibitor application 
(Figure 32). These data demonstrate that the calcium dysregulation seen in 
cultured cortical neurons and hippocampal neurons is accompanied by aberrant 
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Figure 31: Calcium dysregulation in neuronal/astrocyte cultures with 
CaMKII inhibition. A, Average trace (+/- SEM, n=3) of calcium response 
in mixed cultures of cortical neurons and astrocytes treated with 10 µM tat-
CN21 or tat-CN21Ala, as measured by Fluo-4AM. B, Average trace (+/- 
SEM, n=3) of calcium response with tat-CN21 or tat-CN21Ala application 
in cells within the field of interest that responded to a depolarizing 20 mM 
KCl pulse at time -300 seconds (considered neurons). C, Average trace 
(+/- SEM, n=3) of calcium response with tat-CN21 or tat-CN21Ala 
application in cells that did not respond to the KCl pulse at time -300 
seconds(considered astrocytes).  
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Figure 32: CaMKII inhibition dysregulates calcium in neurons and 
astrocytes. A, Representative traces of Fura-2FF calcium response in 
hippocampal neurons (identified by KCl pulse at time 0) following 10 µM 
tat-CN21 application. B, Representative traces of Fura-2FF calcium 
response in astrocytes (which did not respond to KCl at time 0) following 
tat-CN21 application. 
Courtesy of the Brustovetsky Lab 
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calcium signaling of different kinetics (faster onset, oscillations, and decay) than 
the surrounding astrocytes.  
CaMKII Inhibition in Astrocytes 
In order to better understand the impact of CaMKII inhibition specifically 
within the one population of neuronal support cells, cortical astrocytes devoid of 
neurons were cultured. Although we employed a well-characterized methodology 
for astrocyte cultures (McCarthy and de Vellis, 1980)(see Methods), we used 
immunohistochemistry to further characterize the cellular content of specific 
cellular markers within these cultures. Fluorescent immunostaining shows that 
93.9 +/- 10.8 % (n = 6) of these cells were GFAP positive and 78.9 +/- 21.2% (n 
= 6) were vimentin positive (Figure 33A-C), while only 2.3 +/- 3.9% (n = 6) were 
OX42 positive, suggesting these cultures were predominantly reactive astrocytes 
with little microglial contamination. We do not see any MAP-2 immunostaining in 
these enriched astrocyte cultures. In addition, 93.0 +/- 9.8% of our astrocytes in 
culture exhibited CaMKII staining using a pan-CaMKII primary antibody (Figure 
33B-C).  
In addition, because one study has previously published that a significant 
fraction of CaMKII existed in the activated (i.e. autophosphorylated) state in 
cultured astrocytes (Song et al., 2006), we also measured the Ca2+/CaM-
dependent and Ca2+/CaM-independent CaMKII activity, using the highly specific 
CaMKII peptide, AC-2, in our well-characterized in vitro kinase assays (Hudmon 
et al., 1996, Ashpole et al., 2012). The CaMKII activity measured in the presence 
of Ca2+/CaM is defined as the total pool of CaMKII activity, whereas, the CaMKII 
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Figure 33: CaMKII expression and activity in cultured cortical 
astrocytes. A, Representative image of a field of astrocytes 
immunostained with GFAP (green), OX42 (red), and Hoecsht (blue). B, 
Representative image of field of astrocytes immunostained with vimentin 
(red) and pan-CaMKII (green). C, Average number of cells (n=3, +/- SEM) 
positively stained with GFAP, vimentin, OX42, and CaMKII. D, Average 
Ca2+/CaM-stimulated (total) CaMKII activity within astrocyte lysates treated 
with 10 µM tat-CN21 or tat-CN21Ala. Inhibitors were added to the cultures 
10 minutes before lysis and activity was measured in vitro via P-32 
incorporation unto AC-2, a known CaMKII substrate. The asterisk indicates 
significant difference compared to control (*p<0.05, One-Way ANOVA, 
post-hoc Dunnett’s test). E, Average CaM-independent (autonomous) 
CaMKII activity within astrocyte lysates treated with 10 µM tat-CN21 or tat-
CN21Ala as described in D. The asterisk indicates significant difference 
compared to control (*p<0.05, One-Way ANOVA, post-hoc Dunnett’s test). 
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activity measured in the absence of Ca2+/CaM is defined as the pool of 
autonomous, or Thr286 autophosphorylated pool of CaMKII (Lai et al., 1986, Lou 
et al., 1986, Schworer et al., 1988). The fraction of CaMKII autophosphorylated 
at Thr286 is believed to represent the pool of CaMKII activated in situ. We 
observed that under basal conditions, 14.0 +/- 2.6% (n = 4) of the total CaMKII 
activity within our cultured astrocytes was autonomous. Although these results 
differ from a previous study showing that CaMKII is largely autophosphorylated in 
cultured astrocytes (Song et al., 2006), it is important to note that the percentage 
of this autophosphorylated activity can be influenced by the “state” of the 
astrocytes as well during the tissue processing required to make the 
measurement. Thus, we do not see fully autophosphorylated CaMKII within our 
highly enriched astrocyte cultures; however, as shown in neurons and other cell 
types, our data favor the hypothesis that astrocyte activation and calcium 
signaling can further enhance the extent of activated-autophosphorylated 
CaMKII.  
Next, we examined the effect of the high-affinity CaMKII inhibitor, tat-
CN21 (Vest et al., 2007, Ashpole and Hudmon, 2011), on CaMKII activity in the 
astrocyte cultures. To address this, we measured Ca2+/CaM-stimulated and 
autonomous CaMKII activity in the astrocytes after 10 minute exposure to the 
active and control tat-CN21 inhibitor. As expected, tat-CN21 significantly reduced 
autonomous CaMKII activity. We observed a 40.8 +/- 19.9% and 38.7 +/- 13.5% 
decrease in autonomous CaMKII activity in tat-CN21 cultures compared to 
cultures treated with DMSO or control tat-CN21Ala (Figure 33D-E). In an effort to 
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correlate the reduction in CaMKII activity with the uptake of the CaMKII inhibitors, 
we applied the carboxyfluorescein-tagged tat-CN21 to astrocytes and measured 
cellular uptake using fluorescent microscopy. Interestingly, tat-CN21-Fam uptake 
was maximal within minutes (Figure 34), with 46.3 +/- 7.4% of astrocytes 
exhibiting robust inhibitor uptake (tat-CN21Ala taken up in 44.8 +/- 3.1% of cells). 
Remarkably, fluorescent peptide uptake is optically seen by 30 seconds (Figure 
34). These data show that both the uptake of the control CaMKII inhibitor (tat-
CN21Ala-Fam) and the active CaMKII inhibitor (tat-CN21-Fam) is seen in rapidly 
(within seconds) and within 50% of the cells. Together, these data indicate that 
there is a correlation between the percentage of astrocytes that take up the 
peptide inhibitor (45%) and the extent of CaMKII inhibition (40%). The uptake of 
the peptide inhibitors in cultured astrocytes is faster than we previously observed 
in cortical neurons (Ashpole and Hudmon, 2011), suggesting that the rate of 
calcium dysregulation in both cell types is correlated to the rate of peptide 
inhibitor uptake.  
Decreased Glutamate Uptake in Astrocytes 
Our previous studies indicated that inhibition of glutamate signaling 
prevented neurotoxicity associated with CaMKII inhibition. Because the inclusion 
of astrocytes in the neuronal cultures did not prevent this neurotoxicity or the 
calcium dysregulation associated with CaMKII inhibition, we hypothesized that 
CaMKII inhibitors were negatively impacting glutamate uptake in astrocytes. To 
address this, we applied H3-glutamate to astrocytes and measured its uptake in 
the presence and absence of the CaMKII inhibitor tat-CN21. As expected, 10 µM 
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Figure 34: CaMKII inhibitors are rapidly taken up by astrocytes. 
Fluorescently-conjugated tat-CN21 and tat-CN21Ala (10 µM) were applied 
to astrocytes for varying lengths of time. The average number of cells that 
exhibited uptake was examined using fluorescent microscopy. Total cell 
number was determined by Hoecsht staining. Inset, Average number of 
cells with fluorescently conjugated tat-CN21 and tat-CN21Ala 20 minutes 
after application, identified as described above.  
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tat-CN21 significantly reduced the level of H3-glutamate uptake in astrocytes 
compared to control cultures, and cultures treated with inactive tat-CN21Ala 
(Figure 35). Glutamate uptake was reduced when CaMKII inhibitors were applied 
for 4 hours (73.3 +/- 0.96 %), 8 hours (75.9 +/- 7.4%), or 24 hours (78.8 +/- 
1.75%), suggesting that a loss of CaMKII activity in astrocytes negatively affects 
the ability of astrocytes to buffer extracellular glutamate.   
Calcium Dysregulation in Astrocytes 
Having identified that CaMKII inhibition effects astrocyte homeostasis in 
our enriched astrocyte cultures, we next aimed to identify mechanisms that 
contribute to the calcium dysregulation in these cultures when CaMKII is 
inhibited. As in the mixed cultures, application of tat-CN21 rapidly induced 
oscillatory increases in the intracellular calcium levels within astrocytes. Calcium 
transients in a single imaged astrocyte is shown in Figure 36A, whereas time 
traces for multiple astrocytes are shown in Figure 36B. In contrast to the mixed 
culture glia, the intracellular calcium dysregulation seen in pure astrocyte cultures 
peaks (~30 seconds following application) and is slowly reduced over a period of 
several minutes (Figure 36C). As before, only the active CaMKII inhibitor tat-
CN21 and not tat-CN21Ala the inactive control peptide dysregulated intracellular 
calcium levels in astrocytes (Figure 36C-D). Not all cells exhibited this calcium 
dysregulation with tat-CN21 application, which is likely attributed to the limited 
uptake of the inhibitors within the cultures (Figure 34). Although we were initially 
surprised at how quickly we observed calcium dysregulation in astrocytes 
compared to what was observed previously in neurons, the rapid calcium 
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Figure 35: CaMKII inhibition decreases glutamate uptake in 
Astrocytes. Astrocytes were treated with 10 µM tat-CN21 or tat-CN21Ala 
for 20 minutes following which 1.5 µCi/mL [H3]-glutamate/ 0.5 µM 
unlabeled-glutamate were applied for 2 hours. Following incubation, liquid 
scintillation counting of cellular lysates indicated levels of H3-glutamate in 
the cells. Counts were normalized for protein concentration. * indicates 
significant difference compared to tat-CN21Ala (*p<0.05, t-test). 
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Figure 36: Calcium dysregulation in astrocytes with CaMKII inhibition. 
A, Representative image of an astrocyte loaded with Fluo-4AM responding 
to 10 µM tat-CN21 application. B, Representative traces of a field of 
astrocytes in response to tat-CN21 application at time 0. C, Average trace 
(+/-SEM, n=3) of calcium response in astrocytes treated with DMSO 
control, 10 µM tat-CN21, or tat-CN21Ala. D, Average area under the curve 
from time 0-500 seconds (+/- SEM, n=3-5) following treatment with tat-
CN21 and/or co-treatment with various other pharmacological inhibitors, as 
indicated. Pharmacological inhibitors were added at -120 sec; none of the 
inhibitors altered baseline. Asterisk indicates significant difference 
compared to control while the pound sign indicates a significant difference 
compared to tat-CN21 (*#p<0.05, One-way ANOVA, post-hoc Dunnett’s 
test). 
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response induced by CaMKII inhibition is consistent with the rate of peptide 
inhibitor uptake we observed using fluorescently labeled peptides (Figure 34). 
The small membrane permeable inhibitor of CaMKII, KN-93, also produced a 
rapid increase in intracellular calcium concentrations while KN-92 (inactive 
control) had no effect (Figure 36D). Thus, both peptide and small molecule 
inhibitors of CaMKII rapidly dysregulate astrocyte calcium homeostasis. Because 
the calcium dysregulation induced by CaMKII inhibition is rapid and was blocked 
by low extracellular calcium (Figure 36D), we probed the role of multiple CaMKII 
substrates within the plasma membrane that are known modulators of calcium 
signaling. 
Although the functional role of many of the voltage- and ligand-gated 
channels in the astrocyte plasma membrane is not fully appreciated, astrocytes 
express several of these proteins, including L-type (CaV1.2) and N-type (CaV2.2) 
calcium channels and the NMDA receptor (Latour et al., 2003, D'Ascenzo et al., 
2004, Zhou et al., 2010). Thus, pharmacological antagonists of these receptors 
were applied to the astrocytes two minutes before tat-CN21 was administered. 
Pretreatment with MK-801, the NMDA-receptor blocker, had no effect on the 
calcium influx induced by tat-CN21 (Figure 36D). Furthermore, CNQX, the 
AMPA-receptor blocker, and Nifedipine, the L-type calcium channel antagonist, 
did not reduce the calcium influx associated with the CaMKII inhibitors (Figure 
36D). The N-type calcium channel antagonist, omega-conotoxin, completely 
prevented the calcium influx associated with tat-CN21 application (Figure 36D). 
While the contribution of N-type calcium channels in astrocyte signaling is not 
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fully understood, it has been shown that gliotransmitter release (ATP and 
glutamate) from astrocytes is dependent on calcium/SNARE-dependent 
exocytosis (Araque et al., 2000, Parpura and Zorec, 2010, Yaguchi and 
Nishizaki, 2010, Liu et al., 2011, Yasuda et al., 2011). The potential for the 
gliotransmitter ATP being aberrantly released by CaMKII inhibition is particularly 
intriguing, as this glia-neurotransmitter has been shown to regulate calcium 
signaling in neurons and calcium oscillations in astrocytes (McCarthy and Salm, 
1991, Salter and Hicks, 1994, Centemeri et al., 1997, Guthrie et al., 1999). 
CaMKII Inhibition Induces ATP Release 
To test the hypothesis that perhaps aberrant gliotransmitter release is 
produced during CaMKII inhibition, we first determined whether CaMKII inhibition 
led to the accumulation of extracellular glutamate in the astrocyte media after 24 
hours. Previously we had used both a glutamate oxidase assay and HPLC 
chromatography to show that glutamate levels are elevated in the neuronal 
media as soon as 20 minutes following CaMKII inhibition in neurons (Ashpole et 
al., 2012). However, in astrocytes, neither the peptide inhibitor tat-CN21 nor the 
small molecule inhibitor KN-93 were observed to alter the levels of extracellular 
glutamate compared to control astrocytes (Figure 37A). Next we measured 
changes in ATP accumulation in the media using a luciferase assay to measure 
ATP levels in the media. ATP has been shown previously to be one of the most 
abundant gliotransmitters within cortical astrocytes (Guthrie et al., 1999, Cotrina 
et al., 2000, Coco et al., 2003) where its release has been shown to modulate a 
number of different purinergic receptors in neurons and astrocytes (Inoue et al., 
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2007, Koles et al., 2011). Unlike extracellular glutamate, we observed that both 
tat-CN21 and KN-93 significantly increased extracellular ATP concentration 
compared to their matched control inhibitors (i.e. tat-CN21Ala and KN-92) (Figure 
37B). Furthermore, a myristolated version of the autoinhibitory protein of CaMKII, 
termed myr-AIP, also significantly increased extracellular ATP with a 1.88 +/- 
0.50 fold increase over control, suggesting that both small molecule and peptide 
inhibitors of CaMKII with various cell-penetrant motifs are able to induce ATP 
accumulation in the extracellular media.  
Because N-type calcium channel inhibition blocked intracellular calcium 
dysregulation, we pretreated astrocytes with omega-conotoxin and again 
measured extracellular ATP content following CaMKII inhibition. Application of 
omega-conotoxin indeed prevented the accumulation of extracellular ATP when 
CaMKII was inhibited (Figure 37C). This data suggests that CaMKII inhibition 
leads to calcium influx through the N-type voltage-gated calcium channel and 
ATP exocytosis. Because purinergic signaling within astrocytes has been shown 
to induce further release of ATP, we measured extracellular ATP levels when tat-
CN21 was applied to astrocytes in combination with various purinergic receptor 
antagonists. As expected, suramin, the non-selective purinergic receptor blocker, 
decreased extracellular ATP levels compared to cultures treated with tat-CN21 
alone (Figure 37C). However, the small increase in ATP levels were significantly 
different than control astrocytes (Figure 37C), suggesting that the initial phase of 
CaMKII-induced ATP release produced downstream of N-type calcium channel-
activity is initially independent of puringeric receptors. While astrocytes express 
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Figure 37: Aberrant gliotransmitter release with CaMKII inhibition. A, 
Average change in extracellular glutamate concentration (n=6, St Dev) in 
astrocyte cultures following 24 hour application of various CaMKII inhibitors 
and controls (p>0.05, One-Way ANOVA). B, Average change in 
extracellular ATP concentration (n=6, St Dev) in astrocyte cultures 
following 24 hour application of various CaMKII inhibitors and control. The 
asterisk indicates significant difference compared to control (*p<0.05, One-
way ANOVA, post-hoc Dunnett’s test). C, Average change in extracellular 
ATP concentration when tat-CN21 was applied alone or in combination 
with various pharmacological modulators of purinergic signaling and the N-
type calcium channel blocker, omega-conotoxin. The asterisk indicates 
significant difference compared to tat-CN21 while the pound sign indicates 
significant difference compared to control (*#p<0.05, One-way ANOVA, 
post-hoc Dunnett’s test).  
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several purinergic receptors, CaMKII signaling has been previously linked to 
P2Y1 and P2X7 receptors (Leon et al., 2006). Thus, we next examined whether 
pharmacological antagonists of these subtypes of purinergic receptors reduced 
the aberrant increase extracellular ATP concentration induced by CaMKII 
inhibition. Interestingly, co-application of tat-CN21 with either MRS 2179, the 
P2Y1 antagonist, or A 74003, the P2X7 antagonist, led to a significant reduction 
in extracellular ATP concentrations compared to tat-CN21 alone (Figure 37C). 
Importantly, none of the purinergic receptor antagonists had an effect on basal 
ATP concentration (i.e. without tat-CN21) (Figure 38). Although we observed a 
statistical difference in the levels extracellular ATP after 24 hrs following CaMKII 
inhibition, we went ahead and determined the contribution of ectoATPases on the 
level of ATP measured in the astrocyte media following CaMKII inhibition. We 
observed a robust increase in level of extracellular ATP under these conditions 
(Figure 37C), suggesting that CaMKII inhibition within astrocytes negatively 
impacts astrocyte homeostasis by leading to calcium dysregulation and release 
of the gliotransmitter ATP.  
To further connect the immediate dysregulation of intracellular calcium 
homeostasis observed with CaMKII inhibition (Figure 36) to the long-term 
accumulation of extracellular ATP (Figure 37), intracellular calcium levels were 
monitored when purinergic receptors were antagonized prior to tat-CN21 
application. Interestingly, suramin, MRS 2179, and A 74003 all significantly 
reduced the total calcium influx induced by CaMKII inhibition (Figure 39). The 
inability of these inhibitors to reduce calcium influx back to baseline is not 
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Figure 38: Pharmacological purinergic signaling modulators had no 
effect on basal extracellular ATP. Average fold change in extracellular 
ATP levels (n=3-4, St Dev) when astrocytes were treated with various 
pharmacological modulators of purinergic signaling, compared to control 
(p>0.05, One-Way ANOVA).  
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surprising, as the N-type calcium channels appear to be responsible for the initial 
phase of calcium dysregulation and release of ATP. Interestingly, when multiple 
calcium wave forms for the individual astrocytes are plotted rather than simply 
integrating the are under the curve as shown in Figure 5A, it become quite 
apparent that the oscillations of calcium observed with tat-CN21 (Figure 39A-B) 
are absent in the presence of purinergic antagonists (Figure 39B). Together, 
these data support the model that CaMKII inhibition in astrocytes leads to 
aberrant activation of N-type calcium channels which in turn leads to ATP release 
and a feed-forward loop of subsequent calcium dysregulation supported by ATP 
release.  
CaMKII Inhibition in Astrocytes is Detrimental for Neuronal Viability 
Astrocytes play a critical role in maintaining neuronal viability, thus 
alterations in astrocyte homeostasis could have dire consequences on neuronal 
survival. Thus, we examined neuronal viability when neurons were treated with 
astrocyte-conditioned media following astrocyte exposure to CaMKII inhibitors. 
Compared to control media, conditioned media from astrocytes treated with tat-
CN21 significantly increased levels of neurotoxicity (Figure 40). Importantly, 
conditioned media from astrocytes treated with the inactive control, tat-CN21Ala, 
did not induce neuronal death (Figure 40). As described earlier, astrocytes 
treated with tat-CN21 in combination with P2Y1 or P2X7 antagonists (MRS 2179 
or A 74003, respectively) reduced extracellular ATP concentrations compared to 
tat-CN21 alone. Similarly, these combinatorial treatments reduced neuronal 
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Figure 39: ATP signaling contributes to calcium dysregulation with 
CaMKII inhibition. A, Average area under the curve (+/- SEM, n=3-5) for 
calcium influx following treatment with tat-CN21 and/or co-treatment with 
various other pharmacological inhibitors, as indicated. Pharmacological 
inhibitors were added at -120 sec; none of the inhibitors altered baseline. 
Asterisk indicates significant difference compared to control while the 
pound sign indicates a significant difference compared to tat-CN21 (One-
way ANOVA, post-hoc Dunnett’s test, *#p<0.05). B, Representative traces 
of astrocytic calcium response following tat-CN21 application at time 0 with 
suramin pre-treatment at time -120 seconds.  
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Figure 40: Neuronal death with conditioned media from astrocytes 
treated with CaMKII inhibitors. Average neuronal death (n=5-8, ± SEM) 
in neurons treated (24 hr) with conditioned media from astrocytes 
subjected to 10 µM tat-CN21Ala or tat-CN21 alone, or in combination with 
MRS 2179, A 74003, or ARL 67156 for 24 hr. The asterisk indicates 
significant difference compared to control while the pound sign indicates 
significant difference compared to tat-CN21 alone (*#p<0.05, One-Way 
ANOVA, post-hoc Dunnett’s test). 
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death (Figure 40). In Figure 5B, we show that ectoATPase treatment significantly 
increased extracellular ATP concentrations compared to tat-CN21 alone. In 
parallel, we see that this media with the highest ATP concentration results in the 
highest level of neuronal death (Figure 40). Thus, there is a direct correlation 
between the level of extracellular ATP released by astrocytes following CaMKII 
inhibition and the extent of neuronal death. Together, these data indicate that 
CaMKII inhibition in astrocytes dysregulates calcium homeostasis and leads to 
ATP release, which not only exacerbates the calcium dysregulation in astrocytes, 
also ultimately induces neuronal death.     
DISCUSSION 
Following an ischemic stroke, astrocytes are activated and accumulate 
within the ischemic core and penumbral regions (Petito et al., 1998, Kajihara et 
al., 2001, Schmidt-Kastner et al., 2005, Zamanian et al., 2012). This infiltration 
and activation has been shown to have both beneficial and harmful effects. 
Neuroprotection can be seen when astrocytes are properly functioning and are 
able to take up glutamate, buffer K+, and scavenge reactive oxygen species. 
However, astrocytes within this region can also contribute to neuronal death 
when these neuroprotective effects are reversed and glutamate, reactive oxygen 
species, and ATP are released from the astrocytes (Takahashi et al., 1997, 
Parpura et al., 2004, Zhang et al., 2007). Thus, the dysregulation of astrocyte 
homeostasis within the core and penumbral regions contributes to the 
subsequent neuronal death. Interestingly, the extent of damage observed within 
these regions is also correlated with a decrease in CaMKII activity. We have 
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previously shown that CaMKII inhibition within neurons is detrimental to neuronal 
viability by inducing an excitotoxic-like cascade. We now show that inhibition of 
CaMKII in the supporting astrocytes can also negatively affect neuronal viability. 
CaMKII inhibitors induced an aberrant calcium influx in astrocytes immediately 
after entering the cells. While the initial calcium response appears to be the 
largest, the intracellular calcium concentration continues to remain elevated over 
time and oscillations of calcium are prevalent throughout the culture. Calcium 
oscillations and wave propagation from one astrocyte to a nearby astrocyte are 
dependent on purinergic receptor activation (Cotrina et al., 2000, Suadicani et al., 
2006). Consistent with this, we saw that blockade of purinergic receptors resulted 
in a decrease in the calcium influx and ablation of the calcium oscillations 
induced by CaMKII inhibition. Furthermore, an increase in extracellular ATP 
concentration was observed. Importantly, there was a direct correlation between 
the aberrant calcium influx and ATP accumulation; antagonists that reduced 
calcium influx, also reduced extracellular ATP concentrations. These findings are 
in line with the well-understood cyclic relationship between intracellular calcium 
and extracellular ATP within astrocytes. Increases in cytotosolic calcium underlie 
vesicular ATP release (Coco et al., 2003, Pryazhnikov and Khiroug, 2008), which 
then activates purinergic receptors to induce further influx of calcium (McCarthy 
and Salm, 1991, Salter and Hicks, 1994, Centemeri et al., 1997, Guthrie et al., 
1999) thereby inducing a cascade of calcium influx and ATP release. 
Increased purinergic signaling has long-been implicated in 
neurodegeneration (reviewed by (Franke and Illes, 2006)). Upregulation of 
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purinergic receptors and increased extracellular ATP have been associated with 
ischemia (Phillis et al., 1994, Volonte et al., 2003, Franke et al., 2004), traumatic 
brain and spinal cord injury (Ryu et al., 2002, Wang et al., 2004), epilepsy, 
Parkinson’s disease, and Alzheimer’s disease (reviewed by (Franke and Illes, 
2006)). Antagonism of purinergic receptors has been shown to decrease infarct 
size following stroke (Lammer et al., 2006, Kuboyama et al., 2011), and improve 
functional recovery after stroke and spinal cord injury (Wang et al., 2004, 
Kuboyama et al., 2011, Lammer et al., 2011). Although a decrease in overall 
ATP availability is seen within the ischemic core and penumbral regions, there is 
a significant increase in extracellular ATP concentration, suggesting that either 
ATP release is increased or ATP breakdown mechanisms are impaired (Melani 
et al., 2005). Our data suggest that purinergic signaling initiated by CaMKII 
inhibition negatively impacts both astrocytes and neurons. Within astrocytes, it 
sustains the calcium dysregulation initiated by N-type calcium channels. The 
increased ATP in the astrocyte-conditioned media then instigates neurotoxicity 
when applied to cultured cortical neurons. While neurons and astrocytes express 
a variety of purinergic receptors, we chose to focus on two receptors, P2Y1 and 
P2X7; both of which are known to play a role in maintaining astrocyte function 
and regulating neuronal viability. P2X7 receptor activation has been shown to 
produce gliotransmitter release (Sperlagh et al., 2002, Duan et al., 2003, 
Suadicani et al., 2006) and is often associated with cellular death signaling in 
both neurons and astrocytes (Schulze-Lohoff et al., 1998, Ferrari et al., 1999). 
P2Y1 signaling has also been implicated in gliotransmitter release (Jourdain et 
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al., 2007), apoptosis (Sellers et al., 2001, Mamedova et al., 2006), and calcium 
dysregulation (Gallagher and Salter, 2003). Thus, it was not surprising when the 
highly-selective antagonists of both P2Y1 and P2X7 were effective at reducing 
the dysregulation observed in both astrocyte and neuronal cultures. However, we 
initially did not expect both MRS 2179 (P2Y1 antagonist) and A 74003 (P2X7 
antagonist) to be equally effective at preventing ATP accumulation within the 
astrocyte media. This may be explained by the fact that both receptor subtypes 
influence intracellular calcium concentrations and ATP release (Hamilton et al., 
2008) and perhaps blunting one of the effectors is sufficient to block the 
regenerative cascade of calcium influx and ATP release.  
Purinergic receptor signaling has been shown to activate a variety of 
downstream signaling pathways, including the CaMKII pathway. Both P2Y1 and 
P2X7 receptor activation has been shown to lead to the phosphorylation and 
activation of CaMKII (Leon et al., 2006). Not only is CaMKII activated by the 
calcium influx following P2 activation, CaMKII also regulates purinergic receptor 
signaling. For example, P2Y1 receptor internalization secondary to receptor 
activation is dependent on CaMKII activity (Tulapurkar et al., 2006). It is 
interesting to note that several CaMKII substrates (P2Y1, GluN2B, AMPA-R) are 
also known to play a role in regulating CaMKII activity. It is possible that the 
cellular response to a loss of CaMKII activity is to attempt to re-instate the loss of 
this calcium-sensor by enhancing further calcium flux. Our data is consistent with 
this theory. We previously showed that CaMKII inhibition induces glutamate 
release from neurons which subsequently increases intracellular calcium. Here, 
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we show that CaMKII inhibition induces ATP release from astrocytes which also 
subsequently increases intracellular calcium. While excessive levels of 
extracellular glutamate have been shown to lead to CaMKII inactivation, it is not 
known whether excessive extracellular ATP induces CaMKII inactivation as well.  
However, several studies suggest that excessive calcium influx under 
circumstances of decreased intracellular ATP availability lead to the inactivation 
and/or aggregation of CaMKII. Thus, it is possible that CaMKII becomes 
inactivated when P2 signaling is excessively increased. If this were the case, our 
data suggests that CaMKII inactivation would continue the vicious cycle of 
extracellular ATP accumulation and aberrant calcium influx. Regardless of this 
speculation, our data supports our previous model in which a loss of CaMKII 
activity is detrimental to neuronal survival. From this study we can add to our 
model that CaMKII inhibition in astrocytes is also neurotoxic as inhibition leads to 
calcium influx and ATP release from astrocytes which inevitably induces 
neurotoxicity. These data suggest that the loss of CaMKII activity within the core 
and penumbral regions of an ischemic stroke is detrimental for neuronal survival 
by altering neuronal-neuronal and glial-neuronal communications. Therefore, 
avenues of restoring CaMKII activity within these ischemic tissues may be 
imperative for affording neuroprotection and stopping the expansion of cellular 
death away from the core following the insult.  
*This manuscript is under review * 
Ashpole NM, Martin MP, Brustovetsky T, Brustovetsky N, Hudmon A  
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DISCUSSION 
GENERAL CONCLUSIONS 
Over thirty years of work has gone into understanding the role of CaMKII 
signaling within the brain. Since it was first identified, CaMKII has been shown to 
regulate neurotransmitter release, membrane excitability, cellular metabolism, 
and a variety of other cellular processes (as reviewed by (Colbran, 1992, 
Hudmon and Schulman, 2002)). The most recognized role of CaMKII signaling is 
the one it serves as a master regulator of LTP. Following activation, CaMKII 
transduces the incoming calcium signals into long-lasting effects with neurons, 
thereby enhancing synaptic plasticity (see Figure 41). My findings expand the 
role of CaMKII signaling in neurons, identifying that in addition to enhancing 
synaptic plasticity, CaMKII serves as a regulator of neuronal viability. Activation 
of CaMKII during periods of cellular distress leads to prolonged inactivation (≥8 
hours) of the kinase and ultimately induces neuronal death (Figure 41).  
Fluctuations in CaMKII activity have long-been associated with excitotoxic 
insults such as ischemic stroke (Aronowski et al., 1992, Westgate et al., 1994, 
Zalewska and Domanska-Janik, 1996, Zalewska et al., 1996). CaMKII is known 
to be activated following the onset of ischemia (Westgate et al., 1994, Zalewska 
and Domanska-Janik, 1996, Zalewska et al., 1996). This activation is followed by 
a rapid inactivation (Aronowski et al., 1992, Zalewska et al., 1996). The extent of 
CaMKII inactivation in the hours following insult is temporally correlated with the 
extent of neuronal death (Hanson et al., 1994). Despite these correlations, 
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Figure 41: Working model of CaMKII signaling following activation 
under physiological and pathophysiological conditions. Under 
physiological conditions, CaMKII activation leads to substrate targeting and 
synaptic plasticity. Excitotoxic insults can lead to decreased ATP 
availability and decreased pH, which support the prolonged inactivation 
and self-association of CaMKII and ultimately result in neuronal death.  
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chemical and genomic inhibition studies had yielded conflicting results as to 
whether or not it is toxic or beneficial to inhibit CaMKII during excitotoxic calcium 
signaling. Small molecule and peptide inhibitor studies suggest CaMKII activity is 
detrimental to neuronal survival, as inhibition of the kinase during insult is 
neuroprotective (Hajimohammadreza et al., 1995, Hou et al., 2009, Vest et al., 
2010). Yet, αCaMKII knock-out animals exhibit increased infarct size following 
stroke, suggesting the loss of αCaMKII activity predisposes neurons in the 
ischemic area to death (Waxham et al., 1996). While the in vitro studies 
suggested increased CaMKII activity was harmful and the in vivo studies 
suggested decreased CaMKII activity was harmful, one theme was consistent: 
aberrant fluctuations in CaMKII are tied to neuronal death. Thus, we decided to 
examine both the aberrant activation and inactivation of CaMKII in one simplified 
model system, allowing us to identify the contributions of CaMKII activity in 
neuronal death associated with excitotoxic calcium signaling.   
The data presented here unites the concepts that both aberrant activation 
and inactivation of CaMKII contribute to neuronal death. Small molecule and 
highly-specific cell-permeable peptide inhibitors of CaMKII were neuroprotective 
when applied prior to excitotoxic insult. This is consistent with a recent report 
indicating that the peptide inhibitor tat-CN21 is neuroprotective within an 
excitotoxic insult in situ and an in vivo animal model of ischemic stroke (Vest et 
al., 2010). Because aberrant CaMKII activation during times of cellular distress is 
known to lead to aggregation and prolonged inactivation of the kinase, we 
questioned whether these secondary effects were altered by the application of 
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the CaMKII inhibitors during excitotoxic insult. Interestingly, we observed that 
pharmacological inhibition of CaMKII during excitotoxic insult prevented both the 
aggregation and prolonged inactivation of the kinase. These findings led to the 
hypothesis that the activation of CaMKII during excitotoxic conditions is 
detrimental to neuronal viability because it leads to a prolonged loss of CaMKII 
activity, which ultimately underlies neuronal death. While we can not separate 
that aberrant CaMKII activation causes neuronal death because it leads to 
inactivation, we present strong evidence that the long-term inhibition which is 
known to occur following activation under these conditions predisposes neurons 
to excitotoxicity. Moreover, CaMKII inhibition in the absence of excitotoxic insult 
induced cortical neuron apoptosis by dysregulating intracellular calcium 
homeostasis and increasing excitatory glutamate signaling. This led to the 
accumulation of extracellular glutamate which perpetuated a slow-induced 
excitotoxic cascade within the cortical neurons. Blockade of the NMDA-receptors 
and enzymatic degradation of the extracellular glutamate signal afforded 
neuroprotection from CaMKII inhibition-induced toxicity. Surprisingly, co-cultures 
of neurons with glutamate-buffering astrocytes still exhibited toxicity with CaMKII 
inhibition. This was a result of CaMKII inhibitors reducing the ability of astrocytes 
to buffer extracellular glutamate. Furthermore, CaMKII inhibition dysregulated 
calcium homeostasis in astrocytes and led to increased ATP release. This 
increased ATP was neurotoxic when applied to naïve cortical neurons, 
suggesting that, similar to our observations in neurons, a loss of CaMKII activity 
171 
 
in astrocytes leads to calcium dysregulation with subsequent neurotoxic 
transmitter release.  
Together, these findings suggest that activation of CaMKII during periods 
of cellular distress is toxic as it leads to aggregation and prolonged inactivation of 
the kinase. Without CaMKII activity, neurons and astrocytes release stores of 
transmitters and perpetuate the neurotoxic signals. Thus, the role of CaMKII 
signaling in neurons extends beyond a modulator of synaptic plasticity; CaMKII 
serves as a critical regulator of neuronal viability by functioning as a feedback 
mechanism that maintains glutamate/calcium homeostasis.   
BENEFITS AND LIMITATIONS OF THE MODEL SYSTEM 
Several neurodegenerative diseases are marked by excitotoxicity, 
including ischemic stroke. A majority of ischemic strokes occur within the middle 
cerebral artery (del Zoppo et al., 1992). This artery is responsible for providing 
blood supply to the surface of the cerebral cortex and the basal ganglia. Ischemic 
stroke patients often manifest a loss in language expression and comprehension 
because the middle cerebral artery is essential for blood supply to the Broca’s 
and Wernicke’s language areas of the frontal and temporal lobes. Furthermore, 
the blood supply of the motor cortex and sensory cortex are also supplied by the 
middle cerebral artery, which underlies the deficits in movement and sensation in 
stroke patients. Thus, several of the phenotypical characteristics of ischemic 
stroke are produced by the occlusion of blood supply from the middle cerebral 
artery to the cerebral cortex. Because of this, cortical cultures are an optimal 
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avenue for uncovering mechanisms underlying the excitotoxicity that ensues 
following stroke.  
The development of techniques to derive neurons from embryonic mouse 
and rat cortex has afforded the ability of using cortical cultures to model 
excitotoxicity for over 20 years (Dichter, 1978, Choi et al., 1987). While in vivo 
models mimic the pathological disease state, they inherently contain more 
variables than a reduced culture system. Our culture model allowed us to 
effectively answer our questions regarding the physiological role of CaMKII 
signaling in neurons and astrocytes without complications from exogenous 
variables such as immune cell activation and infiltration. While we opted to use 
cortical cultures because the cortex is most-often the site of ischemic stroke 
damage, many studies also use hippocampal cultures to model excitotoxic-
related insults. Hippocampal neurons, particularly within the CA1 region, are 
extremely vulnerable to excitotoxicity (Benveniste et al., 1984, Kirino and Sano, 
1984, Mattson and Kater, 1989). However, the hippocampus is also marked by 
neuronal populations within dentate gyrus that are resistant to this toxicity (Kirino 
and Sano, 1984, Mattson and Kater, 1989). Therefore, hippocampal cultures 
contain a mixture of excitotoxic-sensitive and excitotoxic-resistant neurons. 
Several of our key findings were replicated in hippocampal cultures. For 
example, tat-CN21 was recently reported to display neuroprotection in 
hippocampal neurons subjected to excitotoxic insult in a dose- and time-
dependent manner, similar to my findings (Vest et al, 2010). Moreover, in 
collaboration with our lab, the Brustovetsky lab identified that neurons and 
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astrocytes derived from the hippocampus also displayed robust calcium 
dysregulation when CaMKII was inhibited. Thus, both model systems indicate 
that aberrant activation and inactivation of CaMKII can be detrimental to neuronal 
physiology.  
Proper neuron-astrocyte communication allows for regulation of neuronal 
excitability, synaptic plasticity, and viability. Because excitotoxic insults are 
marked by both neuron and astrocyte dysfunction (and subsequent changes in 
excitability and viability), it was critical to examine the effects of CaMKII 
independently in cultures of neurons or astrocytes, and together within co-
cultures of both cell types. Our in situ model system also afforded the ability to 
manipulate the levels of astrocytes within the neuronal cultures so we could 
address the effects of CaMKII inhibition both in the absence and presence of 
astrocytes. Moreover, this system allowed us to perform live measurements in 
order to determine the immediate cellular response to CaMKII activation and 
inactivation in neurons and astrocytes. Thus, there were several advantages to 
using acutely-dissociated cortical cultures. 
Excessive glutamate stimulation in dissociated neurons is known to induce 
significant levels of neuronal death by activating the NMDA-R and causing 
calcium overload (Choi, 1985, 1987, Choi et al., 1987). Our findings were 
consistent with previous reports indicating that the glutamate concentration which 
induced neurotoxicity is within the range of glutamate observed within ischemic 
brain tissue (Benveniste et al., 1984, Kanthan et al., 1995). The rapid neuronal 
death observed following our stimulation protocol is consistent with the induction 
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of necrosis often observed following excitotoxic glutamate stimulation (Figure 
42). Lower levels of glutamate are known to induce a slow-induced excitotoxic 
apoptosis when applied to neurons for prolonged length of time (Cheung et al., 
1998). The data presented here suggests that CaMKII inhibition in naïve cortical 
neurons resulted in the accumulation of 2-4 μM extracellular glutamate, which 
induced apoptotic cell death (Figure 42). These levels are in line with previous 
concentrations identified to induce apoptosis. Thus, our experimental models and 
acquired data that identify the concentration of glutamate required to induce 
necrosis or apoptosis within neurons are consistent with previous literature. 
Both genetic and pharmacological approaches can be used to determine 
the physiological role of CaMKII signaling in neurons. As stated previously, 
αCaMKII knock-out mice exhibit a predisposition to stroke damage. Furthermore, 
these animals are more prone to epilepsy. Studies using siRNA against αCaMKII 
indicate that knock-down increases basal calcium concentration and reduces the 
ability of hippocampal neurons to restore intracellular calcium concentration in 
response to stimulation (Carter et al., 2006). Thus, these genetic studies have 
yielded similar to results to ours (increased excitability, dysregulated calcium 
homeostasis, predisposition to toxicity); however, genetic studies have largely 
been focused on αCaMKII. While αCaMKII is the predominant isoform within the 
mature cortex (Ouimet et al., 1984, Erondu and Kennedy, 1985), other isoforms 
of CaMKII are expressed in the brain. There are robust levels of βCaMKII 
expression throughout development; the mature brain still cortex still maintains 
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Figure 42: Model of dysregulated CaMKII signaling following excitotoxic 
activation or inactivation in neurons. Under resting conditions (top), 
intracellular calcium is maintained at a low level and vesicles of glutamate are 
ready for release. Excitotoxic stimulation (left), which activates CaMKII, 
induces rapid necrosis by increasing sodium and calcium influx and 
subsequently resulting in hyperexcitability and the release of stores of 
glutamate. On the post-synaptic side, CaMKII activation can lead to increased 
AMPA-R insertion and the perpetuation of increased neuronal excitability and 
increased calcium influx. Prolonged inactivation of CaMKII (right) induces a 
slow-excitotoxic cascade by leading to increased Cav2.2 calcium influx and 
increased glutamate release. This can subsequently increase the excitability of 
post-synaptic neurons and further dysregulate intracellular calcium. The effects 
of both activation and inactivation lead to neuronal death either via necrotic or 
apoptotic mechanisms.  
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low levels of βCaMKII expression as well. Furthermore, δCaMKII and γCaMKII 
are ubiquitously expressed, thus low levels of these two isoforms are also found 
throughout the brain, with δCaMKII predominating in astrocytes (Ouimet et al., 
1984, Erondu and Kennedy, 1985, McGuinness et al., 1985, Burgin et al., 
1990a). Thus, genetic knock-down studies are hampered by the presence of 
multiple CaMKII isoforms in cells. Further studies using genetic knock-down 
techniques may provide insight into the contribution of each isoform during 
excitotoxic calcium signaling. 
We opted to use pharmacological CaMKII inhibitors to examine the role of 
CaMKII activity in aberrant calcium signaling. This was advantageous for multiple 
reasons. First, these pharmacological inhibitors presumably target all CaMKII 
isoforms. Furthermore, pharmacological inhibitors have a distinct advantage for 
potential therapeutic use. While we went on to show multiple disadvantages to 
inhibition of CaMKII, we initially observed that inhibiting CaMKII up to two hours 
after the onset of excitotoxic insult was neuroprotective, potentially within a 
therapeutic time window for ischemic stroke patients. The pharmacological 
inhibitors also allowed us to inhibit CaMKII activity at several different time points 
before and after the onset of excitotoxic insult. This allowed for a better 
understanding of the contribution of CaMKII activity in the hours following insult. 
Furthermore, application of pharmacological inhibitors allowed us to quickly 
reduce CaMKII activity within cells and monitor rapid changes in cellular 
physiology as CaMKII became inhibited. This was particularly beneficial for 
modeling the loss of CaMKII activity observed during excitotoxic insults without 
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having the confounding increased activity that is observed at the onset of insult. 
Thus, pharmacological inhibitors allowed us to tease apart the contributions of 
the aberrant activation and inactivation of CaMKII in a controlled manner. 
Together, I believe our model system was optimal for uncovering the influence 
that changes in CaMKII activity have on neuronal viability.  
SUBSTRATES DYSREGULATED DURING ABBERANT CAMKII SIGNALING 
CaMKII has been shown to regulate a number of proteins associated with 
synaptic function and neuronal excitability. Our data suggests that aberrant 
CaMKII activity dysregulates critical ion channels, leading to dysregulated 
calcium and glutamate homeostasis as well as disrupted neuronal excitability. 
CaMKII activity contributes to excitotoxic signaling following neuronal glutamate 
stimulation. While we did not fully-delineate which downstream substrates were 
responsible for this, increased AMPA-R signaling likely contributes, as illustrated 
in Figure 42. Pharmacological antagonists of the AMPA-R have been shown to 
be neuroprotective in animal models of stroke (Sheardown Nielsen Hansen 
Science 1990, Graham Chen Simon 1996). As described earlier, CaMKII 
phosphorylation of AMPA-R and its accessory protein Stargazin result in 
increased AMPA-R trafficking and increased channel conductance. Thus, it is 
possible the initial activation of CaMKII during excitotoxic Ca2+-signaling leads to 
increased AMPA-R signaling, which further contributes to over-excitation, 
calcium dysregulation, and neuronal death (Figure 42).  
Conversly, inactivation of CaMKII also dysregulates ion channel signaling. 
Pharmacological inhibition of CaMKII led to increased calcium influx. While 
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several voltage-gated calcium channels have been linked to CaMKII signaling 
(See Table 1), only pharmacological antagonism of the N-type calcium channel 
(CaV2.2) prevented the aberrant increase in calcium associated with CaMKII 
inhibition. This is particularly interesting, as CaMKII regulation of CaV2.2 has not 
yet been reported. CaV2.2 plays a critical role in neurotransmitter release 
following neuronal depolarization; thus, it was not surprising when the calcium 
influx associated with CaMKII inhibition correlated with increased neuronal 
excitability and increased neurotransmitter release. While we do not know which 
substrate(s) was essential for the initiation of the neurotoxic cascade, our data 
suggests that increased CaV2.2 activity led to increased calcium accumulation 
and increased release of excitotoxic glutamate. This glutamate subsequently 
activated NMDA-Rs and AMPA-Rs to further perpetuate the neurotoxic signal 
(Figure 42). Together, these data indicate that CaMKII serves as a brake for 
substrates regulating neuronal activity, therefore CaMKII inactivation results in 
aberrant excitability.  
It is interesting that CaV2.2 appears to be dysregulated when CaMKII is 
inhibited within astrocytes as well. Our working model suggests that similar to 
neurons, this increase in calcium influx through CaV2.2 is also accompanied by 
increased transmitter release (Figure 43). However, unlike in neurons, the 
neurotransmitter that is released is ATP, not glutamate. While our data indicates 
that CaV2.2 activity is increased when CaMKII is inactivated, we cannot rule out 
that aberrant regulation of other synaptic release machinery, such as members of 
the SNARE complex, play a role in the increased transmitter release with CaMKII 
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Figure 43: Model of CaMKII inactivation in astrocytes and subsequent 
effects on neuronal viability. Under resting conditions (top), intracellular 
calcium is maintained at a low level, extracellular glutamate is readily taken 
up, and vesicles of ATP are ready for release. Prolonged inactivation of 
CaMKII (bottom) reduces glutamate uptake, increases Cav2.2 calcium 
influx, and increases inter-astrocyte calcium flux. ATP release is also 
increased with CaMKII inactivation, which leads to increased purinergic 
receptor signaling that further dysregulates calcium homeostasis. While 
under physiological conditions astrocytes buffer neurotoxic signals and 
release neurotrophic factors, the decreased glutamate uptake and 
increased ATP release associated with CaMKII inhibition can lead to 
neurotoxicity.  
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inhibition. Indeed, CaMKII has been shown to regulate syntaxin and 
synaptobrevin, two critical proteins within the SNARE complex (Greengard et al., 
1987, Nielander et al., 1995, Verona et al., 2000, Ohyama et al., 2002). Thus, it 
is possible that transmitter release is increased via multiple avenues, including 
dysregulated transmitter machinery and increased calcium channel activity.   
Glutamate uptake mechanisms in astrocytes are also negatively regulated 
when CaMKII is inhibited. Further studies may identify which component of the 
glutamate uptake system is directly affected by CaMKII inhibition as, to date, 
glutamate transporters have not been identified as CaMKII substrates. The 
increased ATP release is associated with increased purinergic signaling within 
the astrocytes. Previously, P2X7 and P2Y1 have been linked to CaMKII 
signaling. Our data suggests that inhibition of these purinergic signaling 
pathways (P2X7 and P2Y1) reduces calcium dysregulation following ATP 
stimulation. Together, all of these examples highlight that multiple ion 
channels/receptors and other cellular proteins may be dysregulated by aberrant 
CaMKII activity (Figures 42-43), which subsequently negatively effect neuronal 
viability.  
A NEED FOR UNDERSTANDING MECHANISMS OF SELF-ASSOCIATION 
As previously discussed, it is well-documented that CaMKII undergoes 
prolonged inactivation after the onset of ischemia (Aronowski et al., 1992, 
Hanson et al., 1994, Zalewska et al., 1996). Several mechanisms may underlie 
this inactivation. While it was first hypothesized that proteolysis may account for 
the loss of enzymatic activity, only prolonged ischemia in one animal model 
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(gerbil) exhibited a significant reduction in CaMKII protein levels (Yamamoto et 
al., 1992) whereas other rodent models of stroke (rats) do not see this reduction 
in protein levels (Aronowski et al., 1992, Hanson et al., 1994). Similarly, I did not 
see a reduction in overall CaMKII protein 24 hours following excitotoxic insult. 
However; I did observe a significant reduction in CaMKII activity, suggesting that 
CaMKII was enzymatically inactivating without being proteolyzed.  
The activation of CaMKII under conditions of limiting ATP has also been 
shown to lead to inactivation of the kinase (Hudmon et al., 1996). Saturating 
levels of ADP and the non-hydroloyzable ATP analog AMP-PNP are able to 
prevent this inactivation, suggesting that occupation of the nucleotide binding 
pocket affords stability of activated enzyme (Hudmon et al., 1996, Vest et al., 
2009). While the mechanisms underlying this inactivation are not fully-
understood, it is interesting that autophosphorylation of Thr253 coincides with 
activation of CaMKII in limiting ATP. It is possible that a structural rearrangement 
occurs during inactivation that allows Thr253 to be available for phosphorylation. 
Importantly, mutagenesis of Thr253 to non-phosphorylatable Ala does not 
prevent CaMKII inactivation, indicating that this phosphorylation event is simply 
correlated with inactivation in low ATP but is not necessary to induce inactivation. 
Recently, an antibody against phospho-Thr253 was used to characterize CaMKII 
inactivation in an animal model of stroke (Skelding et al., 2012). Because the 
phosphorylation of Thr253 appears to be a hallmark of inactivation, this phospho-
antibody opens the possibility of characterizing CaMKII inactivation states in 
other neurodegenerative diseases.  
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 The early studies that showed CaMKII isolated from animal models of 
stroke exhibited a loss of enzymatic activity also indicated that CaMKII 
translocated from the supernatant fractions to the pellet following differential 
centrifugation (Aronowski et al., 1992, Kolb et al., 1995). In fact, this 
phenomenon also led to a gross over-estimation of the levels of CaMKII within 
the post-synaptic density (which is isolated using differential centrifugation) 
(Suzuki et al., 1994). Immunohistochemical analysis demonstrated the formation 
of CaMKII clusters within individual neurons following ischemic-like stimulation 
(Tao-Cheng et al., 2002, Tao-Cheng et al., 2007). These changes in subcellular 
localization correlated with an aggregation of CaMKII holoenzymes (Hudmon et 
al., 2001). Biochemical studies illustrated an activity-dependent aggregation, 
termed self-association, when purified αCaMKII was exposed to an ischemic-like 
environment – reduced pH, reduced ATP availability, and increased calcium 
(Hudmon et al., 1996, Hudmon et al., 2001). My studies suggest that self-
association-induced inactivation is detrimental to neuronal survival, as inhibitors 
that prevent self-association are neuroprotective in excitotoxic insults and a 
prolonged loss of activity (as is seen with self-association) leads to neurotoxicity.  
We directly show that application of CaMKII inhibitors during excitotoxic 
glutamate insult prevent neurotoxicity, αCaMKII self-association, and inactivation.  
While αCaMKII is sensitive to self-association under ischemic conditions, 
βCaMKII exhibits resistance (Hudmon et al., 2001). It is interesting that αCaMKII 
expression is limited in tissues that are less sensitive to excitotoxicity. As 
mentioned before, robust αCaMKII expression predominates in the cortex and 
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βCaMKII expression predominates in the cerebellum (Erondu and Kennedy, 
1985, McGuinness et al., 1985, Miller and Kennedy, 1985). Cerebellar neurons 
(βCaMKII) are more resistant to glutamate toxicity in culture than cortical neurons 
(αCaMKII). Moreover, the CA1 region of the hippocampus is predominantly 
marked by αCaMKII expression and is highly-vulnerable to excitotoxicity. 
However, the granule cells of the dentate gyrus in the hippocampus which is 
resistant to excitotoxicity express βCaMKII (Churn et al., 1992b). Thus, cells that 
are sensitive to excitotoxicity predominantly express αCaMKII; the isoform that is 
predisposed to inactivation via self-association.  
This concept that the expression of αCaMKII underlies neuronal sensitivity 
to excitotoxic calcium signaling is further supported when looking at the 
developmental regulation of CaMKII expression. As neurons mature, they 
become increasingly more vulnerable to excitotoxic damage. Within the nervous 
system, βCaMKII is also largely expressed during development. This is true even 
in tissue types such as the cortex and hippocampus that are largely recognized 
as areas dominated by αCaMKII expression. In early post natal days, αCaMKII 
expression begins to increase (Scholz et al., 1988, Burgin et al., 1990a). By the 
time the tissue is fully matured, αCaMKII will out-number βCaMKII 3 to 1 in the 
hippocampus while during embryonic development, βCaMKII out-numbers 
αCaMKII (Miller and Kennedy, 1985, Burgin et al., 1990a). Several other factors 
may influence the increased sensitivity of neurons to excitotoxicity throughout 
development, such as NMDA receptor expression patterns; however, it is 
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possible that prevalence of a self-association sensitive isoform of CaMKII plays a 
critical role in this vulnerability.   
The mechanism underlying the ability of αCaMKII to self-associate while 
βCaMKII cannot, has not been identified, although we hypothesize that the 
molecular variations between these two isoforms play a key role in this 
sensitivity. The variable domain is typically asserted as the primary difference 
among the CaMKII isoforms (Hudmon and Schulman, 2002); however, we have 
recently identified many residues in both the autoregulatory and catalytic 
domains that vary between αCaMKII and βCaMKII, which may produce this 
isoform-specific sensitivity to aggregation. Recent crystallographic data indicates 
that several of these residues lie in regions that may be important for anchoring 
the regulatory domain to the catalytic domain during activation (pdb #2WEL and 
#2VN9). In the future, it would be interesting to mutate these residues between 
the catalytic surface and autoregulatory domain in αCaMKII to the residues seen 
in βCaMKII in hopes to disrupt αCaMKII self-association in an animal model. 
Preliminary data indicates that mutation of Ser272/His273 in αCaMKII to 
βCaMKII residues (Cys/Gln) prevents self-association in vitro (Ashpole and 
Hudmon, unpublished). Further in situ analysis is required to identify whether 
these residues are the mechanisms that underlie isoform-dependent sensitivity to 
self-association. Once the molecular mechanism has been deciphered, these 
effects of self-association on neuronal viability can be assessed. For this, 
endogenous CaMKII in neurons could be replaced with mutants that are more 
resistant or more vulnerable to self-association and viability could be measured 
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in the absence and presence of excitotoxic insults. A mechanistic understanding 
of the role that CaMKII self-association plays in neuronal viability will illuminate 
long-standing questions associated with the changes in CaMKII localization and 
activity during ischemia. Importantly, these studies may identify a mechanism to 
therapeutically target CaMKII in the time following ischemia/excitotoxic insult.   
My data support the idea that therapeutic intervention should aim at 
restoring the availability of CaMKII after insult rather than inhibiting it. While 
pharmacological inhibitors afforded neuroprotection when applied in the time 
immediately surrounding insult, I believe this was because they prevented 
prolonged inactivation, which induces toxicity. However, it is also conceivable 
that these inhibitors prevented the phosphorylation of key proteins that 
destabilize neuronal excitability and survival during excitotoxic calcium signaling. 
The therapeutic time window for CaMKII inhibitors may be relatively brief, as 
CaMKII is already inactivating and aggregating in the time following insult. To 
date, no inhibitor has been shown to be able to restore activity or reverse 
aggregation. As suggested above, deciphering the mechanism behind isoform-
dependent self-association may provide key information as to how to therapeutic 
target this process following an ischemic event. Furthermore, because protein 
aggregation has become a hallmark of many disease states, we believe self-
association may provide additional insights into how protein aggregation 
influences neuronal survival and function following cellular stress.  
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IMPLICATIONS TOWARDS OTHER NEURODEGENERATIVE DISEASES 
Excitotoxicity that accompanies several neurodegenerative diseases is 
marked by dysregulated calcium signaling, limited ATP availability, decreased 
pH, and the generation of reactive oxygen species. While roles for ATP and pH in 
CaMKII self-association and inactivation have been established, the role 
oxidative stress plays is not understood. As mentioned before, oxidation of 
residues within the autoregulatory domain (Met281/Met282) has been shown to 
increase CaMKII activity in other cell systems (Erickson et al., 2008). 
Interestingly, oxidative stress has been associated with aggregation and 
inactivation within synaptosomes (Shetty et al., 2008). Based on these findings, 
we hypothesize that increased reactive oxygen species may aberrantly increase 
CaMKII activity during periods of cellular stress such as excitotoxic insult, thereby 
enhancing the sensitivity of αCaMKII to self-associate. Consistent with this, we 
have preliminary data correlating increased reactive oxygen species generation 
in neurons following excitotoxic stimulation and the presence of self-associated 
αCaMKII (Ashpole and Hudmon, unpublished). Moreover, in vitro analysis 
indicates that H2O2 treatment induces αCaMKII aggregation (Ashpole and 
Hudmon, unpublished). Thus, oxidative stress during excitotoxic insult could 
contribute to self-association and inactivation of CaMKII.  
Based on the findings presented here, it is likely that CaMKII is aberrantly-
regulated within several neurodegenerative diseases, as they are associated with 
increased intracellular calcium, decreased energy availability, and reduced 
intracellular pH. Aberrant increases in CaMKII activity have been identified 
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following traumatic brain injury (Atkins et al., 2006, Folkerts et al., 2007). 
Inhibition of CaMKII signaling with small molecule KN-62 reduced the extent of 
neuronal damage following traumatic brain injury (Zhang et al., 2012). 
Interestingly, isoforms of CaMKII has been shown to be differentially regulated 
following traumatic brain injury. αCaMKII levels are significantly lower in animal 
models of traumatic brain injury while δCaMKII levels are significantly increased 
in the days following injury (Schwarzbach et al., 2006, Zhang et al., 2012). 
Together, these findings indicate that CaMKII expression and activity are altered 
during traumatic brain injury and may contribute to the damage observed 
following insult.  
Alzheimer’s disease is marked by the formation of cellular plaques and 
tangles, and is associated with a subsequent excitotoxic neurodegeneration. 
Interestingly, the Alzheimer’s associated protein β-amyloid has been shown to 
decrease Thr286 autophosphorylation when applied to neurons in situ (Zhao et 
al., 2004). Furthermore, application of the β-amyloid peptide 1-42 resulted in a 
redistribution of CaMKII away from the dendritic process to the soma (Reese et 
al., 2011). Similarly, the distribution of CaMKII is altered in human patients with 
mild cognitive impairment and late stage Alzheimer’s disease (Reese et al., 
2011). The hallmark senile plaques observed in Alzheimer’s disease have been 
shown to co-localize with αCaMKII (Xiao et al., 1996). While a direct link between 
CaMKII self-association and β-Amyloid plaques has not yet been made, it is 
interesting that Alzheimer’s disease is marked by a decrease in phospho-Thr286, 
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as this decrease would render αCaMKII susceptible to self-association (a 
process I propose contributes to neuronal death).   
A commonality between disease states with aberrant CaMKII activity is 
their association with glutamate-induced neurodegeneration. Ischemia, traumatic 
brain injury, and Alzheimer’s disease are all marked by increased glutamate 
release and neuronal excitation. Several other disease states, such as 
Huntington’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease, are 
all associated glutamate toxicity as well. While CaMKII signaling has not yet been 
implicated in these diseases, it is possible that because aberrant glutamate 
signaling dramatically impacts CaMKII function, CaMKII dysregulation occurs 
with these diseases as well. Further characterization of CaMKII in these disease 
states is necessary. As mentioned above, the phospho-Thr253 antibody may be 
beneficial as an indicator of CaMKII inactivation in these disease states. 
Several HIV-related proteins have also been shown to lead to increased 
neuronal activity, increased glutamate release, and dysregulated intracellular 
calcium. As a consequence, neuronal dysfunction is prevalent within patients 
infected with HIV. One HIV protein that has been implicated in these devastating 
changes is the HIV-coat protein, Tat. Immunological studies have identified that 
many CaMKII signaling pathways are disrupted by HIV-Tat (Poggi et al., 2002a, 
Poggi et al., 2002b). Recent unpublished findings from our lab indicate that HIV-
Tat interacts with CaMKII in neurons and is an effective CaMKII inhibitor 
(Ashpole and Hudmon, unpublished). The portion of Tat that is responsible for 
CaMKII inhibition (a region upstream of the cell-penetrant motif used throughout 
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my studies) has also been shown to dysregulate calcium homeostasis and 
induce neurotoxicity (Ashpole and Hudmon, unpublished). Thus, it is possible 
that some of the deficits associated with HIV-Tat or other HIV-associated 
proteins are due to the disruption of CaMKII signaling. It will be interesting to see 
if disease models of HIV exhibit reduced CaMKII activity. Together, these studies 
would solidify a role for CaMKII inactivation as a global initiator of neuronal 
death.   
CONCLUSIONS 
The findings of this dissertation deepen the understanding of the 
physiological and pathophysiological role of CaMKII signaling in neurons. We 
have strong evidence that aberrant fluctuations in CaMKII activity play a causal 
role in neuronal death. The increases in activity during periods of neuronal stress 
are detrimental as they lead to a prolonged inactivation of the kinase,which 
increases neuronal excitabililty, dysregulates calcium homeostasis, induces 
toxicity, and predisposes neurons to other cellular stressors. These findings are 
consistent with previous studies in other cell systems (bacteria, plants, and 
invertebrates) indicating that the dysregulation of CaMKII leads to toxicity and 
predisposes cells to subsequent toxic insults. Thus, my findings support a role for 
CaMKII within neurons as a master regulator of viability, and universal role for 
CaMKII as a governor of cellular responsiveness to insults.  
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